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Abstract
Kate Gleason College of Engineering
Rochester Institute of Technology
Degree: Doctor of Philosophy

Program: Engineering PhD

Author: Poornima Kalyanram

Advisor: Dr. Anju R. Gupta
Co-Advisor: Dr. Satish G. Kandlikar

Dissertation Title: Interaction of Photosensitizers with Model Membranes and their
applications in Photodynamic Therapy
Cancer is caused by the uncontrolled growth and spread of abnormal cells resulting in 1 in 6
deaths every day. The most common treatment methods include surgery, chemotherapy, and
radiation. These techniques are invasive, aggressive, and non-specific to cancer cells.
Therefore, alternative therapies which are both potent and does not interfere with the quality
of living are on a rise. Photodynamic Therapy (PDT) is an approved alternative remedy in the
treatment of cancer. The efficacy of PDT depends on the penetration power of the
photosensitizer (PS) when injected into to the site of tumor. However, due to complexity
involved in the structure of the PS molecules and its interaction with the cancerous cells, the
potential of this therapy is not fully realized.
The PS molecules exhibit biological effect because of direct interaction with the cell
membranes. Therefore, it is important to investigate this interaction and its effect on the
physicochemical properties of membranes. The focus of this work is to understand the
fundamental mechanism of this interaction with the cell membranes. However, due to the
complexities associated on working with the human cell membrane it is appropriate to conduct
experiments with model cell membranes, commonly known as liposomes. Additionally,
liposomes are extremely biocompatible and are used as drug delivery vehicles or encapsulating
agents.
The work reported in this dissertation is divided into two parts. In the first part, the interaction
mechanism of hydrophilic riboflavin with liposomes was studied as to create a baseline. It was
iii

found out that the hydrophilic nature of riboflavin does not penetrate the hydrophobic lipid
bilayer by using a combination of laser scattering and calorimetric techniques. To further the
bilayer permeation capacity of any hydrophilic PS, the idea of conjugation of hydrophobic
alkyl tail chains to hydrophilic PS molecules was explored. Thereby, hydrophobicity was
induced to amino methyl coumarin, a potent PS molecule, based on the setbacks of the existing
hydrophilic photosensitizers. The interaction between this molecule and model cancerous cell
membranes was investigated using combination of biophysical techniques and MD
simulations. Our findings indicated that the addition of alkyl chains to fluorophores improves
their cellular uptake and targeted delivery. It was concluded that the at longer chain coumarin
fluorophore perturbs the lipid bilayer at higher concentrations by flip-flop mechanism leading
to membrane thinning. Preliminary in-vitro activity reveals the photoactive potential of these
amphiphilic coumarin molecules.
In the second part, alternative strategies such as encapsulation using liposomes was proposed,
for FDA approved existing PS molecules (viz. HPPH and Riboflavin) to increase their efficacy
during treatment. Long circulating liposome formulations of poly ethyl glycol (PEG)
conjugated lipids, polymerizable lipids and cholesterol. The stability and composition of each
component in the formulations was examined using biophysical methods. It was found that
PEGylation increases the stability of liposomal formulation by preventing aggregation through
thermal and physical stability. It was also concluded that cholesterol does not contribute to the
increase in stability of PEGylated formulations. In- vitro and in- vivo studies conducted by our
collaborators at NIH confirmed the efficiency of PEGylated liposome-based carriers
demonstrated through longer circulation times and specificity towards tumor.
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1 Introduction
Cancer is caused by the uncontrolled growth and spread of abnormal cells. According to
American Cancer Society, cancer causes 1 in 6 deaths every day in the world1. It is estimated
that by 2035, 2.4 million new cancer cases will be diagnosed in the US annually as shown in
Fig 1-12.

Figure 1-1: Estimated Number of rise in cancer cases by 2035. Adapted with permission from
American Association for Cancer Research2

The most common treatment methods include surgery, chemotherapy, and radiation3. These
techniques are invasive and non-specific to cancer cells. The aggressive nature of these
treatments causes a destruction of healthy cells resulting in an immunocompromised
individual4. Therefore, there exists a need for alternative therapies that are both potent and does
not interfere with the quality of living4. Photodynamic Therapy (PDT) is an approved
alternative remedy in the treatment of cancer. PDT is a two-step process, which are elucidated
as follows and illustrated in Fig 1-25–7:
i) Application of the photo-responsive drug or the photosensitizer (PS) to the affected area
via injection or topical ointments;

1

ii) Irradiation of the affected area with light of a particular wavelength to produce singlet
oxygen (1O2) from the cellular molecular oxygen (also known as Reactive Oxygen
Species (ROS), which results in cell death.
This treatment is minimally invasive (for insertion of needles and tubes in certain cases) and
target specific. The scarring associated with the exposure to laser light is minimum and
temporary5,6,8. The efficacy of PDT depends on the photosensitizer and the wavelength of
irradiation of the laser light6,8. Widespread research is on to optimize the potency of PDT and
newer PS are being approved by FDA. However, due to complexity involved in the structure
of the PS molecules and its interaction with the cancerous cells, the potential of this therapy is
not fully realized.

Figure 1-2: Schematic Showing steps involved in Photodynamic Therapy

The focus of this work is to understand the fundamental mechanism of the interaction of PS
molecules with the cell membranes. The PS molecules exhibit biological effect because of
direct interaction with the cell membranes. Therefore, it is important to investigate this
interaction and its effect on the physicochemical properties of membranes. However, due to
the complexities associated on working with the human cell membrane it is appropriate to
conduct experiments with model cell membranes, commonly known as liposomes. Liposomes
are structurally similar to human cell membranes9,10. They are used in lieu of human cell
membranes because they are composed of phospholipids which is the same component that
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constitutes 80-90% of cell membranes9,10. Additionally, liposomes are extremely
biocompatible and are used as drug delivery vehicles or encapsulating agents11,12.
The work reported in this dissertation is divided into two parts. In the first part, a novel design
by inducing amphiphilicity to coumarin, a potent fluorescent PS molecule, was proposed, based
on the setbacks of the existing photosensitizers. The interaction between this molecule and
liposomes was investigated using biophysical techniques. It was concluded that the more
amphiphilic the molecule is, higher its penetration power. In the second part, alternative
strategies such as encapsulation using liposomes was proposed, for FDA approved existing PS
molecules, to increase their efficacy during treatment. The effect of each component in the
liposome was examined using biophysical methods to customize liposome-based carriers based
on the nature of the PS molecule.

1.1 Liposomes: Cell Membrane Mimics
Cell membrane is a protective layer that encloses the cell organelles and cytoplasm. The cell
membrane is composed of a phospholipid bilayer13. The lipid molecules are amphipathic in
nature i.e., they have a polar phosphate hydrophilic head group and a non-polar fatty acid
hydrophobic tail13. The phospholipids are oriented in a way such that the hydrophilic head
groups point outwards with the hydrophobic tail group forms a bilayer. According to the fluid
mosaic model, the lipids in the bilayer are assumed to be in motion and continuously glide from
one part of the bilayer to another13. However, they cannot flip flop between the outer and the
inner bilayer leaflets. This layer is selectively permeable to certain uncharged molecules such
as CO2, O2 and H2O14. However, it is impermeable to most of the charged ions and molecules.
Therefore, it is necessary to investigate the mechanism by which pharmaceutically active
components cross the lipid bilayer to design effective drug delivery systems15. Biological
membranes are complex in nature and to study the lipid-drug mechanism in-situ, model cell
membranes, also referred as liposomes, are preferred16. Liposomes are self-assemblies of
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phospholipids and largely resemble a cell membrane as shown in Fig 1-3. They are prepared
either by hydration of the phospholipid film or by electro formation method17.

Figure 1-3: Structure of Liposome

The interaction between the liposomes and the drug molecules can be quantified by various
biophysical and biochemical methods. Thus, in this study, liposomes are used as model cell
membranes to understand the interactions with molecules of interest through biophysical
techniques. This study is important is understanding the pharmacology of novel molecules.
Though the phospholipid membrane is not the final target of the molecule, a knowledge on this
initial interaction is necessary to predict the efficacy of the molecule of interest18.

1.2 Interaction mechanisms of lipid bilayer with drug molecules:
Various mechanisms have been proposed to understand partitioning mechanism of lipid
bilayer. These mechanisms depend on the nature of the molecule (whether hydrophobic,
hydrophilic, and amphiphilic) and are specific to the lipids that make up the bilayer. Any
foreign molecule penetrates the bilayer by two major cellular uptake process:
i.

Endocytosis;

ii.

Direct translocation.

Endocytosis involves two steps: phagocytosis for solid particles and pinocytosis for liquid
particles. Most amphiphilic peptides follow direct translocation processes for membrane
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destabilization. Since the molecules under this study have structural similarities to peptides,
this review is focused on the different mechanisms of direct translocation process. The first
step that precedes the destabilization mechanism is the electrostatic binding of the molecule
with the lipid bilayer. Furthering which, the following mechanisms takes place. These
mechanisms of destabilization are dependent on concentration, peptide and lipid charge and
peptide type.
1.2.1 Pore Formation:
Pore formation was reported by Okumura et.al in 1981 in Mastoparans peptide19,20. This is a
class of venom peptide which was studied with PC/PG vesicles. The peptide after binding
electrostatically to the outer lipid leaflet, slowly translocases to the inner leaflet forming a pore.
The translocation of the peptide is so rapid that it results in flip flop of the lipid molecules. The
flip-flop mechanism is a secondary mechanism which results in reduced membrane elasticity
and eventual pore formation and leakage of contents19,20

Figure 1-4: Schematic of Pore Formation

1.2.2 Carpet Mechanism:
Carpet mechanism was observed first in Dermaseptin peptide by Pouny et al., in 199121,22. In
this mechanism the peptides do not penetrate deep into the membrane. They bind preferentially
like carpets on the surface resulting in orientation with the hydrophilic and hydrophobic parts
of the peptide with the bilayer and results in thinning of the bilayer and eventual destabilization.
Membrane thinning is a secondary mechanism that accompanies carpet mechanism21,22.
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Figure 1-5: Schematic of Carpet Mechanism

1.2.3 Inverse Micelle Formation:
Inverse micelle formation is observed in homeodomain proteins of Drosophila23,24. These
proteins are attracted to the hydrophilic groups on the lipid bilayer and creates membrane
destabilization. This membrane destabilization results in formation of a micelle that travels
across the membrane and releases the protein on the cytoplasmic side. This mechanism in noninvasive and recommended for gene therapies25,26.

Figure 1-6: Schematic of Inverse Micelle Mechanism

Table 1-1 summarizes the selected bilayer interaction studies that have used molecules of
nature and their bilayer partition mechanism. The different techniques used in the each of the
study are also listed. These methods are elucidated in Chapter 2.
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Table 1-1: Summary of different lipid-molecule interaction

Lipids used
in forming
the bilayer

EPC
27

PC
28

Type of
molecules/Name
of molecules
used in
interaction
Study

Techniques
used

Mechanism of
Interaction

Comments/Remarks

Antitumoral drug
Daunorubicin Amphiphilic

Derivative
Spectrometry
and
Zeta
Potential

Electrostatic
interactions
and
hydrophobic forces
stabilize the drug in
the lipid bilayer

This work establishes
the use of spectroscopy
and zeta potential
measurements to locate
the position of the drug
in the bilayer

Molecular
Dynamics and
Fluorescence
Spectroscopy

Hydrophobicity
drives
internalization of
molecules into the
bilayer

Molecular dynamics
study establishes the
location of the probe in
the bilayer

Molecular
Dynamics and
Fluorescence
Spectroscopy

Hydrophobic nature
of the probe drives
binding
and
internalization

This study establishes
the switchable nature
of fluorescence of this
probe in different
environments

Hydrophobic

Molecular
Dynamics

Mechanism
partition is
elucidated

Lays out the effects of
acyl chains of the lipids
in the presence of
pyrene

DiLHydrophobic

Molecular
Dynamics

Charge
induced
perturbation
of
membrane bilayer

This study is important
in determining the
conditions for DiL
perturbation

Molecular
Dynamics

No
significant
perturbation. Probe
lies
in
the
hydrophobic region
of bilayer

Complete study on the
effects of DPH on the
DPPC
membrane
perturbation

Fluorescence
Spectroscopy
and Molecular
Dynamics

Carpet mechanism
of
disruption
induced by charge
and hydrophobicity

The location of the
peptide in the bilayer is
not
determined.
However,
the

2′-hydroxy
derivatives
of
2,5-diaryl-1,3oxazole
Fluorophore
Hydrophobic

POPC, POPG
and
Cholesterol
29

-

2,6-bis(1Hbenzimidazol-2yl) pyridine
FluorophoreHydrophobic

POPC/
PyreneCholesterol
30

DPPC
31

DSC,
DPPC
32

PC/PG
33

DPHHydrophobic

Fluorescent
AMP-PMAP-23Amphiphilic

NMR,
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of
not

mechanism
perturbation
complete

DPPC/

PaclitaxelHydrophobic
Drug

Cholesterol
34

of
is

DSC,
Spin
labelled Electro
Paramagnetic
Resonance
(EPR)

Paclitaxel
penetrates
the
hydrophobic region
of DPPC rendering
instability.
Cholesterol
alleviates
the
instability

Wholesome study on
the location as well as
the release kinetics of
the drug

DSC,
Zeta
Potential, NMR

No
significant
change
in
the
liposomal structure

Study on the design of
liposomal formulation
foe delivery of these
two drugs

DSC and EPR
Spectroscopy

Interaction
only
with the polar
headgroup and does
not
internalize
much

Investigates the effect
of morphine derived
drugs on the bilayer to
design
effective
carriers

Strong interaction
with polar groups
and insertion

Establishes
the
complete activity of
DQ on accumulation in
positively charged lipid
membranes

Charge
based
insertion and lipid
phase separation

Findings suggests that
certain molecules exert
activity
based
on
charge on lipids

General
Polarization

Causes fusion of
membrane resulting
in destabilization of
membrane

Complete study on the
mechanism
using
various techniques and
mice studies

Fluorescence
Spectroscopy
and DSC

Drug is in the
hydrophobic region
of bilayer and

Study focuses on the
antioxidant damage on
lipid bilayer

DPPC/
Cholesterol/

Ofloxacin
rifampicin

DSPC

and

18

DPPC

CodeineHydrophobic

35

Dequalinium
chlorideAmphiphilic

DMPC
36

Zeta,
DSC,
TEM,
SAXS/WAXS,
NMR

DPPC
DPPG

&

FTIR,
Simvastatin
DSC

37

DLS,
ZETA,
DPPC
38

DMPC/DMP
G
39

DSC
BedaquilineHydrophobic

CarvedilolHydrophobic
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causes membrane
destabilization
DPhPC
40

POPC
41

DPPC/DPPS
42

POPC/POPS
43

AlamethicinAmphiphilic
Molecule

βAP
(1-40)Amphiphilic
Molecule

Phase separation of
lipids
bilayer
thinning

Establishes
the
partitioning
mechanism
of
amphiphilic peptide

NMR and CD

Intramolecular
hydrogen bonding
and peptide folding
due to charge-based
interaction

First
of
few
biophysical
studies
focusing on amyloid
peptide-membrane
interactions

DSC,
TEM

Charge
based
binding
and
hydrophobicity
driven partitioning

Hydrophobicity
in
amphiphiles results in
permeation of bilayer

Fluorescent-LPA
Amphiphilic
Peptide

Cryo-

Synthetic
βHairpin Peptides

CD
and
Molecular
Simulation

Barrel mechanism
of pore formation

Complete experimental
and theoretical study
on β-hairpin peptide
association
and
permeation of lipid
bilayer

SVS-1 peptides

CD, Molecular
Simulation and
Fluorescence
Spectroscopy

Charge
based
preferential binding
and transient flipdip mechanism of
folding

Novel mechanism of
flip dip explained
through modelling

Doxorubicin

Molecular
Dynamics

Preferentially
partitions
and
inserts
due
to
hydrophobicity in
the presence of
cholesterol

In-dept investigation
on the influence of
cholesterol
in
partitioning

NSAID

DSC,
MD

Bind
to
the
hydrophobic region

Pharmacological
activity of NSAID is
studied

DPPC/DPPG
44

XRD
and
Circular
Dichroism

DMPC/
Cholesterol/
SM
45

DPPC
46

Raman,

DPPC(dipalmitoylphosphatidylcholine);POPC(palmitoyloleoylphosphatidylcholine);POPG(1-palmitoyl-2oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol));EPC(eggphosphatidylcholine);DPPG(dipalmitoylphosphatidylglycerol);DMPC(dimyristoyl
phosphatidylcholine);DMPG(dimyristoylphosphatidylglycerol);DPhPC(Diphytanoylphosphatidylcholine);DPPS
(dipalmitoylphosphatidylserine);POPS(palmitoyloleoylphosphatidylserine)
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Matos and coworkers12 used derivative spectroscopy and zeta potential measurements to
determine the partial coefficient of daunorubicin when interacted with zwitterionic (presence
of both positive and negative charges on the headgroup) DPPC. The shift in fluorescence
spectra of daunorubicin is due to the penetration of the molecule in the hydrophobic zone of
the bilayer. The authors also reported that at lower concentrations electrostatic attraction caused
the penetration into the bilayer and at higher concentrations, hydrophobicity induced
penetration.
Budai et al35, studied the effect of hydrophobic morphine derivatives on DPPC lipid bilayer
using DSC. It has been reported that the presence of these molecules decreased the main
transition temperature of DPPC. This is attributed to the fact that these molecules reduce the
fluidity of the headgroups of the bilayer which results in reduction in transition temperature.
This work gives an insight on the different thermodynamic parameters and their significance
to the bilayer-drug interaction studies using DSC. However, this study does not investigate the
concentration effects of the drug on the bilayer.
A recent study by Sarilisk et al37., has investigated the effect of partitioning by Simvastatin on
zwitterionic DPPC vesicles and anionic DPPG vesicles. This study presents an in-depth
analysis on the thermodynamic parameters calculated from the DSC thermogram suggesting
that permeation of lipid bilayer was charge dependent. Though this study gives a complete
mechanism of permeation, it does not describe the effects of the drug on the membrane after
incorporation into the bilayer.
Many of the studies involving existing fluorescent probes and drugs listed in the table above
use MD simulations28–33 to investigate the effect on the drug on the bilayer post the
incorporation. A variety of mechanisms of destabilization such as carpet mechanism, flip-dip
mechanism, pore formation mechanism has been proposed when the concentrations of the drug
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is increased or when the relaxation time conditions of the simulations are varied28–33. However,
these studies have not been validated experimentally. Experimental validation is required for
MD simulations as simulations occur at perfect microenvironmental conditions.
It is also been established from the above studies that amphiphilic molecules40–44 penetrate
bilayers better due to their ability to align with the different regions of the bilayer as compared
to pure hydrophobic or hydrophilic molecules.

1.3 Liposomes as carriers:
Cancerous cells have a different vasculature as compared to healthy cells. This imparts a
different pH to the cancerous cells47,48. Drug and fluorophore molecules lack the sensitivity to
adhere on to these cells and have low bioavailability. These molecules, however, localize
themselves on healthy cells causing damage to them and have a reduced specificity towards
tumors49. Most of the fluorescent molecules used are hydrophobic in nature and have aromatic
rings present in them. The presence of aromatic rings makes them aggregate in solution due to
𝞹-𝞹 stacking50,51. To lessen the aggregation in the fluorophores as well as to improve the
specificity and constant delivery, it is imperative to encapsulate the molecule in nano-carriers.
Nano-carriers, owing to their smaller size, escape the body’s immune system and circulate
longer in the body52–54.
The smaller size of nano-carriers also provides a high surface-volume ratio which helps in
effective uptake of the particles by the cells and increased bioavailability of the drug. In
addition to this, they adhere to the site of the tumor due to its leaky vasculature by enhanced
permeation retention (EPR) effect and provide sustained release52–54. To escape the immune
system of the body, the size of the nano-carriers should be between 100-150 nm52.
Nano-carriers are further classified as organic and inorganic carriers55–57. Table 1-2 lists the
types and most reported carriers in literature for PDT. However, most of the organic polymeric
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nanocarriers get accumulated in the liver and spleen, which in-turn are destroyed by immune
cells, thus failing to reach the target organ58,59. Inorganic carriers, on the other hand, pose a
problem of in-vitro toxicity58,59. Quantum dots usually have a coating of organic layer to make
them biocompatible. However, the complexity associated with the Quantum dots is the
exposure of the inorganic core by etching away of the organic layer which makes them
cytotoxic58,59. Carbon and metallic nanoparticles also pose a threat of subacute cytotoxicity58,59.
Table 1-2: Commonly used Nano-carriers
ORGANIC CARRIERS
Type of Carrier

Commonly used Carrier examples

Liposomes

Phosphatidyl inositol, phosphatidyl serine, and
phosphatidyl choline

Natural Polymeric Nanocarriers

Albumin, hyaluronic acid, and chitosan

Synthetic Polymeric Nanocarriers

Poly acrylamide (PAA), Poly lactic acid (PLA),
Poly glycolic acid (PGA), Poly(lactide-coglycolide) (PLGA), dendrimers, and
hyperbranched polymers

INORGANIC CARRIERS
Quantum Dots

CdSe/CdS/ZnS nanocrystals

Ceramic Nanoparticles

Silica based Nanoparticles

Metallic Nanoparticles

Gold Nanoparticles

Carbon Nanoparticles

Functionalized Fullerenes, Single walled
Carbon Nanotubes and Graphene Oxide

Liposomes, on the other hand, are composed of phospholipids making them biocompatible. In
addition, their biophysical characteristics can be tuned to enhance their biological properties60.
They are inactive pharmacologically and negligibly toxic60.
Liposomes are self-assemblies of lipid molecules. The lipids that make up the bilayer have both
a hydrophilic head group and a hydrophobic tail, which self-assemble to give rise to an aqueous
core42,61. Liposomes are preferred as carriers in drug delivery systems over metallic, polymeric,
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or dendritic carries because of their biodegradability, biocompatibility and their versatility to
encapsulate micro and macro molecules58,62,63. Besides, liposomes can be customized
according to size, charge and number of lamellae depending on the applications64,65. The
classification of liposomal drug delivery is broadly divided into conventional and long
circulation liposomes.
1.3.1 Conventional and Long Circulating Liposomes:
Conventional or the first-generation liposomes were developed commercially in the beginning
of 1980s for the delivery of hydrophobic doxorubicin and amphotericin11,66. These liposomes
comprised of a combination of cationic, anionic and zwitterionic phospholipids in conjunction
with cholesterol. However, conventional liposomes were found to attract plasma proteins, also
called as opsonin proteins, from the blood stream. The opsonins serve as identification markers
for macrophages 67,68. Opsonins attach themselves electrostatically to the surface of the lipids.
The presence of opsonins on the liposomal surface makes them susceptible to macrophage
attack and eventually, their removal through the reticuloendothelial system (RES). This
phenomenon is also known as liposomal opsonization69–71. A comprehensive review on
opsonization mechanisms of conventional liposomes is previously presented68. Therefore,
various strategies have been exploited to induce stealth-ness in liposomes to prevent their
opsonization and impart longer circulation in the bloodstream66,72,73. One of the commonly
used techniques is introduction of steric stabilization by augmenting the liposomal surface with
hydrophilic polymers as shown in Fig 1-769,74,75. Fig 1-7 represents the effects of steric
stabilization on RES clearance; opsonins (shown in green) adhere only to conventional
liposomes and not to the sterically stabilized liposomes (polymer chains shown in pink). This
results in attack of conventional liposomes by the macrophage cells and subsequent clearance
by RES. However, sterically stabilized liposomes have longer circulation times and
successfully reach the tumor sites. Stealth nature of the liposomes is responsible for longer
13

circulation times. This stealth nature is affected by the polymer’s hydrophilicity, spatial
conformation, density and molecular weight76–78.

Figure 1-7: Conventional vs Long Circulating Liposomes and its effect on Macrophage clearance

Some commonly reported polymers include PLA (poly lactic acid)79, polystyrene (PSt)80,81,
polyvinyl alcohol (PVA), polyacrylamide80, polysaccharides76,80,82, and Polyethylene glycol
(PEG). However, PLA and PSt are highly anionic with zeta potentials ranging between −20
and −76 mV and these coatings easily attacked by macrophages83–87, polysaccharide coatings
on the other hand activate the immune system, due to the presence of hydroxyl groups, resulting
in elimination78,88. Liposomes coated with PVA and polyacrylamide copolymers have shown
to suffer mechanical degradation and subsequent leaking of contents89.
Amongst the various polymers researched, PEG being hydrophilic, biocompatible, nonimmunogenic and non-ionic70,77,90–93 has demonstrated potential in steric stabilization. DoxilTM
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is the benchmark formulation demonstrating the stealth nature of PEG94,95. The stealth nature
of PEG is attribute to its hydrophilicity and uncharged surface. The inclusion of PEG increases
the hydrophilicity and reduces the overall charge or the zeta potential on the liposomes
preventing opsonization96–98. This has been demonstrated in various research studies, where
the coating of PEG on anionic liposome reduced the zeta potential to a near-neutral value,
thereby increasing the circulation99–101.
1.3.2 PEG (Polyethylene Glycol) linked lipids:
PEG (Poly-ethylene glycol) is non-ionic102, bio-compatible103, hydrophilic97, and easy to
synthesize104 which makes it more favourable. PEGylated lipids consist of PEG chains, a
linker, and a hydrophobic anchor 104. One of the ends of the PEG chain in PEGylated lipids is
attached to the hydrophobic anchor through the linker.
The molecular weight of the PEG chains is usually in the range of 50kDa to 400 Da and can
be functionalized by covalent conjugation with folate, biotin, amine, azide, carboxylic acid
105,106

. The functionalization of PEG lipids which is vital to increase its target specificity has

been reported extensively 107 and is beyond the focus of this review.

1.3.3 Conformation of PEG Chains:
The molecular weight and grafting density affect the conformation of PEG chains on the lipid
bilayer surface. At lower grafting density, the PEG molecules assume a lesser interacting
mushroom regime with conformed chains, and increasing grafting density, the PEG chains
extend and branch out to interact with neighbouring molecules.

108,109

. Brush regime is

preferred to improve the stealth properties of a liposome as in this regime the interaction of the
particle is less and diffuses faster through the tissues than the mushroom regime94. Moreover,
opsonins bind predominantly through hydrophobic and electrostatic interactions. Non-ionic
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PEG chains in brush conformation render the surface of the liposome hydrophilic, reducing the
interactions. Furthermore, some adsorbed opsonins tend to compress the brush like chains to
mushroom like configuration. This change in energy impedes the attractive nature of opsonins
from reaching the surface of the liposomes71,110.
According to Alexander-deGennes theoretical model of polymer regimes, the transition from
mushroom to brush regime depends on the distance (D) between the grafting sites and the
length of the random PEG coils (Rf). Rf or Flory dimension is mathematically represented as
aN3/5, where N is the degree of polymerization and a is the monomer size111. The conditions
for each of the configuration depicted in Fig 1-8 is as follows: (i) D > Rf, the PEG chains have
very little interaction and follow interdigitated mushroom configuration (ii) Rf < D < 2Rf , a
mushroom packing is observed (iii) D ≪ 2Rf, chains are closer and a brush like extended
conformation is observed70,74,111. In all conformations, PEG chains form a fixed aqueous layer
thickness (FALT) around the liposomes. This FALT value controls the regime type and
circulation time of liposomes. It is reported that a combination of shorter and long PEG chain
lengths help in lengthening the circulation time104.

Figure 1-8: Regimes in a PEG coated liposome a) Interdigitated Mushroom; b) Mushroom
Regime; c) Brush Regime
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The PEG chains are further attached to the hydrophobic acyl anchor through linker moieties.
Common linker moieties include phosphate ester, ether, disulfide, carboxyl ester, amide, and
peptide linkages112–116. The linker moieties affect the surface charge and binding properties of
the liposomes. The conventional linker has been the phosphate linker, based on its presence or
absence the PEGylated lipids are categorized as PEG-phospholipids and PEG-nonphospholipids104. The third component of PEG lipids is the hydrophobic anchor comprising of
acyl groups that associate into the lipid bilayer with PEG chains branching into the aqueous
region. The acyl groups determine the lamellar or micellar morphology of the lipid
assemblies117 and the extent of inclusion of PEGylated lipid in the liposome118,119. In case of
PEG-phospholipids, the acyl group is usually a fatty acid chain such as distearoyl, dipalmitoyl
or dimyristoyl that is covalently bonded to the polar phospholipid head group104. These heads
groups are then attached to a linear chain methoxy-PEG (mPEG) as shown in Fig 1-9a. It is
found that the length of the mPEG chains which is directly related to the molecular weight
influences the FALT values, thereby determining the circulation time. Shorter m-PEG chains
(350-750 Da) have shown relatively limited effects to avoid macrophage clearance due to their
inherent mushroom configuration. Increasing the mPEG chain length has shown to increase
the circulation time120–125. Additionally, mPEG phospholipids having a mixture of PEG chain
lengths in the same molecule (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-PEG2)
elongates the circulation time and has increased tumor contact time because of its differing
hydrophilic and hydrophobic properties123. It is also been found that concentration of mPEGphospholipids in a liposome influence the rate of release of drugs. The higher molecular weight
mPEG-phospholipids transform a diffusion-controlled drug release to an interfacial-controlled
drug release126.
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Figure 1-9: Structure of Phospholipid PEG a) DSPE-PEG2000 1,2-distearoyl-sn-glycero-3phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]; Non-Phospholipid PEG b) C8
PEG2000 Ceramide N-octanoyl-sphingosine-1-{succinyl[methoxy(polyethylene glycol)2000]}; c)
DMG-PEG 2000 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000; d) CholPEG600 Cholesterol-(polyethylene glycol-600)

Conventional phosphate linkers are anionic in nature that can activate the complement system,
which is responsible for innate immunity, leading to hypersensitivity reactions, however
neutralizing these anionic charges, with cationic groups or methylation has shown to thwart
this activation127. The costs associated with production of phospholipids is not justified due to
proneness to enzymatic degradation by lipases and phospholipases128–132 that results in their
rapid clearance. Consequently, PEG chains conjugated to glycerolipids, sphingolipids and
cholesterol shown in Figs 1-9 b-d have been explored as alternatives to PEG-phospholipids. A
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study investigating the different lengths of PEGylated ceramides on the circulation times of
liposomes concluded that longer acyl chained ceramides (C24) compared to shorter chain
ceramides (C8), had stronger anchoring properties that resulted in longer circulation time and
higher drug release rates133,134.
Cholesterol linked PEG or Cholesteryl-PEG (Chol-PEG) includes cholesterol as the
hydrophobic anchor. Due to the lipophilicity, compatibility with other lipids and stabilizing
properties, cholesterol is a favourable choice for anchoring PEG chains through ester
bonds128,135,136. Chol-PEG is found to regulate the membrane fluidity, which helps in adding
stability to the bilayer and prevents the leakage of drugs104. Additionally, the drug loading
efficiency of Chol-PEG is found to be dependent on the percentage of Chol-PEG. Lower CholPEG ratios in the formulation could encapsulate more amount of drugs137–139. Studies have
reported the synthesis of pH cleavable PEG chains by linking Cholesterol through succinate
and carbamate linkers140,141. Despite its advantages, Chol-PEG demonstrated shorter
circulation time than PEG phospholipids. This is because cholesterol anchors deep into the
hydrophobic zone of the lipids, counteracting the advantages offered by PEG chains. The
addition of extra linkers is proposed to overcome this limitation, however complicates the
synthesis process.104,142.
Furthermore, it is necessary to cleave the PEG chains after the circulation time is achieved to
increase the absorption of drugs141,142. This is accomplished by attaching linker moieties that
either cleave the PEG chains upon the reaching the target site or when exposed to a suitable
stimulus such as change in pH, temperature, or in the presence of an enzyme in the cellular
microenvironment143,144. Some prominent moieties that are used as cleavers include vinyl ether
bond, hydrazine bond, disulphide, peptide and ester bonds145. Vinyl ether bonds are nonreactive in near neutral and basic conditions that makes them labile in acidic conditions
especially under pH < 5146. Vinyl ether linked PEG to dioleoyl phosphatidyl ethanolamine
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(DOPE) liposomes have demonstrated efficacious release of therapeutic contents post the
cleavage of PEG moiety under varying pH conditions

146

. It is also observed these PEG

conjugated vinyl ether bonds are cleavable by reactive singlet oxygen generated encapsulated
by photosensitizers141. Peptide bonds, are cleaved only in the presence of tumor specific
enzymes such as matrix metalloproteinases (MMPs)147–149. In-vitro studies have shown that
peptide conjugated PEG lipids have longer circulations times and prefer to accumulate on
tumor sites due to the enhanced permeability and retention effect (EPR), which arise from lack
of draining in the tumor tissue147. For intracellular delivery specific, PEGylated liposomes
conjugated with

disulfide bonds are desirable150–152because the disulfide linkage in

nanocarriers gets cleaved in the presence of glutathione, an antioxidant overexpressed in the
cytoplasm of cancerous cells. Furthermore, many studies indicate that antibody delivery by
cleavable PEG linked by disulfide bond can potentially be used in cancer diagnosis and
treatment150,153,154.
1.3.4 Benefits of PEGylated Liposomes in the clinics:
Based on previous discussions on the composition, properties, and advantages offered by
PEGylated it is proven that PEGylated formulations provide shielding effect from
macrophages, longer circulation time, preferential accumulation to sites of interests. Due to
the substantial research in stealth technology, several PEGylated liposomes have been tested
for clinical trials and approved by the FDA for treatment on humans. PEGylated lipids in
combination with regular phospholipids and cholesterol have been used in various
formulations. The very first PEGylated liposomal formulation to be approved was Doxil®.
Doxil®, is an intravenous formulation developed by Sequus Pharmaceuticals, USA in 1995 for
the delivery of DOX (doxorubicin) hydrochloride for the treatment of ovarian and breast
cancer. This formulation has 5 mol% of phospholipid DSPE-PEG 2000, 39 mol% cholesterol
and 59 mol % hydrogenated soy phosphatidylcholine (HSPC) 155–157. Subsequently, Onivyde™,
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which has irinotecan, as the active ingredient, was approved by the FDA for the treatment of
metastatic adenocarcinoma. Onivyde™ contains distearoyl-sn-glycero-phosphoethanolamine
(DSPC), cholesterol and distearoylphosphatidyl ethanolamine (MPEG-2000-DSPE) in the
ratio of 3:2:0.015158,159.
Several other formulations which contain PEG-Phospholipids and Chol-PEG are currently in
different phases of clinical trials. The active ingredient and composition of the formulations
has been tabulated below in Table 1-3160.
Thus, the stealth nature of PEGylated liposomes makes it suitable for encapsulation of a variety
of therapeutics. A very interesting recent application of PEGylated lipids is to use it in
combination with photopolymerizable lipids. The potential of this work is still not completely
explored. The review of several recently published work on the use of PEGylated lipids in
conjunction with photopolymerizable lipids are reviewed as follows. Our previous work
describes utilization of the PEGylated phospholipid DSPE-PEG2000 to fabricate vesicular
morphology to photopolymerizable lipid, DC8,9PC (1,2 bis (tricosa-10, 12-diynoyl)-snglycero-3-phosphocholine)161. DC8,9PC is a polymeric lipid having a tubular morphology.
Previously, DC8,9PC has been successively used in combination with DPPC for delivery of
HPPH photosensitizer and this technology is patented162 and promoted by Nano-RedTM163. It
has been recently discovered that the presence of hydrophilic PEG chains is can induce
formation of lamellar structure, thus resulting in eliminating the need for the presence of DPPC.
The liposomal formulation containing DC8,9PC and DSPE-PEG-2000 in the molar ratio of
90:10 and could encapsulate hydrophobic photosensitizer HPPH

161

. Similarly, another study

has investigated the encapsulation of dexamethasone, a potent rheumatoid arthritis drug164 in
this formulation. Both these researches have concluded longer circulation, stealth nature, and
preferential accumulation of these formulations in the respective sites of interest in animals.
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Table 1-3: FDA approved Formulations involving PEGylated Liposomes

Formulation
Doxil

Active Ingredient
Doxorubicin

Composition
HSPC: Cholesterol: PEG 2000-DSPE
(56:39:5 molar ratio

Irinotecan

DSPC:MPEG-2000: DSPE (3:2:0.015 molar Approved
ratio

155–157

Onivyde
158,159

Thermodox
165

Lipoplatin
166,167

S-CKD602
168,169

2B3-101

Stage
Approved

Doxorubicin

DPPC, Myristoyl stearyl phosphatidylcholine
Phase 3
and DSPE-N- [amino (polyethylene glycol)2000]
Cisplatin
DPPG, soy phosphatidyl choline,
Phase 3
mPEG-distearoyl phosphatidylethanolamine
lipid conjugate and cholesterol
Potent topoisomerase Phospholipids covalently bound to mPEG
Phase 2
I inhibitor
Doxorubicin
Glutathione PEGylated liposomes
Phase 1

Application
Ovarian/Breast Cancer

Company
Sequus
Pharmaceuticals
(1995)
Metastatic adenocarcinoma Merrimack
of the pancreas
Pharmaceuticals Inc.
(2015)
Hepatocellular carcinoma
Celsion
Corporation
Non-small cell Lung Cancer

Regulon
Inc.

Cancer

Alza Corporation

Solid Tumors

2-BBB therapeutic

Metastatic Stomach Cancer

Mitsubishi Tanabe
Pharma Corporation

164

MCC-465
170

Doxorubicin

DPPC, cholesterol and maleimidated palmitoyl
phosphatidyl ethanolamine; immunoliposomes
tagged with PEG and the F(ab0)2 fragment of
human monoclonal antibody GAH
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Phase 1

1.4

Photosensitizers and Photodynamic Therapy (PDT)

1.4.1 Conventional Porphyrin based Photosensitizers:
This class of PS molecules have backbone structures made of four pyrroles linked by methine
bonds as shown in Fig 1-10. Porphyrinoid molecules absorb strongly at 400 nm (Soret Band)
and weakly from 600-800 nm (Q-Band). However, the Q-Band wavelength is preferred for
deep-set tumors. Based on the efficacy of these PS, they are divided as first, second and third
generation porphyrins5,6,8. However, most of the approved porphyrinoid PS makes the skin
highly photo sensitive. The evolving research in this field is focused on naturally occurring or
synthesizing new PS molecules that have low skin photosensitivity, high target specificity,
greater singlet oxygen yield, molecules absorbing in the near-infra red spectrum5,6,8.

Figure 1-10: Structure of Porphyrin

Table 1-4 lists the commercially available porphyrin compounds5,6,8 and their absorption
wavelengths

Table 1-4: List of Porphyrinoid PS
Absorption Wavelength
Compound Name

Commercial Trademark
(nm)

Porfimer Sodium

Photofrin

632

5-Aminoluvenic Acid

Levulan

632

Methyl aminolevulinate

Metvixia

N/A

Hexaminolevulinate

Cysview

N/A

Visudine

689

Meta-tetra(hydroxyphenyl)chlorin

Foscan

652

Tin ethyl etiopurpurin

Purlytin

664

Benzoporphyrin derivative
monoacid ring A

Laserphyrin,
N-aspartyl chlorin e6

664
Litx

2-(1-Hexyloxyethyl)-2-devinyl
Photochlor

665

Palladium bacteriopheophorbide

Tookad

763

Motexafin lutetium (Lu-Tex)

Lutrin,

pyropheophorbide

732
Optrin
Aluminum phthalocyanine
Photosens

676

tetrasulfonate (AlPcS4)

1.4.2 Alternative Non-Porphyrin based Photosensitizers:
Apart from the porphyrinoid PS, several chromophores have also been found to have
phototoxic properties and their potential applications in PDT have been researched upon. Most
of these fluorophores are hydrophilic in nature. Table 1-5 lists the various non-porphyrinoid
PS which are yet to be approved by the FDA for commercial use. It is interesting to note that
most of these PS can be operated in the UV - Visible region5,6,8.
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Table 1-5: Non-porphyrinoid PS and their wavelength

Absorption Wavelength
Compound Name
(nm)
Hypericin

590

Methylene blue

666

Toluidine blue

630

Rose bengal

549

Merocyanine 540

556

Curcumin

420

1.5 Hypothesis and Research Needs:
The understanding of the mechanism of binding and internalization of amphiphilic fluorophore
probes to cell membranes are very limited. To this end, the use of liposomes as model cell
membranes will be useful in predicting the mechanism. It has been demonstrated that,
amphiphilic molecules (linked with hydrophobic tail chains171–173), have better cellular uptake.
Molecules with longer hydrophobic tail chains showed better uptake, due to their ability to
penetrate deeper into the cell membrane due to electrostatic174,175, hydrophobic42,176,177and
hydrogen bonding mechanisms178,179. We hypothesize that the mechanism of binding and
internalization of the amphiphilic fluorophores to the surface of negatively charged cancerous
cell membrane180,181 is similar to that of cell penetrating cationic peptides. The peptide
hydrophobicity drives the perturbation of the cell membrane. The insertion of the amphiphilic
molecule in the phospholipid bilayer results in formation of domains and phase separation of
lipids182. This is used to predict the degree of internalization of the amphiphilic
fluorophores182,183.
In addition to this, there are not many studies that focuses on the concentration effects of
therapeutic molecules on the bilayer. There exists a need to study the effects of concentration
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variation and penetration effects of these molecules on the bilayer through a combination of
experimental methods. This would provide a validation for the MD simulation and better
explanations to predict the mechanistic aspects of permeation and membrane destabilization.
The MD simulations can only serve as a supportive data to experimental analysis as it is
difficult to predict the changes in in-vitro conditions on a computational platform.
Besides, all the major successful liposomal formulations of the previous decade have been
presented. Despite the enormous body of work done, formulations for the delivery of
photosensitizers remain very marginal. Lipids in combination with sterols and polymers have
been employed for increasing the longevity of liposomal formulations. However, the role of
concentration and polymer density in the stability of the formulations have not been
investigated for the delivery of photosensitizers.

1.6 Objectives of this work:
This dissertation harnesses the versatility of liposomes to act as a model cell membrane and as
a carrier for drug delivery to enhance the efficacy of photodynamic therapy using biophysical
techniques. The main objectives of this research are as follows:
i.

To examine the role of amphiphilicity on novel non-porphyrinoid fluorophore
interactions with model cell membranes;

ii.

Based on this information, propose mechanisms of cellular penetration and
destabilization;

iii.

To propose a suitable stable liposomal formulation by optimizing the lipid and polymer
composition biophysically for encapsulation of existing hydrophilic and hydrophobic
photosensitizers.

In this chapter, a basic introduction to liposomes and the various mechanisms involving
liposomes and drug interaction has been addressed. In addition, a review on their role as drug
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delivery carriers and the importance of PEGylated liposomes is discussed. Finally, an
introduction to photodynamic therapy has been introduced to provide the necessary background
for the following chapters.
Chapter 2 provides the discussion on the biophysical techniques used in this dissertation. The
parameters, experimental details for the specific instruments at RIT and the other collaborating
institutes have been provided.
Chapter 3 focuses on the interactions between amphiphilic amino methyl coumarin with mixed
liposomes comprising of zwitterionic dipalmitoyl phosphatidylcholine (DPPC) and anionic
dipalmitoyl phosphoserine (DPPS). DPPC/DPPS liposome mixture is used as model cancer
membranes. The amphiphilic coumarins (Cn) were designed synthesized with varying alkyl
linkage length (n= 5 to 12) represented by Cn. The effect of alkyl chain length on the model
cell membrane was investigated using a combination of biophysical techniques. The efficacy
of amphiphilic coumarins in liposomal lipid bilayers demonstrates the promise of these
molecules as a tool in the treatment of cancer.
In Chapter 4 and chapter 5, the premise of encapsulation of riboflavin to improve its
bioavailability and stability while making the clinical applications more efficient has been
evaluated. This detailed study on cellular inhibition of liposome encapsulated riboflavin-5phosphate investigation and the effect of unencapsulated riboflavin on liposome bilayers aims
to improve the efficiency of cellular delivery of riboflavin. Cell studies demonstrate high
inhibition rates for the liposome encapsulated riboflavin formulations in the presence of blue
light, despite the lower encapsulation loading.
Chapter 6 investigates the effects of chain length and molecular weight of polyethylene glycol
in liposomal formulations for the delivery of photosensitizer for potential photodynamic
therapy applications. Differential Scanning Calorimetry (DSC) studies were performed to
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demonstrate the stability of the formulations. The effects of varying ratios of the PEGylated
lipids in the phase separation of the bilayer is indicated by the changes in the melting transition
profile of the lipids. The effect of encapsulation of hydrophobic photosensitizer HPPH and the
impact on the stability of the Lipid Nanoparticles (LNPs) is correlated through the enthalpy
and thermotropic transition temperature.
Finally, chapter 7 summarizes and concludes this dissertation with future directions,
respectively. In the appendices (Chapter 8), additional supplemental information for chapter 3
and 4 has been provided. Appendix 8.1 includes the characterization data of amphiphilic
coumarin derivatives, type-A Isothermal titration calorimetry (ITC) data conducted to study
the interaction of amphiphilic coumarin with liposomes and the results of apoptosis assay of
amphiphilic coumarin. Appendix 8.2 contains the NMR characterization of riboflavin liposome
interaction. Appendix 8.3 lists the journal publications and conference disseminations
associated with this dissertation.

28

2

Methods and Biophysical Techniques

In this chapter, the principles and theory behind various biophysical techniques employed in
this dissertation are introduced. The techniques and experimental parameters for each of these
are specific to the materials used and the aim of the study and will be explicitly stated in the
corresponding chapters.
Biophysical techniques are important to quantify the physicochemical effect on cell membranes
in the presence of the foreign molecule. However, there is no one possible technique that can
give a complete information on the mechanistic view. A variety of analytical and optical
methods are being used to characterize the physicochemical properties and assess the stability
of PEGylated liposomes for in vivo studies and clinical trials are summarized. The techniques
can be classified according to the information they provide. A variety of biophysical techniques
are used in quantification of the interactions which are described as follows.

2.1 Morphological Information:
The influence of drug on the orientation of the lipids in the membrane can be obtained by
electron microscopy (EM), Phase contrast microscopy (PCM), atomic force microscopy
(AFM) and fluorescence microscopy (FM). Sample preparation in the case of EM and AFM
and presence of other dyes in FM can generate spatial and resolution artefacts184,185.

2.2 Structural Studies:
X-Ray Diffraction (XRD, SAXS, WAXS), Neutron Reflectivity (NR), Nuclear Magnetic
Resonance (NMR), Electron Paramagnetic Resonance (EPR), Atomic Force Microscopy
(AFM), Fluorescence, Differential Scanning Calorimetry (DSC), Circular Dichroism (CD) are
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the techniques that give information on the location of the drug and the changes in the
orientation of the lipid molecules in the membrane184,185.
The use of X-Ray to obtain information on the structural properties is constrained because of
the difficulty arising in crystallizing the samples resulting in lack of long-range order186,187.
NR is preferred for its accurate measurements at the solid water interfaces that is due to the
penetration power of neutrons188,189. NMR is a powerful technique that gives a complete picture
on the orientation, dynamics, and membrane topologies in the presence of a foreign molecules.
NMR exploits the protons, C13, N15 and P31 nuclei to predict the drug-membrane interaction190–
192

. EPR is relatively simple as compared to NMR as it monitors the activity of the drug (such

as folding in the case of peptides) in the presence of membranes. However, EPR requires
chemical tagging of the peptides which might interfere with the measurements193,194.
AFM provides in-depth structural characteristics in systems where peptides interactions are
considered but does not give any information on the chemical properties of the system. AFM
is usually combined with FM to get a complete picture of the membrane-peptide
interaction195,196.
Calorimetric techniques include DSC and ITC (Isothermal Calorimetry). These techniques are
extremely sensitive to the changes in the phase transition of the bilayer in the presence of a
foreign moiety. The thermographs obtained can give information on the changes in the lipid
acyl chain and membrane destabilization due to drug aggregations197,198.
Circular Dichroism is another technique that predicts the behavior of peptides, proteins, and
amino acids in the presence of lipid bilayer. This technique gives information that is useful to
predict mechanism of insertions in the bilayer and membrane destabilization199. Of the different
techniques mentioned above, this research uses Dynamic light Scattering, Fluorescence
spectroscopy, UV-Visible spectroscopy, DSC, ITC, NMR, and MD techniques for
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understanding the mechanism of interaction between bilayer and molecules. The underlying
physics beneath these techniques are elaborated as follows:
2.2.1 Dynamic Light Scattering (DLS):
DLS provides hydrodynamic diameter, polydispersity index, and zeta potential of the liposomal
solution as shown in Fig 2-1. A monochromatic light reflected in the liposomal solution gets
scattered due to the Brownian motion of the liposomes in the solution136,200–202. The motion is
related to the diffusion coefficient of the liposomes. Temperature and viscosity of the liposomal
solution also influences the size measurement. The diffusion coefficient (Dτ) is related to the
hydrodynamic radius (RH) is given by the stokes-Einstein equation203:
Dτ =

𝑘𝐵 𝑇
6𝜋η 𝑅𝐻

(1)

Where 𝑘𝐵 is Boltzmann coefficient (1.380×10−23 kg.m2. s−2.K−1), T is an absolute temperature,
and η is the viscosity of the aqueous medium. In addition to the hydrodynamic radius
measurements, this technique also generates the poly dispersity index (PDI) of the liposomes
which determines the size uniformity of the liposomes.
When an electric field is applied to a liposomal suspension, the liposomes move towards the
oppositely charged electrodes of zeta potential measurement cell. The ratio between the
velocity of motion of the particles and the electric field is called the electrophoretic mobility
(µe) which is related to zeta potential (z) by the Henry equation,
µ𝑒 =

2 𝜀𝑧𝑓(𝑘.𝛼)
3𝜂

(2)

Where ε and η are the dielectric constant and the absolute zero-shear viscosity of the aqueous
medium. 𝑓(𝑘. 𝛼)is known as “the Henry function”, where α is the radius of the particle and k
is known as the Debye-Huckel parameter, which represent the thickness of the electrical double
layer201,204.
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The zeta potential can be calculated from the electrophoretic velocity of the particles using
Helmholtz-Smoluchowski equationµ𝑒 = VpE = ζεη

(3)

where Vp is the electrophoretic velocity, ζ is the zeta potential, ε is the permittivity, and η is the
viscosity of the medium.
Another important parameter that determines the circulation ability of the PEG liposomes is
the FALT, which is derived from the zeta potential or surface charge of the liposomes 205–207.
The Zeta potential is measured using the Laser Doppler electrophoresis technique. When
PEGylated liposomes are dispersed in water and when voltage is applied, a layer of ions from
the solution strongly bind to the liposome surface forming a stern layer. This charged layer
induces loose adhesion of ions of opposite charge called the diffuse layer. The two layers
combined is called the electrical double layer. The electrical potential measured at the surface
of the electrical double layer is called the zeta potential. The FALT measurement is calculated
from the slope of the graph of the zeta potential vs Debye-Huckel parameter.

Figure 2-1: Dynamic Light Scattering graphs a) Particle size and distribution b) Zeta Potential

2.2.2 Differential Scanning Calorimetry (DSC):
Differential scanning calorimetry (DSC) is used to gain an insight on the thermal stability and
stressed induced in the lipid bilayer due to annealing and presence of peptides, and porphyrin,
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non-porphyrin amphiphilic fluorophores42,136,202,208. DSC is a thermo-analytic technique that
measures the differential heat flow from the reference pan to the sample pan. DSC measures
change in c heat capacity (Cp)as a function of temperature. Lipid molecules have characteristic
pretransition and melting temperature that is accompanied during their thermal transition from
gel to fluid crystalline transition which is endothermic in nature as shown in Fig 2-2. The nature
of the thermal transition is affected in the presence of foreign molecules in the lipid bilayer.
Change in enthalpy of transition is measured from the area under the melting transition and
mathematically represented by the following equation 42,136,201,202,208–210:
Calorimetric Enthalpy: ΔHC = ∫ 𝐶𝑃 𝑑𝑇

(4)

The change in shape of the melting peak of the lipids imply the presence of surface bound or
encapsulated therapeutic molecules. Additional information on the cooperativity of these
molecules can be obtained by computing thermodynamic parameters of the lipid-molecule
system197,198.

Figure 2-2: DSC thermograph of lipid melting

2.2.3 Isothermal Titration Calorimetry (ITC):
Isothermal Titration Calorimetry (ITC) is a useful technique to study interactions between two
molecules in a solution i.e., between a photosensitizer and a liposome. It provides information
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on the binding kinetics and the thermodynamic process associated with the interaction211,212.
Like the DSC, the ITC consists of a sample cell and a reference cell, in addition to the syringe.
Typically, two kinds of titrations are performed using an ITC- Type A and Type B. In type A,
liposome is in the cell and the photosensitizer (PS) in the syringe. In type B, the PS molecule
is in the cell and liposome is in the syringe. The refence cell contains the DI water. As the
titrant from the syringe is injected into the cell, heat is released. This heat released in the sample
cell is measured and compared with the reference DI water at isothermal conditions. The ITC
thermogram shown in Fig 2-3a, is a plot of injection rate vs time. Each spike represents one
injection. In the first few injections, the titrant is very less and gets bound to the titrate releasing
high heats. As the number of injections increase, the system gets saturated resulting in a
sigmoid curve (Fig 2-3 b). The slope of the curve gives the association constant.
The Gibbs Free energy (∆𝐺) is related to the association constant by,
∆𝐺 = −𝑅𝑇 𝑙𝑛𝐾𝑎

(5)

∆𝐺 = ∆𝐻 − 𝑇∆𝑆

(6)

Figure 2-3: Regimes in a PEG coated liposome a) Interdigitated Mushroom; b)
Mushroom Regime; c) Brush Regime
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Where R and T are the ideal gas constant and temperature, respectively. Since binding is driven
by enthalpy and entropy, it is possible to infer the entropy of binding from equation 5 and 6213–
215

.
2.2.4 Fluorescence and UV-Visible Spectroscopy:

The two different kinds of spectroscopic characterization are Fluorescence and UV-Visible
spectroscopy. Both these techniques operate in the same wavelength range of 200-800nm216.
Fluorescence spectroscopy is the measure of intensity of emission when the sample is excited
at a select wavelength. When a fluorescent molecule is excited, the electron on excitation fall
to the ground state with emission of light. This phenomenon is called fluorescence and is
exploited in many biomedical applications217,218. The property of fluorescence of a molecule
changes in the presence of other molecules, with pH and temperature. Change in fluorescence
is used to detect lipid bilayer-drug molecule interactions219. The absorption and emission
spectrum indicate the spatial position of the fluorescent molecule’s dipole in the
microenvironment, when excited by a polarized light. The subset of the fluorescent molecules
that are vertical to the direction of the polarized light absorbs the light and gets excited220,221.
The resulting emission gives information about the relative position of the fluorescent molecule
in the vertical and horizontal planes. Fluorescence anisotropy (r) is related to the intensity of
emitted light from the horizontal (𝐼𝑉𝐻 ) and vertical planes (𝐼𝑉𝑉 ) by220,221
𝐼

−𝐼

𝑟 = 𝐼 𝑉𝑉+2𝐼𝑉𝐻
𝑉𝑉

(7)

𝑉𝐻

This technique is called fluorescent anisotropy and is used extensively to understand bilayer
fluidity and bilayer interactions221,222.
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Figure 2-4: Graphical representation of excitation and emission spectra

In the case of UV-Visible spectroscopy, the sample under study, absorbs a photon in the UVVis range and gets excited from the ground state to the excited state. This absorbed light is
measured as a function of wavelength in the UV-Vis range (200-800 nm)216.

UV-Vis

spectroscopy is used to measure the efficiency of drug encapsulated in the liposomes223–
225

.Spectrometers usually have a sample holder a detector and a source of light which provides

the light of a wavelength to excite the molecule201,226.
2.2.5 Nuclear Magnetic Resonance:
NMR relies on the fact that subatomic particles, such as protons and electrons, have a quantum
property called nuclear spin, which gives two distinct energy levels when brought into a
magnetic field. This nuclear spin causes a small magnetic dipole moment, and the relationship
between this magnetic dipole moment and the nuclear spin is characterized by the
gyromagnetic ratio. The four most common nuclei to study using an NMR are 1H, 13C, 19F, and
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P. These four nuclei are also classified as having a spin of ½, meaning that the magnitude of

their magnetic moments in any given direction has only two equal, but opposite, observable
values that correspond to spin quantum numbers equal to +½ and –½ 227,228. The different kinds
of NMR are solvent suppression, One-dimensional NMR, Two-dimensional NMR and
Diffusion Ordered Spectroscopy NMR (DOSY-NMR). In this work, proton NMR and DOSY36

NMR were used to understand the interaction between lipids and PS molecules. Proton NMR
is the one of the most common types of 1D NMR that can be run. This is because the proton is
the most sensitive NMR nuclei, so samples do not need to be very concentrated to produce
spectra that have a large signal to noise ratio. As stated before, chemical shifts are a result of
the different chemical groups that surround the nuclei in being studied. Proton chemical shifts
typically lie within the range of 0-10 ppm and because the shift is dependent on the chemical
environment of the proton, they can be used to determine the chemical structure of a sample
229

. Another common type of 1D NMR is 31P NMR. Phosphorous, like proton has a spin of ½

and the 31P nuclei has 100% abundance. While this is promising, the transverse relaxation is
accelerated considerably by chemical shift anisotropy meaning that 400 MHz is the best
compromise between sensitivity and line broadening caused by chemical shift anisotropy. 31P
NMR can be used to identify the presence of Z-DNA or changes in the torsion angles involving
phosphate, and can also be used to report on the phosphate backbone
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. Diffusion ordered

spectroscopy (DOSY) is a pseudo 2D experiment and has been developed from earlier 1D
pulsed gradient spin echo diffusion NMR as a means to measure the diffusion coefficients of
molecules in solution
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. It is called a pseudo 2D experiment because while the spectrum

contains axis like other 2D experiments, the other axis is not another nucleus, but it represents
the diffusion axis. Diffusion spectra can be obtained by incrementing the areas of the gradient
pulses (q) in PFG-NMR and transforming the NMR signals amplitudes with respect to q2. The
result is diffusion ordered NMR spectroscopy (DOSY) 232.

2.3 Computational Study- Molecular Dynamics Simulation:
Molecular Dynamics (MD) is an exhaustive research tool to study the drug induced changes,
position, orientation, and effect on surrounding lipids at a molecular level233,234. It is a N-body
simulations atoms and molecules considering the macroscopic properties such as pressure,
temperature, volume, and microscopic properties such as velocities and positions of the system.
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These simulations depend on a force field for calculations. The force field is the energy field
depicting the motion of atoms and molecules. The total energy involved in the calculation of
the force field is the sum of potential and kinetic energies235,236.

Etotal = EKinetic + Upotential

(8)

The kinetic energy is calculated from the velocities of the atoms/molecules in a 3-dimensional
topology. The potential energy arises from bending, vibrational and columbic interactions in
an atom. One such force field used in simulating the interaction of particles is coarse grained
(CG) model. The common model used for lipids and proteins is MARTINI. The particle is
categorized under one of the four types based on the chemical groups present: Q-Charged, PPolar, N-Nonpolar and C-Apolar. The subtypes in each of the main type are divided based on
the hydrogen bonds and polarities (acceptor, donor, both, none). The MARTINI model is based
on a four-to-one mapping scheme, where four heavy atoms and their associated hydrogen
atoms are combined into a single CG site233–235,237. The output of the MD simulations comes in
the form of ensemble of frame. Time dependent ensemble is called trajectory, which is further
divided into canonical, micro-canonical and isothermal-isobaric ensemble. In a canonical
ensemble, number of atoms (N), volume(V), and temperature are fixed. In microcanonical
ensemble no exchange of mass, volume and temperature is allowed and isolated. In an
isothermal and isobaric ensemble, both temperature and pressure are fixed 234. However, MD
does not give accurate results due to the assumptions made in the force field methodology and
smaller relaxation times in the simulations184 and hence is used as a validation tool only.

2.4 In-Vitro Studies:
Any biophysical study requires a practical validation. This is accomplished by in-vitro studies.
In-vitro studies is the study on isolated cells and tissues from an organism.
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2.4.1 Cell culture:
Cancer cells of known origin in a cell culture flask with Dulbecco’s modified Eagle’s medium
(DMEM)

supplemented

with

10%

Fetal

Bovine

Serum

(FBS),

Streptomycin/Penicillin/Fungizone (SPF), Glutamine, Pyruvate) for 24 hr. After 24 hr., the
cells were removed and washed with 0.25% (w/v) solution of Trypsin- 0.53 EDTA to remove
residual traces of the medium. This was followed by addition of the cell culture serum to 24
well cell culture plates and 200 µl of molecules of interest. The cells were incubated for 4, 24
and 48 hr. at 37 °C at 5% CO2.
2.4.2 MTT Assay:
To evaluate the toxic nature of molecules of interest, at the mentioned time intervals, 50 µl of
5 mg/ml MTT reagent without phenol red was added to the wells. On incubation for 6 hr,
crystals were formed due to the metabolism of the living cells. The residual media was
removed, and the formed crystals were dissolved in Isopropanol/10% Triton/0.1 N HCl
mixture. The samples were placed in an EL 340 Bio Kinetics microplate reader
spectrophotometer (Bio-Tek Instruments, Winooski, VT) and the absorbance of the samples
were measured at 540 nm from which the inhibition percent was calculated. This procedure for
cell culture and MTT assay has also been reported elsewhere238–240. No phenol red was used in
the cell culture preparation consistent to our previous works238–240.
2.4.3 Apoptosis Assay:
e-Bioscience™ Annexin V Apoptosis Detection PE and 7-AAD Kits for flow cytometry were
used to measure early and late-stage apoptosis in cancer cells of known origin. The treated cells
were collected and washed with ice-cold phosphate buffered saline (PBS) followed by cells
resuspension in 100 μl of 1X Annexin V binding buffer on an ice-cold bath. 5 µl of Annexin
V was added to the 100 µl of cell suspension and incubated for 10-15 mins at room temperature.
Next, the cells were washed with ice-cold PBS and resuspended in 200 µl of 1X binding buffer.
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Then, 5 µl of 7-AAD viability staining solution was added to the cell suspension. Finally, flow
cytometry was used to detect the fluorescence of stained cells at excitation/emission maxima:
Annexin V PE® : 499/521 nm; 7-AAD® : 535/617 nm with BD FACSAria IIu High-Speed Cell
Sorter flow cytometer from BD Biosciences (Becton-Dickinson, San Jose, CA, USA).The data
were viewed and analyzed using FlowJo v10.2 software from FlowJo LLC (Ashland, OR,
USA).
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3 Interaction of Amphiphilic Coumarin with DPPC/DPPS Lipid
Bilayer: Effects of Concentration and Alkyl Tail Length
This chapter was originally published in Phys. Chem. Chem. Phys., 2020,22, 15197-15207 by
Poornima Kalyanram, Huilin Ma, Shena Marshall, Christina Goudreau, Ana Cartaya, Tyler
Zimmermann, Istvan Stadler, Shikha Nangia, Anju Gupta. In addition to the published work,
this chapter also contains ITC modelling. In this work, interactions between amphiphilic amino
methyl coumarin with dipalmitoyl-sn-glycero-3-phosphocholine/dipalmitoyl-sn-glycero-3phosphoserine (DPPC/DPPS) lipid bilayer were investigated. A combination of experimental
techniques (zeta potential, fluorescence spectroscopy, differential scanning calorimetry) along
with molecular dynamics simulations was employed to examine the influence of alkyl tail
length and concentration of the amphiphilic coumarin on the lipid bilayer. Alkyl tails
comprising of 5(C5), 9(C9), and 12(C12) carbon atoms were conjugated to amino methyl
coumarin via a single-step process. The binding and insertion mechanisms of the amphiphilic
coumarins were studied in increasing concentrations for short-tailed (C5) and long-tailed (C12)
coumarins. The simulation results show that C5 coumarin molecules penetrate the lipid bilayer,
but owing to the short alkyl tail, they interact primarily with the lipid head groups resulting in
lipid bilayer thinning; however, at high concentrations, the C5 coumarins undergo continuous
insertion-ejection from the outer leaflet of the lipid bilayer. On the contrary, C12 coumarins
interact favorably with the hydrophobic lipid tails and lack the ejection-reinsertion behavior.
Instead, the C12 coumarin molecules undergo flip-flops between the outer and inner leaflets of
the lipid bilayer. At high concentrations, the high-frequency flip-flops lead to lipid
destabilization, causing the lipid bilayer to rupture. The simulation results are in excellent
agreement with the toxicity of amphiphilic coumarin activity in cancer cells. The efficacy of
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amphiphilic coumarins in liposomal lipid bilayers demonstrates the promise of these molecules
as a tool in the treatment of cancer.

3.1 Introduction
Coumarin is a well-known, naturally occurring fluorescent compound belonging to the
benzopyrone class.241 It is well-studied for its anti-tumor and anti-inflammatory activities.242–
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Besides, derivatives of coumarin are of interest due to the high quantum yield, intense

fluorescence bandwidth and sensitivity, resistance to photochemical degradation and biocompatibility.245–248 They find applications in bio-imaging as fluorescent dyes and probes and
as chemical sensors.249–252 There have been numerous coumarin derivatives namely 7hydroxycoumarin, linear and angular pyranocoumarins, 6-7-dihydroxycoumarin, 7methoxycoumarin, aminocoumarins that have been investigated for both their diagnosing and
curative properties.253–257 Out of these derivatives, 7-amino-4-methylcoumarin (AMC) is of
importance because of the presence of electron donating amino group in the 7th position, 253,258
which can donate electrons and acts as fluorescence enhancers for probing applications with
longer wavelengths and improved intensity.259,260 The ability of 7-amino-4-methylcoumarin to
function as a therapeutic and diagnostic fluorophore probe in the treatment of cancer is of
paramount interest in this study.
It has been demonstrated that amphiphilic fluorophore probes (linked with hydrophobic tails171–
173

) have better cellular uptake. Probes with longer hydrophobic tails showed better uptake, due

to their ability to penetrate deeper into the cell membrane due to electrostatic,174,175
hydrophobic,42,176,177 and hydrogen bonding interactions.178,179 Most common hydrophobic
groups include alkyl,42,208,261 acyl,262,263 or prenyl chain.264–266

We hypothesize that the

mechanism of binding and internalization of these amphiphilic fluorophores to the surface of
negatively charged cancerous cell membrane180,181 is like that of cell penetrating cationic
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peptides. Most amphiphilic cationic peptides have reported to disrupt the cell membrane
offering a therapeutic promise.42,267–269 The cationic peptide binds to the anionic phospholipid
head group of the cell membrane through electrostatic interaction.42,208,270 Further, the peptide
hydrophobicity drives the perturbation of the cell membrane. The insertion of the amphiphilic
molecule in the phospholipid bilayer results in formation of domains and phase separation of
lipids.182 This is used to predict the degree of internalization of the amphiphilic
fluorophores.182,183
In this study, 7-amino-4-methyl-coumarin was conjugated with hydrophobic alkyl tails of
lengths 5, 9 and 12 are represented as C5, C9, C12, respectively. A mixture of 1,2-dipalmitoylsn-glycero-3-phosphocholine(DPPC))/1,2-dipalmitoyl-sn-glycero-3-phosphoserine (DPPS) in
85:15 ratio was

used to model the liposomal lipid bilayer to study the binding and

internalization of the newly designed amphiphilic coumarin fluorophores. To understand the
interaction of these fluorophores with liposomal lipid bilayer, the fluorophores were added to
the preformed liposome. This approach is in alignment with our previous works.42,136,208 The
encapsulation of these probes are being investigated for future dissemination, however it is
beyond the scope of this work.
The binding of the fluorophores to the lipid head groups was investigated using Zetasizer and
Spectro fluorometer and Isothermal Titration Calorimetry (ITC). Differential scanning
calorimeter (DSC) was used to observe the temperature induced phase transitions in the lipid
bilayer. Preliminary cytotoxicity assays were conducted using human bladder carcinoma cell
lines to test the efficacy of the amphiphilic coumarin for potential cancer applications. In
addition, coarse grained molecular dynamics (CGMD) simulations were performed to
determine the mechanism of perturbation in the lipid bilayer in the presence of fluorescent
probes with respect to the alkyl tail lengths at varying concentrations. It is observed that the
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(i) fluorophores bind to the lipid bilayer through electrostatic attraction and insert into the
bilayer by means of their alkyl tails and (ii) the degree of insertion of the fluorophore is
dependent on the alkyl tail length and its movement across the bilayer is concentration
dependent.

3.2 Experimental Methods
3.2.1 Materials and Methods
3.2.1.1 Synthesis and Characterization of Amphiphilic Coumarin
All reagents were purchased from Sigma Aldrich without further purification.
Dichloromethane solvent purification was conducted according to Purification of Laboratory
Chemicals 2nd ed. (Perrin, D. D., Armarego, W. L. F. and Perrin, D. R., Pergamon Press:
Oxford, 1980). Reactions were monitored by thin layer chromatography (TLC) supplied by
EMD Millipore Corporation, Merck (Germany). Visualization was accomplished with UV
light.
3.2.1.1.1 Synthesis:
An oven-dried round bottom flask equipped with a stir bar was charged with 7-amino-4methylcoumarin (1.0 equiv), 10 mL of dichloromethane, and the anhydride (2.2 equiv). The
solution was stirred at room temperature for 48 hours and monitored by TLC. The solution was
diluted in 15 mL of dichloromethane and washed with 3x 10 mL aliquots of 1M NaOH. The
organic layer was dried with MgSO4, filtered, and concentrated in vacuo to give the product as
summarized in Figure 3-1. The resulting C5 product was compared with previously reported
characterization data271 and the chemical structure of C9 and C12 products were fully
characterized.
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Figure 3-1: Synthesis of alkyl tail conjugated coumarin molecules of lengths: C5, C9 and C12

3.2.1.1.2 Characterization of Amphiphilic Coumarin:
The resultant white solid at 90% yield substance was characterized using 1H NMR and

13

C

NMR in d-DMSO at room temperature on Bruker 300 and 500 instruments. The chemical shifts
(𝛿) were recorded in parts per million (ppm). The infra-red (IR) spectra were recorded on
Shimadzu FT-IR Prestige-21 spectrometer using attenuated total reflectance (ATR) method.
High-resolution mass spectra (HRMS), shown in Figure 8-5, was obtained from University at
Buffalo Mass Spectrometry Facility.
3.2.2 Preparation and Characterization of liposomes:
The DPPC and DPPS lipids were purchased from Avanti Polar Lipids (Alabaster, AL). The
DPPC/DPPS (85/15 mol%) liposomes of 10 mM concentration were prepared using the steps
reported by Gupta et al.42 Invivogen endotoxin free water maintained at 45°C (average
weighted melting temperature of DPPC and DPPS lipids that constituted the lipid bilayer) used
to the thin dry film of lipids to form liposomes. The liposomes were extruded through 100 nm
polycarbonate membranes to obtain unilamellar liposomes. The extruder was kept on a
hotplate and maintained at 45°C during the extrusion process.

Amphiphilic coumarin

fluorophores were suspended in DMSO (99.9%, Fisher chemicals) at 5- and 25- mM
concentrations. The amphiphilic coumarins were added to the preformed liposomes at 25°C
and the ratio of liposomes to fluorophores were maintained at a ratio of 2:1 by volume.
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3.2.3 DLS and Zeta Potential measurements:
The DLS and zeta potential experiments were recorded using Zetasizer nano-series (Malvern
Nano-ZS). The size distribution of the liposomes was obtained by placing 1 ml of sample in
SARSTEDT polystyrene cuvettes at 25°C and at a 173° backscatter angle with 120 s
equilibration time. The size of the DPPC/DPPS liposomes was measured to be 118±2 nm. The
zeta potential measurements were made using DTS1070 folded capillary cells. The
fluorophores were added to the liposomes and the zeta potential was measured at 37°C
(physiological temperature), 43°C (melting transition of DPPC) and 55°C (melting transition
of DPPS). The zeta potential of the liposomes in the absence of the fluorophores was also
measured under the same conditions.
3.2.4 Fluorescence Spectroscopy:
The fluorescence experiments were carried out in a Shimadzu spectrofluorometer (RF-5301
PC) equipped with a xenon lamp as the light source. The intensities were measured at excitation
wavelength of coumarin at 350 nm over the range of melting temperatures (37°C, 43°C, and
55°C). The temperatures were controlled using Fisher Scientific Isotemp® water bath.
3.2.5 Differential Scanning Calorimetry:
DSC studies were performed on a Q-2000 TA instrument DSC in T-zero Hermetic pan. The
phase behavior of the lipid bilayer in the presence of these fluorophore was studied at 5 mM
and 25 mM. About 20 mg of sample was sealed using a sample press and were subjected to
five continuous cycles of annealing in the range of 25 to 75 °C at the rate of 5 °C /min, under
ultra-pure nitrogen environment at 40ml/min.
3.2.6

Isothermal Titration Calorimetry:

ITC studies were performed in a TA instrument Affinity-ITC. The temperature of the cells was
maintained at 25°C. Both the liposome solution and C9 solution was degassed. The period
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between two successive titrations was typically 200 sec. The experiments were performed, and
the resulting curves and thermodynamic parameters were calculated with the Nanoanalyze™
software (TA instruments inc.,). The two different types of titration and the concentrations of
the solutions are as follows:
i.

Type A: C9 solution in the syringe (0.5 mM), liposome suspension in the cell (0.05 mM
and 0.025 mM);

ii.

Type B: Liposome suspension in the syringe (5 mM), C9 solution in the cell (0.50 mM
and 2.5 mM).

3.2.7 Molecular Dynamics Simulations
A four-to-one Martini coarse grain (CG) mapping approach272 was adopted for C5 and C12
coumarin fluorophores. Based on the atomistic structure, CG beads were assigned (Figure 2)
PyCGTOOL was used to generate the CG models and the force field parameters for C5 (Table
S1) and C12 (Table S2) as well as their related topology files. The PyCGTOOL automates the
process of generating the CG equilibrium parameters and force constants from atomistic
molecular simulations, which significantly improves the reliability and quality of CG
models,273 The CGMD simulations of C5 and C12 molecules in contact with 85:15 DPPC/DPPS
lipid bilayer was performed using GROMACS MD package (version 2018.1).274,275 A 10×10
nm2 patch of lipid bilayer was built with 166 DPPC/29 DPPS (MARTINI_v2.0) in both leaflets
of the bilayer.276 A total of eight systems were generated, including a control (no coumarin)
and seven other concentrations of C5 and C12 (Table 3-1) coumarins. We have used the naming
convention Ci-j, where i = 5 for 12 for coumarin chain length and j is the number of coumarin
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molecules in the system. The remainder of the simulation box was solvated with explicit
standard MARTINI water. Periodic boundary conditions were applied in the three dimensions.

Figure 3-2: MARTINI CG mapping and bead types for (a) C5 and (b) C12 coumarin. Color
scheme: Head groups (red) and alkyl tails (yellow). Numbers in the bracket indicates the index of
the beads used in Tables 8-1 and 8-2

A flat-bottomed position restraint was applied in the z-direction to prevent coumarin molecules
from crossing periodic boundary and interacting with the inner leaflet.
Energy minimization was performed using the steepest-decent algorithm276 until the maximum
force on any bead was below the tolerance parameter of 10 kJmol−1nm−1. The isothermalisochoric NVT and isothermal-isobaric NPT equilibration runs were performed for 20 ns. A
semi-isotropic pressure coupling was used, and the systems were maintained at 1 bar using the
Berendsen barostat276 with time constant, τp = 4.0 ps. The temperature was maintained at 323
K by independently coupling the coumarin, DPPC/DPPS lipids and the solvent to an external
thermostat with τT = 1.0 ps.276 The neighbor list was updated every 25 steps using 1.4 and 1.2
nm for short-range van der Waals and electrostatic cutoffs, respectively. The production NPT
simulations were performed for 8 µs using a 20-fs time step. Molecular visualization and
graphics were generated using visual molecular dynamics (VMD) software.277
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Table 3-1: System details of Coumarin simulations
Number of molecules in the system
Systems

Coumarin
DPPC DPPS Water
(C5 or C12)

Control

-

332

58

8376

Ci-42

42

332

58

8376

Ci-74

74

332

58

10140

Ci-106

106

332

58

10140

Ci-138

138

332

58

10140

Ci-166

166

332

58

10140

Ci-184

184

332

58

10140

Ci-209

209

332

58

10140

3.2.8 Cytotoxicity Studies: MTT Assay
Human bladder carcinoma cells HT-1376 (American Type Culture Collection (ATCC) no.
CRL1472) were grown in a cell culture flask with Dulbecco's modified Eagle's medium
(DMEM)

supplemented

with

10%

Fetal

Bovine

Serum

(FBS),

Streptomycin/Penicillin/Fungizone (SPF), Glutamine, Pyruvate) for 24 hr. After 24 hr, the
cells were removed and washed with 0.25% (w/v) solution of Trypsin- 0.53 EDTA to remove
residual traces of the medium. This was followed by addition of the cell culture serum to 24
well cell culture plates and 200 µl of amphiphilic coumarin molecules dispersed in DMSO.
Pure DMSO was used as negative control. The cells were incubated for 4, 24 and 48 hr. at 37
°C at 5% CO2. To evaluate the toxic nature of these probes, at the mentioned time intervals, 50
µl of 5 mg/ml MTT reagent without phenol red was added to the wells. On incubation for 6 hr.,
crystals were formed due to the metabolism of the living cells. The residual media was
removed, and the formed crystals were dissolved in Isopropanol/10% Triton/0.1 N HCl
mixture. The samples were placed in an EL 340 Bio Kinetics microplate reader
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spectrophotometer (Bio-Tek Instruments, Winooski, VT) and the absorbance of the samples
were measured at 540 nm from which the inhibition percent was calculated. This procedure for
cell culture and MTT assay has also been reported elsewhere.238–240 No phenol red was used in
the cell culture preparation consistent to our previous works.238–240

3.3 Results and Discussion
3.3.1 Characterization of amphiphilic coumarin
C9 amphiphile: The C9 molecule was fully characterized using 1H NMR and

13

C NMR

techniques. The results of these techniques are reported in the appendix section (Figures 8-1
and 8-2).
C12 amphiphile: The FTIR spectra of the C12 amphiphile (Figure 3-3) showed two prominent
peaks at 2916 cm−1 and 1681 cm−1, respectively. The peak at 2916 cm−1 corresponds to C-H
stretch278 which confirmed the presence of alkyl tails, and the peak at 1681 cm−1 represents
carbonyl group (C=O) inferring the linkage of the alkyl tail to coumarin.279 This was further
confirmed by 1H NMR and

13

C NMR studies (Figures 8-3 and 8-4). The 1H NMR and

13

C

NMR showed characteristic peaks and the suitable chemical shifts (𝛿) are tabulated in Table 32. This confirmed the conjugation of the alkyl tails by carbonyl linkage (atom number (12)
=179.8) to the aminocoumarin molecule. The following abbreviations were used to explain the
multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet, and
coupling constants (J) are reported in Hertz (Hz).
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Figure 3-3: FTIR spectra of the C12 coumarin amphiphiles
Table 3-2: NMR data for C12 amphiphile
Atom Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23

C (δ)
160.8
112.5
19.4
152.7
115.2
124.3
118.3
138.1
111.9
154.8
179.8
38.3
25.6
28.6
28.9
29.6
29.3
29.3
29.3
31.9
22.7
14.1

13
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H (δ)
6.25 (s, 1H)
2.39 (s, 3H)
7.88 (d, J = 1.8 Hz, 1H)
7.77 (m, 2H)
7.45 (m, 2H)
10.31 (s, 1H)
2.34 (t, J = 8 Hz, 2H)
1.63 (m, 2H)
1.23 (m, 16H)
1.23 (m, 16H)
1.23 (m, 16H)
1.23 (m, 16H)
1.23 (m, 16H)
1.23 (m, 16H)
1.23 (m, 16H)
1.23 (m, 16H)
0.85 (t, J = 6.5 Hz 3H)
1

3.3.2 Electrostatic binding and aggregation of amphiphilic coumarin on DPPC/DPPS
liposomes
The zeta potential of the various sample was recorded at 37°C (the physiological temperature)
and 43°C and 55 °C (the melting temperatures of DPPC and DPPS lipids respectively). The
control studies of pure zwitterionic DPPC liposomes reported a zeta potential values as
0.022±0.03 mV and 0.015±0.009 mV for DPPC at 37°C and 43°C, respectively. DPPC lipid
has both negative and positive charges in the headgroup, rendering the surface charge of the
liposome neutral. Hence, DPPC liposome was taken as a negative control.
The zeta potential of Pure DMSO and all the amphiphilic coumarin compounds suspended in
DMSO were recorded to be -8.89 mV and 7.79±1.4 mV at all the above-mentioned
temperatures.
At 43°C, the zeta potential of the neutral DPPC liposomes, in the presence of C5 increased to
6.93±0.02mV, with C9 increased to 6.78±0.10 mV and with C12 increased to 7.45±0.30mV.
Since there was no significant change in the zeta potential of the DPPC liposomes (negative
control), an absence of electrostatic binding was concluded with the neutral liposome.
The zeta potential of DPPC/DPPS liposomes were recorded as -7.20 mV at 37°C, −8.3 mV at
43°C and −28.1 mV and 55°C. The apparent change in zeta potential from 43° to 55 °C is
attributed to the negative PS (phosphoserine) group of DPPS lipid. At 55 °C, the DPPC lipids
headgroups tilt owing to the tail fluidity which further exposed the negatively charged moiety
on the phosphate groups of DPPC lipids thereby altering the surface charge density.280–282
The change in zeta potential of liposomes in presence of C5, C9 and C12 at 37 °C (yellow) 43 °C
(blue) and 55 °C (red) is shown in Figure 3-4. The measured zeta potential of DPPC/DPPS
increased with addition of lower concentration (5mM) of amphiphilic coumarin and
temperature of measurement. In the presence of C5, the zeta potential yielded, 0.095 mV at
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37°C, 0.14 mV at 43°C and increased to 0.22 mV at 55°C. Similarly, with C9, the zeta potential
of the liposomes was observed to be 0.242 mV at 37 °C and 0.247 mV at 43°C, which increased
marginally to 0.257 mV at 55°C. On addition of C12 at 5 mM, a slight increase in zeta potential
was recorded at 0.268 mV, 0.272 mV and 0.28 mV at 37 °C, 43°C and 55°C, respectively. The
change in the negative zeta potential of DPPC/DPPS liposomes to a positive potential in the
presence of amphiphilic amino coumarin fluorophores confirms the electrostatic binding
between the amino coumarin derivatives and the lipid headgroups. The amphiphilic coumarin
molecules were suspended in DMSO before being added to the preformed liposomes. The pKa
of the amide moiety of the coumarin DMSO was approximated to 21.6.283 Upon addition, this
amide proton bonded with the negative groups on the lipids through hydrogen bonding that
altered the pKa environment of the amide proton to 15.6,283 because the liposomes were
prepared in DI water. It is postulated that this deviation from a less acidic environment of
DMSO to proton rich DI water resulted in the stabilization of the amide proton and aided in
the binding of the amino coumarin probes to the lipid headgroups.

Figure 3-4: Zeta Potential plots representing the interaction of fluorometric probes of a) 5 mM
concentration and b) 25 mM concentration with DPPC/DPPS liposomes at different
temperatures. Y-axis represent the change in the zeta potential of DPPC/DPPS liposomes in the
presence of C5, C9 & C12 fluorophores (x-axis)
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This trend was also observed at 37°C for 25mM (Figure 3-4b) amphiphilic coumarin added to
DPPC/DPPS liposomes (C5=0.15Mv, C9=1.98mV & C12=3.75mV). However, when measured
at 43°C and 55°C, the increased zeta potential was on the negative scale. The zeta potential of
the liposomes with C5 was measured to be −1.16 mV at 43 °C which decreased to −7.45 mV at
55°C. Similarly, with C9, the zeta potential of the liposomes was observed to be 0.206 mV at
43°C which decreased to −8.63 mV at 55°C. With C12, the zeta potential values again decreased
with temperature and were found to be -0.524 mV and -9.08mV at 43 °C and 55 °C,
respectively. This was mainly because at increased concentration of amphiphilic coumarin,
molecules exceed the critical aggregation concentration and began to aggregate.284,285 This
aggregation behavior of amphiphilic coumarin molecules is attributed to the electrostatic
attractions between aromatic rings and overlapping of the benzopyran rings.286,287 In case of
C5, formation of strong intermolecular hydrogen-amide bonding results in parallel displaced
structures that tend to form C5 clusters due to their the shorter alkyl tail,50,51 causing lesser
individual molecules to bind on the liposomes. With respect to C12, the aggregation is lower
due to the longer tails that may hinder the stacking of the rings.288,289 Furthermore, the C12 may
be inserting themselves into the bilayer as opposed to being bound on the surface, due to
increased lipid fluidity at melting temperature of lipids.290 Thus, as the lipid bilayer
permeability increases, the agglomerated fluorophore molecules enter the hydrophobic tail
region. This reduced the surface charge on the liposomes, lead to a negative zeta potential.
The aggregation effects of electrostatic binding were further confirmed by fluorescence
spectroscopy shown in Figure 3-5. For unconjugated coumarin the excitation and absorption
wavelength were noted as 350 nm and 420 nm in DMSO at 55°C, and 389.5 nm for C5 and C12
at 5 mM concentration in DMSO. The emission spectra of 5 mM C5, C9 and C12 in DMSO
(shown in black, red, and blue dotted lines in Figure 3-5a.) had an absorption wavelength (λmax)
of 386.5 nm. When added to pre-formed liposomes, absorption spectrum of C5 showed a shift
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towards higher wavelength (red shift) to 391.3 nm, C9 to 395nm and C12 (black, red and blue
line resp. in Figure 3-5a.) showed a red shift to 424.6 nm. The red shift in fluorescence of the
C5, C9 and C12 in the presence of liposomes, which is the characteristic of amino coumarins,
indicated the electrostatic binding and insertion of the C5, C9, and C12 in the lipid bilayer.219

Figure 3-5: Fluorescence spectroscopy of amphiphilic fluorometric probes at 55 OC

Shift in fluorescence occurred when the coumarin moieties experience a change from polar to
non-polar environment, indicating the insertion of the coumarin molecules in the bilayer.219
The magnitude of shift in fluorescence was more in C12 as compared to C5 and C9 because of
the longer alkyl tails that forms intermolecular hydrogen bonds with the lipid alkyl tail
regions.178,179 At 25mM concentration of amphiphilic coumarin (Figure 3-5b.), the intensity of
fluorescence was halved due to fluorescence quenching as a result of aggregation291–294 . The
inner filler effects have not been considered in this work and being investigated for future
dissemination.

3.3.3 The Effect of amphiphilic coumarin on DPPC/DPPS lipid bilayer Phase
Transition
The melting temperatures of pure DPPC and DPPS were reported as 41 °C and 53 °C
respectively42 . Amphiphilic coumarin showed a melting temperature between 150-175 °C as
opposed to unconjugated coumarin (melting ̴ 230 °C). This is because the presence of alkyl
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tails in the coumarin molecules resulted in a shift in the melting transition. The range of melting
of amphiphilic coumarin was beyond the lipid transition temperature.
The thermogram of DPPC/DPPS (85/15 mol%) showed 3 transition peaks - a DPPC rich peak
at 42.5°C, a mixed peak at 49.35 °C and a DPPS rich peak at 57.4 °C 201 (refer to Figure 8-8 in
the supporting information for DSC thermogram).
To understand the effect of DMSO on the phase transition of the DPPC/DPPS (85/15 mol%),
pure DMSO (1 mol%) was added to the preformed liposomes prior to DSC. In the presence of
DMSO, a single broad peak was recorded (refer to Figure 8-8 in supporting information for
DSC thermogram). This is because, at lower concentrations, DMSO helps in better mixing of
the lipids. It has also been demonstrated that DMSO does not disturb the bilayer conformation
at lower concentrations.295,296
Figure 3-6 represent the DSC thermograms of DPPC/DPPS liposomes in the presence of 5 and
25 mM of C5, C9, C12 at heating scans 1 and 5. In heating scan 1 (Figure 3-6a), it was observed
that on addition of 5 mM of C5 to the liposomes, a the DPPC-rich transition disappeared and a
peak was observed at the mixed domain regions 52.7 °C as compared to the thermogram devoid
of fluorophores. The peak associated with the DPPC-rich melting disappeared, this is possibly
due to better mixing of lipid domains in the presence of C5. In the fifth heating scan, the peak
that corresponded to the mixed domain transition broadened, indicating a reduction in
calorimetric enthalpy (from 46.5E-3 to 44E-3cal/g °C) as the heating scans increase. The
calorimetric enthalpy is measured as the area under the DSC peak. A decrease in enthalpy in
the mixed domain is indicative of the reduction in van der Waals force that exists between the
lipid head groups and acyl chains.297 This occurs when a molecule is present in the hydrophobic
tail region of the outer bilayer leaflet, indicating the perturbation of C5 in the tail region.297 This
was consistent with the intermediate heating scans (not shown here), inferring that the C5
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doesn’t internalize further on annealing. As the concentration of C5 is further increased to 25
mM (Figure 3-6b), there was initially formation of multiple domains in the first heating cycle,
which was assumed to be the result of probe-induced uneven thinning of the lipid bilayer at
higher concentrations.298,299 Further, with continuous annealing in heating scan 5, a clear phase
separation in the DPPC and DPPS regions was indicated by presence of two prominent DPPC
and DPPS domains and their higher enthalpy of transition (51E-3 cal/g °C). This occurs at
higher concentrations of the probe where the molecules interact with the lipid head groups and
induce disordering causing phase separation.298,299 This was also confirmed by the MD
simulation results shown in the following section.

Figure 3-6:DSC thermogram showing interaction of a) 5mM concentration of fluorophore probes
with PC/PS b) 25mM concentration of fluorophore probes with PC/PS. H.1 & H.5 indicates
heating scans 1&5 respectively

C9 probe exhibited a similar behavior to C5 probe with the enthalpies of transition reducing
from 40.17E-3 cal/g °C to 38.15E-3 cal/g °C in the first and the fifth heating cycles respectively
at 5mM concentration (Figure 3-6a). At 25mM concentration (Figure 3-6b), initially there were
no lipid domains peaks observed in the presence of C9 probes which might be a result of
forming of carpet like aggregates of C9 probes on the lipid bilayer resulting in thinning of the
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bilayer. On annealing, these probes try to insert themselves by displacing the lipid molecules
and flip-flop between the bilayer leaflets and the outer surface, which was indicated by the
presence of a prominent peak at 55 °C in the fifth heating cycle in the thermogram.
On addition of 5mM concentration of C12 to liposomes (Figure 3-6a), three peaks appeared in
the mixed domain region at 48 °C, 54.2°C and 58.6°C in the heating scan 1. These peaks
disappeared on annealing and only one single broad peak around 53 °C is seen in the mixed
domain region, in heating scan 5. This indicates that the order in the lipid acyl chains are
reduced initially due to the insertion of C12 in the bilayer in heating scan 1 and the insertion of
C12 leads to a well-mixed system of lipids in the bilayer. The transition of DPPC-rich region,
which was absent in the heating scan 1, appears on annealing with a broad transition at 39°C,
showing an increased melting cooperativity. Measurement of cooperativity or cooperativity
unit (CU) is calculated from calorimetric enthalpy300 (∆𝐻𝑐𝑎𝑙 ) which is the area under the
melting curve ,
2
6.9 𝑇𝑚

𝐶𝑈 = ∆𝐻

𝑐𝑎𝑙

(1)

𝑇1
2

where, Tm is the temperature of melting transition, and T1/2 is the peak half width.
Similarly, in the presence of 25mM concentration of C12 (Figure 3-6b), DPPC-rich domain did
not show any peaks and three broad peaks appeared in the mixed domain region at 47.2 °C and
52 °C and 57.5 °C (for 25 mM) in heating cycle 1. The mixed domains in the DSC of heating
scan 1, disappeared on annealing. A prominent narrow peak appears, in the heating scan 5,
which is accompanied with an increase in enthalpy. This is assumed to occur because C12,
owing to its longer alkyl tail length, traverses to the inner leaflet of the lipid bilayer. This
insertion of fluorophore probes caused a cavity in the arrangement of the lipid molecules, which
resulted in the narrow transition301. This cavity formation is probable consequence of the flip58

flopping of the amphiphilic coumarin molecules between the bilayer leaflets which was
confirmed by MD simulations.
3.3.4 Cytotoxicity Studies:
MTT assay was performed to assess the toxicity of these amphiphilic coumarin on cancer cells.
All the probes (C5, C9 and C12) showed a minimum inhibition (damage to cancer cells) between
15-25% at the end of 4hr. The inhibition rate increased with time and reached a maximum of
70% at the end of 48 hr. as shown in Figure 3-7.

Figure 3-7: MTT Cytotoxicity Assay in human bladder cancer cells

The cytotoxicity studies substantiate that C9 shows intermediate activity between C5 and C12.
To obtain further insight into the concentration mechanisms of these probes, MD simulations
were undertaken. We have considered to examine the activity of C5 and C12 probes only for the
MD simulations that are explained below. The binding studies to validate the driving force
behind these molecules was examined using ITC experiments and modelling, with C9 as the
reference molecule and is presented in the last section of this chapter.
3.3.5 Simulation results:
The CGMD simulations were performed to compare the lipid bilayer penetration and
partitioning behaviors of C5 and C12 in the DPPC/DPPS lipids as a function of amphiphilic
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coumarin concentration (Figure 3-8). The C5 and C12 head groups interact with the headgroups
of the DPPC and DPPS lipids, while the hydrophobic alkyl tails insert in the bilayer’s
hydrophobic core. These results are consistent with the zeta potential and fluorescence
spectroscopy studies (Figures 3-4 and 3-5). Although, both C5 and C12 insert into the lipid
bilayer, they have different effect on the lipid bilayer stability, also evidenced experimentally
in the DSC thermographs (Figure 3-6). The C5 amphiphilic coumarin insertion spans a wide
range of concentrations without bilayer disruption, however, higher C12 coumarin
concentrations (system C12-166 and higher), disrupt the lipid bilayer as observed in Figure 7d.

Figure 3-8: Side-view snapshots of the initial (upper panel) and final (lower panel) system
configurations: (a) C5-42, (b) C5-209, (c) system C12-42 , and (d) C12-209. Color scheme:
DPPC/DPPC lipid head groups (blue beads), acyl chains (grey beads); C5 and C12 head groups
(red beads), and alkyl tails (yellow beads); water (cyan dots)

To capture the effects of coumarin insertion, area per lipid (AL) and bilayer thickness (DM) of
the lipid bilayer were computed for each system.
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3.3.6 Insertion into the Lipid Bilayer:
Even though the C5 amphiphilic coumarin molecules insert in the bilayer they were seen
primarily interacting with the lipid head groups because their short alkyl tails prevented their
effective interaction with the lipid chains. The insertion of C5 coumarin molecules, however,
disrupted the lipid head-head interactions and modified the bilayer properties resulting in the
increase in AL and decrease in DM. This change in the AL and the DM is clear in C5-42 and C6166 system profiles (Figure 3-9). On the contrary, in C12-42 and C12-166 systems, longer C12
alkyl tails resulted in stable interactions with 16-carbon DPPC/DPPS acyl chains due to their
insertion in the lipid bilayer leaflet without changing the area per lipid and lipid bilayer
thickness substantially shown in Figure 8. It is worth noting that in system C12-209, the lipid
bilayer was disrupted by high concentration of C12 in this system, leading to the formation of
an aggregate C12 coumarin with lipids removed from the membrane. System C12-184 also
showed similar phenomena (data not shown for C12-184); due to disruption, the lipid bilayer
thickness failed to be a good marker for comparing the bilayer properties.

Figure 3-9: Membrane properties. Panel (a) AL and (b) DM of DPPC/DPPS versus simulation time
plots for C5-42 (solid blue) C12-42 (solid red), C5-166 (dashed blue), C12-166 (dashed red), and
control (green).

Flip-flop mechanism: Both amphiphilic coumarin C5 and C12 molecules showed dynamic
interleaflet transport or flip-flop behavior in the lipid bilayer, similar to cholesterol in the
physiological membranes.302–304 The coordinates of the each amphiphilic coumarin molecule
were recorded as it traversed between the upper and lower leaflet of the lipid bilayer during a
simulation; position of amphiphilic coumarin head group is shown for a subset of 20 randomly
selected C5 (Figure 8-7) and C12 (Figure 8-9) molecules. The C5 coumarin molecules
demonstrated three modes of interleaflet transport: one-flip to the inner leaflet (no return or
flop back to the outer leaflet), regular flip-flop (back and forth transport between the two
leaflets with short stays on each leaflet), and no-flip (remains on outer leaflet). Remarkably, C5
coumarin molecules also showed regular ejection into the solution and rapid reinsertion into
the lipid bilayer in the flip-flop plots shown in Figure S8, indicating an unstable insertion of C5
molecules. Although C12 coumarin molecules show the same three flip-flop modes (Figure 8-

7), they lack ejection-reinsertion behavior that is prominent in C5 molecules. Thus, MD
simulations concur with the DSC studies that confirm C12 coumarin molecules stabilizes in the
lipid bilayer owing to their longer carbon tails that aid in hydrophobic interactions with the
lipids in the bilayer.
Table 3-3: Flip-flop percentages of C5 and C12
C5
System

C12

≥1 flip ≥ 2 flip-flops ≥ 1 flip ≥ 2 flip-flops

(i = 5 or 12)
Ci-42

31%

0%

36%

5%

Ci-74

39%

7%

54%

16%

Ci-106

54%

11%

56%

22%

Ci-138

59%

20%

65%

30%

Ci-166

46%

7%

54%

21%

Ci-184

42%

5%

-

-

Ci-209

33%

1%

-

-
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The percentage of flip-flops in both C5 and C12 systems were computed and are summarized in
Table 3-3 (except in lipid bilayer disrupted C12 systems). It is observed that for the same
concentration, C12 systems had higher flip-flop than C5. This phenomenon is due to the
instability of C5’s in the lipid bilayer, which causes them to jump back to water or flip to the
inner leaflet, thereby reducing the probability of flip-flop within the lipid bilayer. We observed
that the flip-flop percentage is sensitive to the concentration and the highest percentage of flipflop for both C5 and C12 occurs for an optimal concentration (Figure 8-10). The plots
demonstrate that the number of flip-flops increase with the concentration of the amphiphilic
coumarin molecules, however, at very high concentrations the bilayer is saturated with
amphiphilic coumarin molecules, consequently, it either disrupts the bilayer as seen in C12
systems or causes C5 coumarin molecules to eject and reinsert at a higher frequency. This
occurs because, amphiphilic coumarin molecules insert themselves into the outer leaflet of the
lipid bilayer and then undergo a flip to the inner leaflet. This flip-flop phenomena is observed
for other amphiphilic molecules such as cholesterol305.

There are examples, where

fluorophores flip-flop between the outer and inner leaflets to achieve an equal distribution
across the bilayer.306–308
Highest flip-flop is observed with mid-range concentrations; supporting the findings from the
binding and DSC studies to concur that concentration is critical parameter for amphiphilic
coumarin insertion into the lipid bilayer.
3.3.7 ITC Modelling and Data Analysis:
The thermodynamic parameters of C9 binding to DPPC/DPPS liposomes by applying the
sequential three site model. This model is applicable because the binding and insertion of the

C9 molecule is sequential and follows these three steps as elucidated by the previous
studies309,310
i.

C9 has an electrostatic attraction to the lipid headgroups

ii.

The alkyl tails of C9 inserts itself partially into hydrophobic zone of the bilayer

iii.

The entire C9 molecule flip-flops between the bilayer leaflets

Each of these steps have a binding constant (dissociation constant- Kd, association constantKa), enthalpy and entropy change associated with it. Our preliminary results of type-A (refer
to plot in appendix B) titration are tabulated in Table 3-4 as follows. When the DPPC/DPPS
liposomes (0.5 mM) was titrated with two concentrations of C9 0.025 mM and 0.05 mM, the
resulting binding parameters are as follows:
Table 3-4: Kd and ΔH estimated for Type-A titration:

List of Variables
Kd₁ (M)
Kd₂ (M)
Kd₃ (M)
ΔH₁ (kJ/mol)
ΔH₂ (kJ/mol)
ΔH₃ (kJ/mol)
Ka₁ (Mˉ¹)
Ka₂ (Mˉ¹)
Ka₃ (Mˉ¹)
ΔS₁ (J/mol·K)
ΔS₂ (J/mol·K)
ΔS₃ (J/mol·K)

Concentration of C9 in the syringe
0.025 mM
7.38E-05
1.00E-01
1.00E-10
-1274
2547
-2052
1.36E+04
1.00E+01
1.00E+10
-4.20E+03
8.56E+03
-6.69E+03

0.05 mM
1.89E-04
8.36E-02
7.11E-06
-1030
-4998
-2343
5.30E+03
1.20E+01
1.41E+05
-3.39E+03
-1.67E+04
-7.76E+03

However, type-A titration has an inherent drawback to it. Towards the end point of the
titration, the saturation of the C9 molecules bound to the liposomes is achieved resulting in
more molecules binding to the same liposomes. Hence destabilizing the bilayer309,311,312.
However, for type-B titration, more liposomes are present for the C9 molecules, thus the
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saturation point is not reached, and the accuracy of the results is valid. The plot (Fig 3-10) and
the binding parameters for type B titration, with liposome concentration of 5 mM in the syringe
(table 3-5) are as follows:
Table 3-5: Kd and ΔH estimated for Type-B titration:
List of Variables
Kd₁ (M)
Kd₂ (M)
Kd₃ (M)
ΔH₁ (kJ/mol)
ΔH₂ (kJ/mol)
ΔH₃ (kJ/mol)
Ka₁ (Mˉ¹)
Ka₂ (Mˉ¹)
Ka₃ (Mˉ¹)
ΔS₁ (J/mol·K)
ΔS₂ (J/mol·K)
ΔS₃ (J/mol·K)

Concentration of C9 in the cell
0.025 mM
6.70E-03
6.73E-03
1.09E-02
-7945
-2198
-73.1
1.49E+02
1.49E+02
9.20E+01
-2.66E+04
-7.33E+03
-2.08E+02

0.05 mM
3.79E-03
4.71E-03
5.00E-03
-9999
-4914
-2482
2.64E+02
2.12E+02
2.00E+02
-3.35E+04
-1.64E+04
-8.28E+03

Figure 3-10: ITC data chart and corresponding modelling fit for Type-B titration with differing
C9 concentrations in the cells and 5 mM liposome concentration in the syringe

3.3.8 Thermodynamic Parameters of C9 molecules binding to Liposomes:
The total association constant, enthalpy, entropy, and Gibbs Free energy associated for type-B
titration are calculated as follows and tabulated in table 3-6:

66

𝐾𝑎−𝑡𝑜𝑡𝑎𝑙 = 𝐾𝑎1 + 𝐾𝑎2 + 𝐾𝑎3

(2)

∆𝐻𝑡𝑜𝑡𝑎𝑙 = ∆𝐻1 + ∆𝐻2 + ∆𝐻3

(3)

∆𝑆𝑡𝑜𝑡𝑎𝑙 = ∆𝑆1 + ∆𝑆2 + ∆𝑆3

(4)

∆𝐺 = −𝑅𝑇 ln (𝐾𝑎 )

(5)

Table 3-6: Thermodynamic Parameters of C9 molecules binding to Liposomes
Concentration of
C9

𝑲𝒂−𝒕𝒐𝒕𝒂𝒍
(Mˉ¹)

∆𝑯𝒕𝒐𝒕𝒂𝒍
(kJ/mol)

∆𝑺𝒕𝒐𝒕𝒂𝒍
(J/mol·K)

∆𝑮
(kJ/mol)

-TΔS/∆G

0.025 mM
0.05 mM

3.90E02
6.76E02

-10,216
-17,395

-3.4E04
-5.81E04

-14.78E03
-16.15E03

-0.0006
-1.07

The binding of molecules to liposomes is predominantly driven by entropy, predominantly
driven by the lipophilicity of the molecules. This is called the classical hydrophobic
effect313,314. However, in this case the driving force is enthalpy change. The non-classical
hydrophobic effect occurs because of differences in the water surrounding the bulk and
hydrophobic lipid bilayer315,316. The -TΔS/∆G value, which signifies the dependence of
entropy on free energy change, is negative311,314. This implies that enthalpy is the significant
driving factor behind the binding and insertion of these amphiphilic coumarin molecules. This
enthalpy driven binding is called non-classical hydrophobic effect.

3.4 Conclusions
In this study, we presented the synthesis, and mechanisms of interaction with lipid bilayers of
novel amphiphilic fluorophores consisting of amino methyl coumarin headgroup with C5, C9
and C12 alkyl tails. A detailed binding, bilayer phase transition, and MD simulation studies
reveal:
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1. The amphiphilic coumarin molecules interact with the lipid bilayer and insert
themselves into the bilayer by virtue of their alkyl tails and their driving force behind
binding is enthalpy;
2. At smaller concentrations, C12 coumarin molecules insert into the bilayer, which causes
phase separation in the lipid bilayer, however, with subsequent annealing, the insertion
of C12 results in a well-mixed system of lipids in the bilayer. This is evident by the
presence of a broader transition peak that correlates to an increased melting
cooperativity represents greater number of lipid molecules undergoing transitions. On
the contrary, C5 molecules, due to their shorter tail lengths remain on the outer leaflet
of the bilayer. Insertion behavior of C9 is concentration dependent and has a transitional
activity pattern that conforms to both C5 and C12;
3. The MD simulations confirm coumarin’s lipid bilayer penetration dependency on the
coumarin concertation. The C5 coumarin molecules penetrate the lipid bilayer, but due
to the short alkyl tail, they interact primarily with the lipid head groups resulting in lipid
bilayer thinning. At high concentrations, however, the C5 coumarins undergo
continuous insertion-ejection from the outer leaflet of the lipid bilayer. In contrast, C12
coumarins interact favorably with the hydrophobic lipid tails and undergo flip-flops
between the outer and inner leaflets of the lipid bilayer. At high concentrations, the
high-frequency flip-flops lead to lipid destabilization, causing the lipid bilayer to
rupture.
The preliminary MTT studies in conjunction with the interaction studies with the lipid bilayer
indicate the potency of these amphiphilic coumarin molecules in cancer inhibition.
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4 Interaction of Riboflavin-5-Phosphate with Liposome Bilayers

This chapter was originally published in Journal of Nanotoxicology and Nanomedicine (JNN)
3.1 (2018): 49-59 by Poornima Kalyanram, Istvan Stadler and Anju Gupta. This work was
conducted in collaboration with Rochester General Hospital.
Riboflavin presents tremendous potential as a photosensitizing agent for photodynamic therapy
(PDT) for treating microbial infection and cancer therapy. Encapsulation of riboflavin can
improve its bioavailability and stability while making the clinical applications more efficient.
Our detailed study on cellular inhibition of liposome encapsulated riboflavin-5phosphateinvestigation, and the effect of unencapsulated riboflavin on liposome bilayers aims
to improve the efficiency of cellular delivery of riboflavin. Liposomes composed of 1,2dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and cholesterol were used in this study. Cell
studies demonstrate high inhibition rates for the liposome-encapsulated high concentration
riboflavin formulations in the presence of blue light, despite the lower encapsulation lading.
Our Differential Scanning Calorimetry (DSC) confirm the incorporation of riboflavin in the
outer leaflet of the bilayer with moderate phase separation of the lipids and cholesterol which
further provides the mechanism of photoactivation and triggered release confirmed by in-vitro
studies. DSC studies also confirmed that high concentration of riboflavin that may be
encapsulated in the liposomes do not disrupt the lipid bilayer integrity.
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4.1 Introduction
A beam light at a visible or near infrared (NIR) wavelength to destroy the target cells bases
photodynamic therapy (PDT) or a photodynamic reaction involving a light-sensitive substance
(a photosensitizer) combined with the irradiation. It is emerging as a highly effective, noninvasive therapeutic approach in the struggle against cancer and other infectious diseases

317

.

Despite the significant progress and scientific reports, PDT is yet to be established as an
effective and safe technique to eradicate microbes and tumors 318. Riboflavin-5-phosphate, also
referred as vitamin B2, is a potent antioxidant and is used as a supplement in chemotherapy due
to its anti-carcinogenic properties

319,320

. In addition to the anti-carcinogenic properties,

riboflavin has also reported as a potential photosensitizer for PDT. The photosensitive property
of riboflavin has been investigated in eliminating tumor, ocular and skin and bacterial
infections

321–327

. However, the hydrophilic nature of riboflavin causes rapid clearance of the

drug in the blood stream and lowers the intracellular absorption, thereby, reducing its
therapeutic efficacy

328

. Liposome based carriers have been exploited to encapsulating

hydrophilic drugs to prevent their rapid clearance and increase their circulation time upon
administration 328–331.
Liposomes are self-assemblies of lipids, which are amphipathic in nature consisting of a
hydrophilic head and a hydrophobic tail. Liposomes are characterized by a lipid bilayer
surrounding aqueous core which self-assemble to give rise to an aqueous core 42,61. Due to this
unique structure, they are capable of entrapping both hydrophobic and hydrophilic molecules
58

. A variety of simple and economic methods such as dry film hydration, solvent exchange,

electro formation methods have been investigated to form liposomes with variable size, surface
charge, and number of bilayers17. Addition of cholesterol improves the circulation of liposomes
in the blood stream while providing the steric stabilization through increasing the rigidity of
the bilayer60. Although the efficacy of liposome encapsulated riboflavin-5-phosphate
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formulations has been reported332,333however, the effects of interaction between the freefloating riboflavin-5-phosphate, a potent riboflavin derivative on the stability of liposome
carriers remain unaddressed.
The objective of the current work is two folds, first to test the efficacy of liposome encapsulated
riboflavin riboflavin-5-phosphate in the presence and absence of blue light for their potential
application in photodynamic therapy against cancer and infectious diseases. Secondly, to gain
insight on the interaction of unencapsulated riboflavin-5-phosphate at higher concentrations on
the liposomal bilayers. Accordingly, a combination of analytical studies such as zeta potential,
DSC (Differential Scanning Calorimetry) were used to examine the electrostatic binding
between the riboflavin and lipid headgroups. DSC was used to obtain information on the
perturbations and disordering of the lipid bilayer due to the presence of riboflavin. A detailed
quantification of thermodynamic properties associated with incorporation of riboflavin within
the lipid bilayer was also conducted.

4.2 Materials and methods:
4.2.1 Materials:
DPPC (1,2-Dipalmitoyl-sn-glycero-3-phosphocholine) dissolved in chloroform was purchased
from Avanti Polar Lipids. Sigma Aldrich supplied cholesterol in powdered form. Riboflavin5-monophosphate sodium salt (98% purity) was purchased from VWR. Invitrogen Ultra-pure
distilled water was used in the preparation of Liposomes and riboflavin-5-phosphate solutions.
Table 4-1 enlists the molecules used in this study along with their chemical structure and the
properties.
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Table 4-1: Chemical Structure of molecules investigated in this study
Component

Structure

Property

1,2-Dipalmitoyl-snglycero-3-phosphocholine
(DPPC)
(MW = 734.039 g/mol)

Zwitterionic
Membrane Lipid

Cholesterol
(MW = 386.65 g/mol)

Membrane
Component

Riboflavin-5-phosphate
(MW = 456.344 g/mol)

Negatively
Charged
Fluorophore

4.2.2 Preparation of Liposomes:
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine

(DPPC),

cholesterol

and

polycarbonate

membranes were purchased from Avanti Polar Lipids (Alabaster, AL). DPPC/Cholesterol
(90/10, 10mM) liposomes were prepared by mixing the DPPC and Cholesterol in known
volumes. The mixture was left to dry under a stream of nitrogen followed by vacuum drying
for 20 minutes. The dried lipid film was re-hydrated with Invivogen endotoxin free and the
liposomes were extruded through 100 nm polycarbonate membranes to obtain unilamellar
liposomes. To prepare the riboflavin-encapsulated liposomes, the dried lipid film was hydrated
with 0.5 mM and 10 mM riboflavin-5-phosphate.
4.2.3 DLS and Zeta Potential Measurements:
DLS (Dynamic Light Scattering) and Zeta potential experiments were recorded using Zetasizer
nano-series (Malvern Nano-ZS). The size distribution of the liposomes was obtained by placing
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1 ml of sample in SARSTEDT polystyrene cuvettes at a 173° backscatter angle with 120 s
equilibration time. Zeta potential measurements were made using DTS1070 folded capillary
cells. Size and zeta potential measurements were conducted at 25 and 43°C.
4.2.4 Differential Scanning Calorimetry:
DSC studies were performed on a Q-2000 TA instrument DSC in Tzero Hermetic pan. About
20 mg of sample was sealed using a sample press and were subjected to three continuous cycles
of annealing in the range of 25 to 65 ºC at the rate of 10 ºC/min, under nitrogen environment
at 40ml/min.
4.2.5 Fluorescence Spectroscopy:
The fluorescence experiments were carried out on a Shimadzu spectrofluorometer (RF-5301
PC) equipped with a xenon lamp as the light source. The intensities were measured at excitation
wavelength of riboflavin-5-phosphate was 450 nm at 43 ºC. The temperature was controlled
using Fisher Scientific Isotemp® water bath.
4.2.6 Cell Studies and Imaging:
Human bladder carcinoma cells HT-1376 (American Type Culture Collection (ATCC) no.
CRL1472) were grown in a 1.7 cm2 cell culture well with Dulbecco's modified eagle's medium
(DMEM)

supplemented

with

10%

fetal

bovine

serum

(FBS),

Streptomycin/Penicillin/Fungizone (SPF), glutamine, pyruvate at 37 ºC and 5% CO2. After the
growing cells formed a monolayer on the wells in approximately 24 -36 hours, the cell culture
media was removed. The wells were rinsed with PBS (phosphate buffered saline) and new
media along with liposome-encapsulated riboflavin-5-monophosphate was added. The cells
were incubated for 4 hours to ensure absorption of the encapsulated riboflavin. After the
absorption, the photo-activation of liposome-encapsulated riboflavin-5-monophosphate, blue
light at 450 nm was irradiated to some of the wells. This was followed by the addition of 50µl
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of 5mg/ml MTT (2h-Tetrazolium, 2-(4,5-dimethyl-2-thiazolyl)-3,5-diphenyl-bromide) reagent
to evaluate the toxicity induced by riboflavin 5-monophosphate.
On incubation for 6 hr., the metabolism of the living cells resulted in the formation of crystals.
The residual media was removed, and the crystals were dissolved in isopropanol/10% triton/0.1
N HCl mixture. The samples were placed in an EL 340-bio kinetics microplate reader
spectrophotometer (Bio-Tek instruments, Winooski, VT) and the absorbance of the samples
were measured at 570 nm from which the inhibition percent was calculated.
To evaluate the photodynamic therapy effectiveness of the encapsulated riboflavin the
following control groups were created.
1. Absolute control: did not received any encapsulated riboflavin, light irradiation
2. Control 1: Irradiation by blue light irradiation for 10min without encapsulated RBP
3. Control 2: Received only encapsulated riboflavin (no light irradiation)
4. Control 3: Received only encapsulated riboflavin with blue light irradiation
4.2.7 UV-Vis Spectroscopy:
Encapsulation was quantified using Shimadzu UV-2501PC – High Resolution UV-Vis
Spectroscope. A calibration curve was prepared by dissolving Riboflavin-5-phosphate in DI
water. Absorbance of riboflavin-5-phosphate was recorded at 445 nm.

4.3 Results and discussion
4.3.1 Cell inhibition studies of Liposome encapsulated Riboflavin-4-phosphate
The DPPC/Chol encapsulating liposomes used for cell studies were tailored to be in the size
range of 100-200 nm based on the guidelines provided by FDA to design effective
nanocarriers160. The resultant liposomes were sized using 100 nm membranes; however, the
hydrodynamic diameter of riboflavin-5-phosphate encapsulated liposomes were measured to
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be 173 nm with a Polydispersity Index (PDI) of 0.230. This increased size and moderate PDI
arises due to the presence of unencapsulated molecules on the liposome surface that may result
in minimal aggregation. These effects of unencapsulated molecules on liposomes are
investigated in the following section.
The cell inhibition studies were conducted using 0.25, 1, 2.5 and 5 mg/ml riboflavin
encapsulated in DPPC/Chol liposomes (denoted as RBNP) in the absence (control 2) and
presence (control 3) of blue light. The encapsulation relied on the self-assembling of the lipids,
and additional encapsulation techniques such as freeze thawing were not used to prevent the
degradation of riboflavin 5-monophosphate The drug loading and entrapment efficiency of
Riboflavin-5-phosphate encapsulated liposomes were calculated by

Drug Loading(%):=

Final Concentration of Fluorophores
Initial Concentration of Liposomes

Encapsulation Efficiency (%):

×100

Conc. of drug added−Conc. of unentrapped drug
Conc. of drug added

(1)

× 100

Figure 4-1 shows around 20% or less cell inhibition rates with lower and higher concentration
Riboflavin encapsulated in liposomes (RBNP) in the absence blue light. However, the cell
inhibition rate increases to 78% with 5 mg/ml Riboflavin encapsulated liposomes in the
presence of blue light almost three times greater than the same concentration of encapsulated
riboflavin-5-phosphate treated without the blue light. The absolute control without riboflavin
and blue light showed no inhibition while control 1 showed a minimum inhibition of 0.25%.
Overall, it was observed that the inhibition rate of cancer cells increased linearly with
increasing the concentration of Riboflavin-5-phosphate in the liposomes. It is inferred that; a
combination of the higher concentration of riboflavin and blue light is necessary for a
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(2)

successful inhibition of cancer cells. Another noteworthy observation is the inhibition rate of
78% at a low encapsulation efficiency of 24%.

Figure 4-1: Inhibition of cancer cells in the presence and absence of blue light by DPPC/Chol
liposomes encapsulating Riboflavin-5-phosphate
4.3.2

Effect of unencapsulated Riboflavin-5-phosphate on Liposome Bilayers

The DPPC/Chol liposomes used to study the effects of unencapsulated riboflavin were
prepared using the same technique and were measured to be 118±2 nm in diameter with a low
PDI of 0.186. The zeta potential of the unencapsulated DPPC/Cholesterol was found to be
0.828 ±0. 50 mV congruous to the zwitterionic nature of the DPPC lipids. The measured zeta
potential of Riboflavin-5-phosphate dispersed in endotoxin free water was -2.44± 0.40 mV.
When riboflavin-5-phosphate was added to the preformed DPPC/Cholesterol liposomes, the
resultant zeta potential decreased to -6.20±3.00 mV at 43oC. This is attributed to the
electrostatic binding between the positively charged choline moieties of DPPC headgroup and
monophosphate groups of riboflavin-5-phosphate (as shown schematically in Figure 4-2). At
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Figure 4-2: Electrostatic Binding of Riboflavin-5-phosphate onto the choline head group of the
DPPC lipids

the transition temperature of the lipids (43oC for DPPC), the lipid headgroups tend to get titled
and the negatively charged surface is exposed, which further decreases the surface charge 280–
282

. This explains the decrease in zeta potential value on addition of riboflavin to the liposomes.

The thermodynamic behavior specifically, the phase transitions, subsequent enthalpy change
and resultant domain formations in the lipid bilayer in the presence of encapsulated and/or unencapsulated therapeutics is studied using Differential Scanning Calorimetry334,335. Figure 3
represents the thermographs of DPPC and DPPC/Chol (90/10) liposomes in the presence of
varying concentrations of riboflavin. When lipids are heated, they undergo a pre-transition and
a transition phase. During the pre-transition phase, the gel like lipid undergoes a rippling effect
in the tail region. On further heating, the rigid tail region of the bilayer becomes fluid in nature,
with an expansion of molecules in the head group. This happens during the melting phase and
is exhibited by a sharp peak201,336. The transition temperature (Tm) of the DPPC liposomes
occurs at 43 °C as seen by single melting peak (Fig 4-3a). In the presence of cholesterol, the
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melting peak of DPPC liposomes (Tm) broadened and shifted to a lower temperature of 40.8
°C as seen on Fig 4-3b. This is attributed to the presence of cholesterol between the alkyl chains
of the lipids that restricts the mobility of the lipid tails 337,338.
To observe the additional effects of riboflavin on the phase transition of DPPC/Cholesterol
liposomes, the samples were also subjected to annealing. Exposure to laser during
photodynamic therapy causes localized heating at the affected area to approximately 42°C and
the annealing studies conducted on DSC compares to this intermittent exposure of the light339.
The thermograph in Fig 4-3c shows the first heating cycle when 0.5 mM riboflavin was added
to DPPC/Cholesterol. Although the addition of riboflavin did not cause a significant shift in
the transition temperature, the melting peak was broadened significantly, due to the of binding
of the cationic riboflavin to the negative moiety of the DPPC lipid headgroups, which causes
perturbation in the organization of the DPPC molecules 340. We hypothesize that the broadening
of the peak is partially due to the interdigitation effect that causes the tail group of lipids to
overlap in the presence of small hydrophilic molecules236,341. Fig 4-3d line representing the
heating cycle 3, with 0.5 mM riboflavin shows a modest peak or a shoulder of the main
transition peak along with the narrowing of the main peak. The formation of such shoulder is
attributed is the characteristic to the phase separation of the lipids that arises from the insertion
of the riboflavin molecules in the outer leaflet of the lipid bilayer

342

. The narrowing of the

main phase transition peak suggests the cooperative nature of the transition which is reported
as increase in the motional freedom and collective movement of the lipid molecules343.
Effects of excessive riboflavin on the lipid bilayer was also studied by adding 10 mM of
riboflavin (corresponding to 5 mg/ml riboflavin used in the cell inhibition studies) to the
preformed liposomes. The first heating cycle (Fig 4-3e) shows broadening and a right-hand
side shift of the main transition peak of DPPC/Chol compared to Fig 4-3b. This increase in
temperature could possibly be due to the change in the surface hydration behavior of the lipid
78

headgroups by larger number of round riboflavin

340

. In the third heating cycle with 10 mM

riboflavin, however, a left shoulder appears on the main transition similar to the one observed
with 0.5 mM in Fig 4-3d representing phase separation and the narrowing of the peak is also
the indication of increased cooperativity. Thus, annealing studies confirm the absence of pore
formation and destabilization of the lipid bilayer that poses detrimental effects to the cell
membrane integrity 344. These studies substantiate the moderate disordering of the lipid bilayer
in the presence of low and high concentration of riboflavin-5-phosphate, thus, indicating the
safety of normal cells when subjected to PDT with hydrophilic fluorophores such as riboflavin.

Figure 4-3: DSC thermograph of DPPC/Cholesterol with Riboflavin-5-phosphate

A detailed quantification of the thermodynamic properties associated with cooperativity of
DPPC/Chol lipid bilayer in the presence of riboflavin is presented. Table 4-2 summarizes the
calculated calorimetric enthalpy and vant Hoff enthalpy values for DPPC/Chol in the presence
and absence of riboflavin. Calorimetric enthalpy, HC is the area under the transition peak, and
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vant Hoff enthalpy (ΔHvH) is the function of melting or the transition temperature, Tm and half
width of transition peak, ΔT1/2297 .

∆𝐻𝑣𝐻 =

4𝑅𝑇𝑚2
⁄𝛥𝑇
1/2

(3)

Table 4-2:Calculated Thermodynamic Properties

Sample Name
Pure DPPC/Cholesterol
0.5mM_H1_DPPC/Chol
0.5mM_H3_DPPC/Chol
10mM_H1_DPPC/Chol
10mM_H3_DPPC/Chol

Calorimetric
Melting
Cooperativity
Enthalpy(cal/kg) Temperature
Units *103
ΔHC
Tm (°C)
(C.U)
49.02
34.11
30.37
41.01
24.19

40.80

8.59

40.99

10.76

40.74

28.17

41.64

8.8

42

21.44

Increased
Cooperativity
compared to
DPPC/Cholesterol
Increased
Cooperativity on
annealing

The broadening of the transition peak due to the moderate lipid disordering in the presence of
riboflavin as seen in Fig 4-3c-f is accompanied by a decrease in calorimetric enthalpy of the
DPPC/Chol. With subsequent heating, the transition enthalpy further dips validating the
insertion of riboflavin in the outer leaflet of the bilayer. Cooperativity or the number of DPPC
molecules undergoing phase is the function of calorimetric and vant Hoff enthalpies. In a
unilamellar DPPC liposome of 100 nm diameter the total number of DPPC lipids is
approximately 80047, and 90/10 DPPC /Cholesterol solution consists of nearly 6.8E12
liposomes are present per ml of solution. Accordingly, 0.5 mM riboflavin corresponds to 551
molecules of riboflavin with respect to one DPPC lipid molecule and 10 mM riboflavin
represents 11153 molecules to one DPPC lipid molecule. The calculated cooperativity units on
Table 4-2 demonstrate a surge in cooperativity of DPPC/Chol liposomes with the increasing
concentration of riboflavin-5-phosphate. At 0.5 mM, riboflavin-5-phosphate molecules occupy

80

a small number of binding sites as compared to 10 mM riboflavin-5-phosphate, and the
unoccupied binding sites on the lipid decreases causing an increase in vant Hoff enthalpy.
In summary, the riboflavin-5-phosphate molecules bind electrostatically with the DPPC lipid
headgroup via weak hydrogen bond with the positively charged choline head group of the
DPPC lipids. Furthermore, DSC studies demonstrated the insertion of riboflavin molecules in
the outer leaflet of the lipid bilayer causing minimal perturbation of the lipid bilayer.
Consequently, confirming no detrimental effects of unbound and free-floating high
concentration of riboflavin on the liposome bilayers. Cancer cell inhibition studies confirmed
the PDT activity in the presence of the blue light despite lower encapsulation efficiencies of
the liposomes.

4.4 Conclusion
In this study, DPPC/Cholesterol based liposomal formulation for the encapsulation of
riboflavin-5-phosphate derivative for potential photodynamic therapy are presented. The
encapsulation resulted from the self-assembling properties of the lipids posing no detrimental
effects on the functionality of the riboflavin molecule. Despite, the lower encapsulation
efficiently of 24%, a cell inhibition of 78% was observed in the presence of blue light for high
concentration riboflavin. Cell studies also showed very low inhibition in the absence of blue
light acknowledging, the safety of non-targeted healthy cells. The effects of unencapsulated on
liposome bilayers were also studied using differential scanning calorimetry that further
confirmed the bilayer integrity and inferring the safety of unbound riboflavin on the stability
of the liposome carriers. A detailed quantification of thermodynamic properties associated with
the lipid bilayer and the presence of therapeutics was conducted.
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5 Insights on the Thermal and Physical Stability of the Modified
Polymerizable Liposomes for Improved Photoactivity

This chapter by Poornima Kalyanram, Noor Hussein, Amit Tiwari and Anju Gupta has been
accepted for publication in International Journal of Lipids, Special Issue. This work is a
continuation of Chapter 4. In this work, we have improvised the liposomal formulation detailed
in chapter 4, thereby provide increased stability for the delivery of Riboflavin.
We investigated physical steric and thermal stability effects induced by cholesterol and
polyethylene glycol (PEG) in liposomes encapsulated with riboflavin. The composition of
liposome was varied systematically to decipher the individual and combined effects of
cholesterol and PEG on the stabilization of liposomes, specially the photopolymerizable
liposomes for their potential applications in photo-treatments. Our results indicate that
inclusion of PEG in the lipids enhances the steric stabilization by adopting a brush-like regime
that prevents the agglomeration of encapsulated liposomes. A mechanistic differential scanning
calorimetry studies reveal the phase transitions and enthalpy changes in the lipid bilayer due to
the presence of cholesterol suggesting its role in regulating membrane fluidity. Supporting invitro studies confirm the efficacy of PEGylated formulations encapsulating riboflavin.

5.1 Introduction:
Liposomes or phospholipid vesicles offer several advantages in theragnostic due to their
biocompatibility345,346, ease of surface functionalization347,348, and their ability to entrap both
hydrophilic62,349 and hydrophobic drugs and targets 350,351. However, the stability and leakiness
of the phospholipid-based vesicles pose limitations for their applications in targeted delivery
that require longer circulation periods in human bodies
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352,353

. Several strategies such as

inclusion of cholesterol, photopolymerizable lipids, polymeric lipids through conjugation of
polyethylene glycol (PEG) have been exploited to overcome the poor stability of the
liposomes65,354,355. Photopolymerizable lipids consist of conjugated diynes in their alkyl tails,
that can be stimulated by UV (ultra-violet) light356,357, this aids in prevention of leakage and
sustained release of contents358–360.
The PEG molecules are known to cause steric stabilization in the liposomes. The hydrophilic
PEG chains cover the surface of the lipid bilayer and extend and stay associated with the
aqueous bulk instead of interacting with other molecules on the nearby liposomes 361,362.
Additionally, as the concentration of the PEG molecules increases in the bulk, the water
molecules balance out by diluting the bulk concentration of PEG by keeping the PEG
molecules apart, thereby preventing the agglomeration of PEGylated liposomes224,362,363. In
addition to PEG, cholesterol is also used in liposomal formulations to induce rigidity to the
bilayer to further control the inherent leakiness of the liposomes364,365. Cholesterol is also
known to regulate the fluidity, permeability and packing of the bilayer211,366. Both cholesterol
and PEG enriched liposomes have been approved by FDA for delivery of the potent drugs
including doxorubicin as (Doxil®) and irinotecan (Onivyde™)160. However, cholesterol has
shown to undergo oxidization in the presence of reactive oxygen species (ROS) resulting in the
production of cholesterol oxidation products (COPs) or derivatives of oxysterols such as 7ketocholesterol, 20α-hydroxycholesterol, 25-hydroxycholesterol, α,β-epoxycholesterol, and
7α, 7β-hydroxycholesterol, that cause atherogensis in humans364,367–372. Additionally, the
majority of the cholesterol used in commercially available and FDA approved liposomal
formulations in drug delivery and vaccine are derived from animal sources such as egg or wool
grease that poses a threat of contamination and allergies 373.
In this work, we have investigated the stability of a Riboflavin encapsulated liposomes
comprising of photopolymerizable lipid DC8,9PC lipids along with DSPE-PEG2000 and
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cholesterol. Riboflavin was used as a model photosensitizer to test the efficacy of liposomal
formulations in vitro for potential applications in Photo Dynamic Therapy (PDT)

320,322,374

.

The work primarily focused on:
(i) thermal stability of the liposomal formulations through phase transition thermodynamics
studies using Differential Scanning Calorimetry (DSC);
(ii) assessing the contributions of PEG and cholesterol in the physical stability of liposomal
formulation.
Our findings indicate that the thermal and physical stability of the liposomal formulations can
be achieved by exploiting the PEG ratio, and the choice of the lipid, thereby, eliminating the
need of cholesterol. Such cholesterol-limiting liposomal formulations can address the safety
concerns associated with the use of animal-derived cholesterol and further investigations are
warranted to determine the optimum lipid type and PEG ratio for enhanced stability for the
liposomes.

5.2 Materials and Methods:
5.2.1 Materials:
23:2 Diyne PC [DC8,9PC] (1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine) and
DSPE-PEG-2000(1,2-distearoyl-sn-glycero-3-phosphoethanolamineN[methoxy(polyethylene glycol)-2000] (ammonium salt)) suspended in chloroform were
purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol and Riboflavin-5-phosphate
sodium salt dihydrate were procured from Sigma Aldrich. Invitrogen™ RNase-free PBS Phosphate-Buffered Saline (PBS) pH 7.4 was purchased from Fisher Scientific. Invitrogen™
e-Bioscience™ Annexin V Apoptosis Detection Kit PE and 7-amino-actinomycin D (7-AAD)
components were purchased from Fisher Scientific.
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5.2.2 Preparation of Liposomes:
Lipids and cholesterol were suspended in chloroform. The lipid mixtures were dried under
ultra-pure nitrogen environment to obtain a thin film in the bottom of the tubes that were
hydrated with PBS buffer (10X) of pH 7.4. For the encapsulated liposomes, riboflavin was
suspended the PBS buffer prior to hydration of dried films. On re-hydration, liposomes were
uniformly sized by extruding through polycarbonate membrane of pore size 100 nm.
Liposomes were prepared using thin film hydration technique and sized as described in prior
literature42,136,200,202,208. Details of the formulations are given in Table 5-1. The unencapsulated
riboflavin was removed by ultracentrifugation followed by rinsing with fresh batch of PBS
buffer. The total liposome to riboflavin ratio was maintained at 20:1 by weight ratio in this
study.
Table 5-1: Details of the formulations used in the study

DC8,9PC (L1) /DSPE-PEG2000 (L2) / Cholesterol mole
ratio (mol%)

Formulation Name

90/ 10
80/ 20
87.5/ 7.5/ 5
77.5/ 17.5/ 5
90/ 10/ 0
87.5/ 7.5/ 5

L1/L2 (90/10)
L1/L2 (80/20)
L1/L2 (90/10) + Chol (5)
L1/L2 (80/20) + Chol (5)
L1/L2 (90/10) + RB
L1/L2 (87.5/7.5) + Chol (5) + RB

Riboflavin (RB)
added at
lipid: RB (20:1) w/w
ratio
NO
NO
NO
NO
YES
YES

5.2.3 Dynamic Light Scattering (DLS):
The size, polydispersity index (PDI) and surface charge of both encapsulated and
unencapsulated liposomes were analyzed using a Malvern Instruments Zetasizer by dynamic
light scattering method at 25 °C and at 173° backscatter angle with 120 s equilibration time.
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5.2.4 Differential Scanning Calorimetry:
10 µl of the liposome samples were placed in T-zero Hermetic pan. The pans were sealed with
a sample press prior to placing them on a TA Instruments Q-2000 DSC. The DSC scans were
performed in an inert nitrogen environment maintained at 40 mL/min in the temperature range
of 25 to 65ºC at a heating rate of10 ºC/min. The stability study for these formulations was
conducted using a Differential Scanning Calorimetry (DSC) for a four-week time frame. DSC
measures the specific heat capacity as a function of temperature. In this case lipids, on heating
undergo a gel to fluid crystalline endothermic transition. These transitions are detected by the
DSC and the main transition is a sharp intense peak that occurs at the melting point. The nature
of the transition is affected in the presence of other molecules338,375. Any changes in the
enthalpy of transition is measured from the area under the peak given by:
Calorimetric Enthalpy: ΔHC = ∫𝐶p𝑑𝑇

(1)

Where Cp is the heating capacity. The changes in enthalpy is an indicator of stability.
5.2.5 Apoptotic Studies:
e-Bioscience™ Annexin V Apoptosis Detection PE and 7-AAD Kits for flow cytometry were
used to measure early and late-stage apoptosis in human prostate cancer cells (DU145).Briefly, the cells were grown in cell culture media (DMEM) supplemented with 4.5 g of
glucose, 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin). The cells were grown
in cell culture flasks to form adherent monolayers and were stored in a humidified incubator
at 37 °C and 5% CO2.. , The cells were washed with PBS, seeded at a density of 5000 cells/well
in 24 well plates, and allowed to grow overnight. Next day, riboflavin encapsulated liposomes
at 200 µl volume were added to the cells. The cells were incubated overnight to ensure uptake
of the liposomes. After 24 hr, the cells were treated with UV-light to cause photopolymerization of DC8,9PC lipids and subsequent activation of the riboflavin-encapsulated
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liposomes. The cells were then collected and washed with ice-cold phosphate buffered saline
(PBS) followed by cells resuspension in 100 μl of 1X Annexin V binding buffer on an ice-cold
bath. 5 µl of Annexin V was added to the 100 µl of cell suspension and incubated for 10-15
mins at room temperature. Next, the cells were washed with ice-cold PBS and resuspended in
200 µl of 1X binding buffer. Then, 5 µl of 7-AAD viability staining solution was added to the
cell suspension. Finally, flow cytometry was used to detect the fluorescence of stained cells at
excitation/emission maxima: Annexin V PE® : 499/521 nm; 7-AAD® : 535/617 nm with BD
FACSAria IIu High-Speed Cell Sorter

flow cytometer from BD Biosciences (Becton-

Dickinson, San Jose, CA, USA).The data were viewed and analyzed using FlowJo v10.2
software from FlowJo LLC (Ashland, OR, USA).

5.3 Results:
5.3.1 Characterization of liposomal formulation: hydrodynamic diameter and
surface charge
The size and surface charge of the liposomal formulations were recorded for four weeks. It was
observed that the measured zeta potential of the formulations were in the range of 0.347±0.0075 mV or near neutral consistent to the zwitterionic nature of the DSPE lipids376.
The near constant zeta potential also confirms the absence of un-associated and excess
riboflavin in the liposomal solution. The average hydrodynamic diameters and polydispersity
indices (PDI) of the formulations measured over a period of weeks are summarized in Fig 5-1.
The size measurements studies conducted in Week 1 indicated that all the formulations were
within the acceptable size range of 70-140±5 nm at a PDI of less than 0.25±0.0005 mV
indicating the uniformity of the extruded liposomes. However, after week 4, most of the
formulations agglomerated with a significant increase in the measured average diameters. The
presence of cholesterol did not affect the size or PDI of the formulations. It is also observed
that with an increase in DSPE-PEG 2000 by 10 mol% the aggregation and dispersity of the
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particles also increased with time. It is implied that the presence of cholesterol has minimal
influence on the physical stability of the liposomes with regards to the controlling the size and
possibly their aggregation.

Figure 5-1: Size and PDI of the formulations for a) Week 1 b) Week 4

5.3.2 Differential Scanning Calorimetry-Thermal Stability Studies:
In this work, we have focussed on the stability study through thermal characterization (DSC)
technique. DSC was used to study the phase behaviour and changes in DC8,9PC and DSPE lipid
in the presence of PEG and cholesterol. The resultant changes in the melting temperature and
shape of the melting peak as summarized on Fig 5-2. The melting temperature represents the
transition from gel to fluid phase of the lipid molecules represented on the x-axis, whereas the
area under the melting peak corresponds to the calculated change in enthalpy, ΔHC = ∫𝐶p 𝑑𝑇
of the lipid formulations summarized on Table 5-2. Cp is the specific heat capacity of the lipids
plotted on the y-axis. In a lipid bilayer, the fluidity and the movement of the lipid molecules
constitute the internal energy of the system. The fluidity of the bilayer is more as we get closer
to the transition temperatures of the liposomes. This is demonstrated by the change in enthalpy.
The change in enthalpy (ΔH) is represented as follows 377,
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∆𝐻 (𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝐸𝑛𝑡ℎ𝑎𝑙𝑝𝑦) = ∆𝑈 (𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝐸𝑛𝑒𝑟𝑔𝑦) +
∆(𝑃𝑉) (𝐶ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝑥 𝑉𝑜𝑙𝑢𝑚𝑒)

(2)

The internal energy represents various molecular interactions occurring within the system.
Since the liposomal formulations were sealed in T-zero hermetic pan during the DSC studies,
the change in pressure (P) and volume (V) is considered negligible. Therefore, the change in
enthalpy depends mostly on the inter-molecular interactions such as van der Waals forces
occurring between the lipid, PEG and encapsulated riboflavin and intramolecular polar bonds.
The melting temperatures of pure DC8,9PC, DSPE-PEG , and cholesterol are reported as 45°C,
52°C and 150°C respectively.

161,378,379

. Fig 5-3a) represents the thermograms of the

formulations DC8,9PC liposomes containing 10 and 20 mol% of DSPE-PEG-2000 labelled as
L1/L2 (90/10) and L1/L2 (80/20) by mol% respectively and measured at weeks 1 and 4. A
slight decrease in the melting transition temperature of 0.43°C was observed for the
formulation L1/L2 (90/10 mol%) over the four-week period. The associated enthalpy with the
melting transition, which is also the indicator of the stability of the liposomal formulations was
computed from the area under the melting peak and tabulated in Table 5-2. Despite the
negligible shift in the melting temperature, the enthalpy of transition was found to be nearly
doubled. With increased PEG from 10 to 20 mol% in the formulation L1/L2 (80/20 mol%), a
significant shift towards a lower temperature from 43.16 °C to 41.81 °C denoted by blue lines
on Fig 2a was observed. The temperature shift was accompanied a dramatic increase in the
enthalpy by 178%. A discrepant observation in Fig 5-2b) thermograms was made in the
presence cholesterol. 5 mol% of cholesterol was added to both L1/L2 at 90/10 and 80/20
formulations to study the effects of cholesterol on the stability of the formulations. L1/L2
(90/10) + 5 mol% cholesterol had imperceptible increase in transition temperature of 0.14°C
and a decrease in enthalpy of 14.5% from week one to week four as observed in Fig 5-2b.
However, L1/L2 (80/20) + 5 mol% showed a more prominent change in the temperature from
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42. 48 °C to 43.58 °C and a significant decrease in enthalpy of 68.18% from week one to week
4. From Figs 5-2 a) and b), the L1/L2 (90/10) formulation demonstrated more consistent
thermal behaviour with regards to change in enthalpy and melting temperature in the presence
and absence of cholesterol observed in a period of four weeks. Fig 5-2c) compares the thermal
stability of L1/L2 (90/10) formulations encapsulated with riboflavin in the presence and
absence of cholesterol. A dramatic decrease in the enthalpy by 89% was noted by week 4 with
L1/L2 (90/10) encapsulated formulations. However, the same formulations impregnated with
5 mol% cholesterol demonstrated a slight change in the enthalpy and melting temperature. DSC
studies imply the role of cholesterol in acquiring thermal stability of the liposomal
formulations.
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Figure 5-2: DSC thermograms of liposomal formulations measured in weeks 1 and 4 a)
DC8,9PC:DSPE-PEG-2000 (L1/L2) at (90/10) and (80/20) mole ratios b) L1/L2 (90/10) and (80/20)
+ 5 mol% cholesterol c) L1/L2 (90/10) only + 5 mol % cholesterol, encapsulated with riboflavin

5.3.3 Apoptotic Studies:
Previous studies have extensively reported the toxicity of encapsulated riboflavin in cancerous
cells136,380–382 and the non-toxic behaviour of the lipid formulations

161,225

. This in vitro work

further delved into investigating the nature of apoptosis of encapsulated riboflavin under UV
radiation. The apoptosis was assessed using Annexin V PE and 7-AAD quadrants in DU145
cells as shown in Fig 5-3. Apoptosis is indicated by the increased intensity of Annexin V as it
bind to the phosphatidylserine in the cancerous cells383.Q1 represents dead cells by necrosis
(Annexin V PE-/7-AAD+),Q2 demonstrates dead cells by late apoptosis (Annexin V PE+/7-
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AAD+), Q3 represents early apoptosis (Annexin V PE+/7-AAD-) and Q4 represents live cells
devoid of apoptosis or necrosis (Annexin V PE-/7-AAD-)384.

Figure 5-3: Apoptosis assay using Annexin V PE/7-AAD a) Control-Cells treated with UV b) Cells
seeded with Unencapsulated Riboflavin and UV treated c) Cells seeded with Formulation L1/L2
(90/10 mol%)/RB and treated with UV d) Cells seeded with Formulation L1/L2/Chol (90/10/5
mol%)/RB and treated with UV e) Graphical representation of cell apoptosis in the four
quadrants

Control UV treated cells (Fig 5-3a) were 65.4% viable. The addition of riboflavin and
photoactivation resulted in increase in necrotic cells at 68.6% as seen in Figs 5-3b and e.
Similarly, cells treated with photoactivated formulations L1/L2 (90/10 mol%) with encapsulated
RB, and L1/L2 (90/10) + 5 mol% cholesterol with encapsulated RB showed an increase in necrotic

cells by 71.4% and 66.6% respectively as depicted in Figs 5-3c-e. Riboflavin is known to
produce reactive oxygen species (ROS) upon activation by UV radiation which are lethal to
cancerous cells7,374. The cancerous cell lines in the presence of unencapsulated riboflavin
showed a maximum necrotic rate of 68.6%. Riboflavin encapsulated photopolymerizable
formulations, showed an equal to higher necrotic rate in the same cell lines. Our previous
studies have shown that riboflavin encapsulated riboflavin formulations have >50%
encapsulation efficiency

136

. This is noteworthy as encapsulated formulations shown similar
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rate of effectiveness as free riboflavin. The necrotic rate of cholesterol based formulation L1/L2
(90/10) with 5 mol% cholesterol was found to be lower than L1/L2 (90/10) alone, which
probably attributes to the lower drug loading capacity by the liposomes in the presence of
cholesterol. This could be due to the lower reduced fluidity caused by the cholesterol molecules
in the lipid bilayer during the encapsulation process 385,386. This was also supported by our DSC
studies that demonstrated insignificant change in melting behaviour of the liposomal
formulations impregnated with cholesterol. It should also be noted that riboflavin in the
absence of photoactivation does not induce apoptotic pathways and in fact, exhibits antiproliferative/anti-migratory effects 384. The mechanism of apoptosis/necrosis by ROS produced
by encapsulated riboflavin is subject to further research.

5.4 Discussion:
5.4.1 Physical steric stability:
Agglomeration of liposomes is a key issue in drug delivery and vaccine design that can be
addressed through electrostatic and steric stabilization shown schematically in Figs 5-4a and
b. Another key requirement is their longer circulation times which can be achieved by
rendering electrostatic stabilization that may be achieved by employing zwitterionic or
uncharged surfaces to prevent their adherence to charged plasma proteins in vivo 71. This work
focused on using zwitterionic lipids to create liposome formulations, and to address the
agglomeration issues, PEGylated lipids were incorporated. The incorporation of conjugated
PEG or PEGylated lipids in liposomal formulations prevented the overall agglomeration as
seen from the size measurements. PEG chains are grafted to the surface of the liposomes on
one end and based on their concentration and density they result in mushroom or brush-type
configuration as depicted in Fig 5-4.
At lower concentrations, the PEG chains do not interact with each other and assume a
mushroom-like random coiled configuration shown in Fig 5-4c. With an increasing
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concentration, the mushroom regime transitions to brush regime in which the PEG chains begin
to uncoil or branch out and interact with each other as shown in Fig 5-4d. The transition from
mushroom to brush regime happens when the following condition is fulfilled74.
𝐴

𝑋𝑝𝑚→𝑏 > [𝜋𝑎 1 2 ]𝑛𝑝−1.2

(3)

𝑚

Where 𝑋𝑝𝑚→𝑏 is the mole fraction of PEG; for PEG lipids with chains of molecular weights
2000 (np=45) is presumed to occur at 0.014.
A1 is the membrane surface area per lipid molecule74.
Brush regime is preferred for drug delivery application for steric stabilization and longer
circulation time387–389. However, when the concentration of PEG chains in the brush regime
increases the surrounding aqueous layer dehydrates resulting in aggregation390. This is

Figure 5-4: Schematic representation of a) steric stabilization of liposomes, b) electrostatic
stabilization via opposite charges , c) mushroom regime with coiled PEG chains , and d) brush
regime with extended PEG chains
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observed in when the concentration of PEG lipids is increased from 10 to 20 mol% in LI/L2
(80/20 mol%) formulation, which aggregates after four weeks.
The hydrophilic nature of the elongated PEG chains in the brush regime tends to interact more
with aqueous bulk than with the other grafted PEG chains of neighbouring liposomes, thereby
preventing the agglomeration of the liposomes. The steric stabilization, 𝑊(ℎ)𝑠𝑡𝑒𝑟𝑖𝑐 between
two liposomes of rendered PEG chains in brush regime of thickness Lb is quantified by
𝑊(ℎ)𝑠𝑡𝑒𝑟𝑖𝑐 =

100𝑅𝐿2𝑏
𝜋𝑠3

𝑘𝐵 𝑇𝑒𝑥𝑝(

−𝜋ℎ
𝐿𝑏

…(4)

)

where kB is the Boltzmann constant, Lb = (NEO × l5/3 /s 2/3). NEO is the number of monomers in
the PEG chain, l is the effective segment length and s is the distance between the grafting
points391.
5.4.2 Thermal stability:
The presence of DSPE-PEG2000 at 10 mol% in L1/L2 (90/10) formulation enabled the steric
stabilization of DC8,9PC vesicles as evidenced by the size and zeta potential measurements in
Fig 1, which is further supported by previous studies 161.
The enthalpy of transitions which quantifies the inter and molecular interactions, was found to
increase in L1/L2 (90/10) and L1/L2 (80/20) formulations from week 1 to 4 with an
accompanying decrease in the melting transition temperature as shown in Fig 5-2a. This is
attributed primarily to the interaction and subsequent entangling of PEG chains which further
increases the van der Waals forces. The energy required to overcome this van der Waals forces
which is represented by an increase in enthalpy. Based on the DSC studies, it is noteworthy
that increased concentration of PEGylated lipids from 10 to 20 mol% in the liposomal
formulation, the resultant enthalpy of transition increases due to intermolecular interactions
between the various lipid bilayer components.
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Fig 5-2b) summarizes the combined effects of cholesterol and PEG on the thermal stability of
the liposomal formulations. In L1/L2 (90/10) mol%, for every DSPE-PEG lipid there are 114
DC8,9PC lipid molecules. When 5 mol% cholesterol is added, there are 2 cholesterol molecules
per one PEG molecule. It is implied that the addition of cholesterol to PEGylated lipids render
thermal stability to the lipid bilayer owing to their known stabilizing properties of the
liposomes. This is could possibly due to the lowered molecular interactions between the lipid
components in presence of cholesterol in the lipid bilayer. Cholesterol, being hydrophobic gets
incorporated in the bilayer region of the liposomes that results in an reorganized packing and
respacing of lipids in the bilayer386,392 limiting the interaction among the PEG chains which in
turn lowers the van der Waals force
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.This results in a slight increase in melting transition

temperature is accompanied by a decrease in the enthalpy. Additionally, the presence of PEG
and cholesterol also induce heterogenicity to the bilayer, resulting in a lateral phase
separation338,394 which is supported by the broadening of melting peaks mostly seen during
week 4 measurements indicated by blue lines on Fig 5-2b.
DSC and size analysis indicated the stability of DC8,9PC/DSPE-PEG2000 (90/10) with and
without 5 mol% cholesterol, which were further encapsulated with riboflavin. The riboflavin
encapsulated formulations in absence of cholesterol showed an enormous change in enthalpy
suggesting major intermolecular events in the lipid bilayer as seen on Fig 5-2c. This is
attributed to the hydrophilicity of riboflavin that results in their encapsulation in the aqueous
core and bound on the hydrophilic headgroup region of the bilayer that further increases the
spacing and packing between the lipids136. The presence of cholesterol, however,
counterbalances this lipid disorganization due to riboflavin binding consequently reducing the
molecular forces responsible for the enthalpy change. Additionally, it is proposed that the
presence of riboflavin in the aqueous core also prevents the entanglement of PEG chains in the
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formulation further reducing the interactions between the PEG groups thereby concurrently
reducing the enthalpy change in encapsulated formulations.

5.5 Conclusion:
The present study elucidated the distinct roles played by cholesterol and PEG in liposomal
formulations by investigating varying concentration of each of the components in photopolymerizable liposomes in the presence and absence of encapsulated riboflavin over a
duration of four weeks. Following conclusions can be drawn based on the combined
experimental and mechanistic studies:
a) PEG chains extend outward creating a layer around the liposomes that creates a steric layer
that prevents liposomal agglomeration as supported by the lower polydispersity index, small
hydrodynamic diameters, and surface charge measurements
b) Inclusion of cholesterol with PEGylated lipids at lower ratios lowers the overall enthalpy
change arising from intermolecular interactions indicating the role of cholesterol in minimizing
the molecular interactions and probably the bilayer fluidity
c) Encapsulated riboflavin further stabilized the formulations as confirmed by changes in the
specific heat capacity and transition temperatures of the formulations
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6 Thermotropic study of polyethylene glycol-based lipids on the
stability

of

HPPH-encapsulated

photoactive

Lipid

Nanoparticles (LNP)
This chapter is prepared by Poornima Kalyanram, Anu Puri and Anju Gupta for submission to
an internationally recognized journal. This work is in collaboration with National Institutes of
Health. In this work, we present the effects of size and ratio of polyethylene glycol (PEG) in
photo-polymerizable lipids based liposomal formulations for the delivery of photosensitizer for
potential photodynamic therapy applications. We also demonstrate a remarkable reduction in
liposomal size and improved monodispersity due to the presence of hydrophobic HPPH
photosensitizer in the lipid bilayer. Differential Scanning Calorimetry (DSC) studies were
performed to demonstrate the stability of the formulations. The effects of varying ratios of the
PEGylated lipids in the phase separation of the bilayer is indicated by the changes in the melting
transition profile of the lipids. The effect of encapsulation of hydrophobic drug and the impact
on the stability of the Lipid Nanoparticles (LNPs) is correlated through the enthalpy and
thermotropic transition temperature.
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6.1 Introduction
Liposomes or lipid nanoparticles are the self-assemblies of lipids in aqueous environment. Due
to the presence of hydrophobic and hydrophilic regions, they can be used to encapsulate a
variety of molecules. However, liposomes are susceptible to leakage and aggregation64 hence
stability of liposome is an important consideration for their applications in drug delivery346,395
and vaccine design63,396,397. The headgroup and the chain length of the constituent lipids
influences the overall packing , surface charge of the lipid bilayer and the stability of the
liposomes or lipid nanoparticles (LNP’s)398,399. An approach to overcome the leakage is to
crosslink the acyl tail chains of lipids. Partial polymerization of lipid tails prevents the leakage
of liposomal contents. The lipid tails are activated in the presence of light of a suitable
wavelength to release the contents in the organ of interest400,401. Further, steric stabilization to
prevent aggregation can be achieved by coating the surface of LNP’s by polyethylene glycol
(PEG), polyvinyl alcohol (PVA)402,403, polylactic acid (PLA)404,405, and polyglycolic acid
(PGA) polymers406,407 and block co-polymers408,409. Amongst these, only PEG polymer has
shown an efficient and lasting steric stabilization407,409.
DC8,9PC (1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine) is phospholipid which
contains polymerizable diacetylene linked to the tail
photopolymerizable

lipid

that

assembles

into

chains410. DC8,9PC is a

tubule-like

structures

in

aqueous

environment411,412. It is observed that DC8,9PC forms vesicle-like structures in the presence of
matrix phospholipids like DPPC and other polymeric lipids like DSPE-PEG. The photoactivation of these liposomes results in release of the encapsulated molecules225,357,413,414. Our
recent work demonstrated the inclusion of only PEGylated-DSPE lipids along with DC8,9PC,
in the absence of any matrix or helper lipids, resulted in formation of LNPs resulted in the
formation stable vesicular lipid nanoparticles (LNP’s) structures in the nanometer size range161.
This unique lipid packing was found to be dependent on the included mole ratios of the
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pegylated lipids (DSPE-PEG), with optimal concentrations of up to 20 mol%. Furthermore,
these LNP’s composed of this polymeric, DC8,9PC along with DSPE-PEG2000 successfully
encapsulated of the photodynamic therapy (PDT) drug, 2-[1-hexyloxyethyl]-2-devinyl
pyropheophorbide-a (HPPH) at relatively high concentrations. HPPH is a well-known
hydrophobic photosensitizer, which has demonstrated faster skin clearance and deeper tumor
penetration at lower dosage rates as opposed to various other FDA approved
photosensitizers415–417.
These LNP formulations were found to be stable at room temperatures and in the presence of
serum components. The HPPH-loaded LNPs exhibited remarkable PDT efficiency and animal
survival compared to the current formulations being tested in the clinical trials161. (Patent
application, NIH E-154-2018; PCT/US2019/041464).These LNP have been demonstrated to
have biomedical applications for enhanced drug delivery161,418 .
Inclusion of hydrophilicity of the PEGylated lipids in LNP’s induces stealth protection and
stabilization preventing the attachment of macromolecules from the blood stream thereby
resisting phagocytosis104,110,419–421. PEGylation also increases the packing order in the
headgroup and the bilayer region108,422–424. It is also assumed that PEG molecules attract water
and as a result form a steric barrier to the adherence of other macromolecules425–427. The
PEGylated lipids usually assume mainly two conformations namely mushroom and brushes
within the lipid bilayer based on their density. At lower PEG concentrations, the lipid head
groups do not interact and follow random configurations, described as mushroom
configurations. In contrast at high concentrations of PEG lipids, the surface associated
mushrooms begin to overlap and transitions to brush conformations which results in expansion
of membrane area due to the lateral pressure exerted by the brush conformations109,393,428.
The thermal transitions in a lipid bilayer indicates the fluidity of the bilayer which has been
widely studied using Differential Scanning Calorimetry (DSC)341,375,429. DSC has also been
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used to study the encapsulation, stability, and thermal stresses of the liposomes. DSC is a
sensitive technique which detects the changes to the pre-transition and the transition peak
exhibited by the melting of lipids in the bilayer345,430. The composition of the constituent lipids
in the LNP changes the thermal stresses of the system and affects the nature of the transition
peaks. In addition, presence of encapsulated foreign molecules such as drug and protein in the
bilayer has an impact on the thermogram42,136,200,202. These factors influence the shape of the
thermogram and thereby the thermodynamic parameters of the liposomal formulations are
calculated.
In this study, we investigated the steric stabilization and effects on lipid packing exerted by the
DSPE-PEG lipid when mixed with DC8, 9PC lipids at various ratios between a 1 and 50 mol%.
The effects of varying molecular weights of PEG, MW= 1000, 2000 and 5000 is also reported.
An extensive thermal analysis of the liposomal formulation encapsulating HPPH was
conducted to study the phase changes and segregation of the lipid bilayer, quantify the
thermotropic properties such as enthalpy (ΔH) and transition temperature (Tm) to test the
stability of the formulations. This work provides a mechanistic understanding of the increased
stability of the liposomal formulations in the presence of PEG. The novelty of the work lies in
providing an insight on the effect of molecular weight and molar ratios of PEGylated lipid
DSPE-PEG in a lipid bilayer comprising of a photopolymerizable lipid DC8, 9PC. The
experimental investigation on the effect of stability by varying the molecular weights of DSPEPEG in a photo-polymerizable liposome formulation has not been reported elsewhere.
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6.2 Experimental Methods
6.2.1 LNP Formulations
(a) Materials Used:
The lipids used in this study were purchased from Avanti Polar Lipids- DC8,9PC (1,2bis(10,12-tricosadiynoyl))-sn-glycero-3-phosphocholine (cat# 870016); DSPE-PEG1000 (1,2distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
(ammonium

salt),

cat#

880720);

DSPE-PEG2000

glycol)-1000]

(1,2-distearoyl-sn-glycero-3-

phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt), cat # DSPEPEG2000));

DSPE-PEG5000

(1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-

[methoxy(polyethylene glycol)-5000] (ammonium salt), cat # 880220). HPPH (2-[1hexyloxyethyl]-2-devinyl pyropheophorbide-a) was synthesized by Dr. Gary Pauly (Chemistry
Core, Chemical Biology laboratory, CCR). HBS buffer of pH 7.4 of reagent grade was used.
(b) Preparation and Characterization of LNP’s:
Lipids suspended in chloroform were mixed in glass tubes. Details of various formulations are
provided in Table 6-1. To prepare HPPH containing LNP’s, known volumes HPPH solution
(in DMSO) were added to the lipid mixtures prior to making the films. LNP’s were prepared
at 5 mg total lipid/ml in HBS, pH 7.4. Lipid suspensions were subjected to at least 5 freezethaw cycles and sonicated using a Probe sonicator (Branson Sonifier, Microtip probe, Fisher
Scientific; 5-10 cycles, 1 minute per cycle followed by 1 minute of rest) using an ice bath.
Unincorporated HPPH was removed by low speed centrifugation and LNP’s in the supernatant
were analyzed by dynamic light scattering (DLS).
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Table 6-1: LNP’s Formulations used in this study

DC8,9PC: PEGylated
lipid mole ratio

Liposomal (LNP)
Formulation*

PEGylated lipid
Type

100:00

DC8,9PC only

None

HPPH
Added
(20:1 lipid:
drug w/w)
NO

90:10

DC8,9PC /1K (10)

DSPE-PEG1000

NO

99:1

DC8,9PC /2K (1)

DSPE-PEG2000

NO

95:5

DC8,9PC /2K (5)

“

NO

90:10

DC8,9PC /2K (10)

“

NO

80:20

DC8,9PC /2K (20)

“

NO

50:50

DC8,9PC /2K (50)

“

NO

99:1

DC8,9PC /5K (1)

DSPE-PEG5000

NO

90:10

DC8,9PC /5K (10)

“

NO

80:20

DC8,9PC /5K (20)

“

NO

90:10

DC8,9PC /1K (10)

DSPE-PEG1000

YES

90:10

DC8,9PC /2K
(10)/HPPH
DC8,9PC /2K
(20)/HPPH
DC8,9PC /5K
(10)/HPPH

DSPE-PEG2000

YES

DSPE-PEG2000

YES

DSPE-PEG5000

YES

80:20
90:10

*The numbers in parentheses indicate the mol% of PEGylated lipid in the liposomal formulations added

6.2.2 Dynamic Light Scattering
Liposomal formulations containing PEGylated lipids and DC8, 9PC were suspended by probe
sonication and diluted in HBS at either 1:20 or 1:40 (v/v) ratios. The size and dispersity index
of the liposomes in the sample was measured using a Malvern Zetasizer (NANO ZS, Malvern
Instruments, CA, USA).
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6.2.3 Differential Scanning Calorimetry
DSC studies were performed on a TA Instruments Q-2000 DSC. 10 microliters of the sample
were placed in T-zero Hermetic pan and sealed using DSC sample press. The samples were
scanned from 25 to 75ºC at a heating rate of 10ºC/min in an inert nitrogen environment
maintained at a flowrate of 40 mL/min.

6.3 Results and Discussion:
6.3.1 Size and surface charge of the LNPs:

Figure 6-1: Size and PDI of a) LNP formulations prepared without HPPH; b) LNP’s formulations prepared
in the presence of HPPH (20:1 w/w, lipid: drug ratios, ref. Table 1)

Fig 6-1 indicates the average particle hydrodynamic diameter and polydispersity indices (PDI)
of the liposomal formulations with (a) and without (b) encapsulated HPPH corresponding to
the ones enlisted on Table 6-1. The results were reproducible from at least three independent
experiments.
DC8, 9PC lipids have reported to form larger tubular structures in aqueous solutions which is
consistent with the large particle size of 1580 nm with a PDI >1161,367. Upon the addition of
PEGylated DSPE to DC8, 9PC lipids, the measured diameter of the resultant LNPs sizes reduced
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from 1580 nm to the range of 50 to 110 nm with lower PDIs between 0.2 and 0.45. This 9396 % reduction is size and induced uniformity in the particle diameters is attributed to the
inclusion of DSPE-PEG in the tubular DC8, 9PC bilayer. Owing to the large hydrophilic head
group, DSPE-PEG, induces curvature in the tubular morphology at smaller concentrations.
With an increase in concentration of DSPE-PEG, the outer layer of the tubular bilayer is
increased resulting in a favorable shape transformation i.e., the formation of vesicles.(Fig 61a)425,431–433. It is also observed that the formulations with 10 mol% DSPE-PEG in the case of
1K and 5K DSPE- PEG and 10 mol% and 20 mol% DSPE-PEG2000 are found to be uniformly
monodisperse. Since these formulations were found to be monodisperse and within the
acceptable nano-carrier size range of 70-200nm434,435, they were used to encapsulate
hydrophobic drug HPPH. Fig 1b represents the change in hydrodynamic diameter and PDI of
the selected formulations. The encapsulation of hydrophobic HPPH is seen to further reduce
the average diameter of the LNPs representing an overall 5-15 % in size reduction at lower
PDIs of 0.2. This is attributed to the tighter packing of the lipids induced by the presence of
HPPH. The presence of donor hydrogen electrons in the porphyrin ring of HPPH molecules
forms intermolecular bonds with acceptor oxygen atoms on the glycerol moiety in the lipids.
An in-depth mechanistic study of the influence of varying concentration of HPPH in the lipid
bilayer is under investigation. Preliminary studies indicate that higher concentrations of HPPH
molecules in the bilayer leads to stronger bilayer packing and thus increases the stability of
the lipid bilayer 425,431,436,437
6.3.2 Thermal analysis of the LNPs
The scope of the current work it to investigate the changes in thermotropic phase behavior of
DC8,9PC liposomes in the presence of DSPE-PEGylated lipids. The influence of varying
concentration, molecular weights of PEG, and the presence of hydrophobic HPPH on the lipid
segregation that leads to phase separation and domain formation in the lipid bilayer was
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observed by DSC. Further quantification was performed by analyzing melting peak and
calculation of associated enthalpy. The melting temperatures of pure DC8,9PC is 45 ˚C, pure
DSPE-PEG dispersions (irrespective of molecular weight) was 52 ˚C and porphyrin
photosensitizers degrade around 200-300 ˚C378,438,439.
6.3.3 Effect of lower molecular weight DSPE-PEG (1000 & 2000) on Phase
Transitions of DC 8,9 PC/PEG- DSPE LNPs without HPPH:
Fig 6-2 shows the DSC thermogram of DC8, 9PC/DSPE PEG 2000 with varying DSPE PEG
2000 concentrations.

Figure 6-2: The DSC thermograms of DC8, 9PC/DSPE-PEG 2000 LNPs varying in PEG lipid
concentrations

Fig 6-2a. shows the thermograms of the formulation measured at the end of week 1 that shows
a clear shift of the main melting transiting peak towards lower temperature with increased in
mole ratio of PEG-2000 associated DSPE lipids. Pure DC8, 9PC liposomes show a melting peak
(Tm) at 45˚ C with a small pretransition peak around 38˚C (shown in black) which is reported
to occur due to the melting of the characteristic tubular microstructures of DC8, 9PC that are
formed at lower temperatures440. These microtubular structure were observed during the size
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analysis as shown earlier in Fig 6-1a. In the presence of 1 mol% of DSPE-PEG2000 lipid (red),
no significant change was observed except a slight broadening of the melting peak compared
to pure DC8, 9 PC. However, at 5 mol% DSPE-PEG2000, a very sharp melting peak at a slightly
lower temperature of 43.97˚ C with larger heat capacity was observed in addition to the
disappearance of the small peak at 38 ˚C. On further increasing the DSPE-PEG2000
concentration to 10 mol%, the main transition peak broadened and shifted to 42.87 ˚C. With
subsequent addition of DSPE-PEG2000 at 20 and 50 mol%, the main transition peak began to
diminish while shifting towards lower temperature. The thermographs for the corresponding
formulations in the week 4 on Fig 6-2b showed similar trends however, with reduced
prominence of the melting peak. We also observed that at the end of 4 weeks (Fig 6-2b.), except
for formulations (2K (5) & 2K (10)), all the other formulations were devoid of significant
enthalpies of transition. Further quantification of the melting behavior was performed by
calculating the area under the peak or the enthalpy of transition and the half width of transition
that reflects the nature of the transition. The nature of the transition is affected by the
constituent lipids molecules (DSPE-PEG and DC8, 9PC) in the bilayer. The presence of foreign
molecules (HPPH) and their effect on the cooperativity of the bilayer in undergoing a transition
is also indicated by the enthalpy and the half-width of transition202,341,429.
In week four, formulation 2K (5) has a 66% decrease in enthalpy with broadening of the Tm
peak and a transition shift to 42.96 ˚C. Similarly, 2K (10) exhibited a 61% decrease in enthalpy
with negligible change in Tm. This decrease in enthalpy after four week is possibly due to the
steric exclusion experienced by the overlapping of the grafted PEG on the head groups leading
to the dehydration of the lipid bilayer441,442. This results in disrupting the bilayer surface, which
is represented by the widening of the peak.
The addition of DSPE-PEG2000 lipid to DC8, 9PC in the examined range (1 mol% to 50 mol
%), during the formation of LNP’s, decreased the transition temperature and altered the
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associated enthalpy of transition of DC8,9PC bilayers as reported in Table 6-2. Table 6-2
enlists the thermodynamic properties associated with the melting peak observed in Figs 6-1a
and b.
Table 6-2: Calculated Thermodynamic Parameters
Week 1
Sample
Name

Transition
temperature
˚C (Tm)

Enthalpy of
transition
(J/g ˚C)

DC8,9PC
1K (10)
2K (1)
2K (5)
2K (10)
2K (20)
2K (50)
5K (1)
5K (10)
5K (20)

45.09
42.42
45.19
43.97
42.87
42.04
41.66
42.06
42.06
43.17

3.6
1.18
4.55
8.54
8.66
2.5
0.8
3.33
6.08
0.49

Week 4
Half
Transition Enthalpy of
Half
Width of temperature transition
Width of
Transition
˚C (Tm)
(J/g ˚C)
Transition
(∆T1/2)
(∆T1/2)
1.67
41.67
2.05
2.4
2.8
42.66
0.81
2.1
4.02
41.9
0.626
2.89
1.37
42.96
2.9
2.28
2.03
43.02
3.4
2.02
2.5
41.17
0.74
2.94
1.65
No peak Observed
1.92
44.11
1.69
1.3
1.99
42.92
1.24
1.93
4.76
42.79
0.627
2.18

According to the first law of thermodynamics, ΔH(Enthalpy) = ΔU (Internal energy) + Δ(PV);
since pressure and volume remains constant in a DSC cell, enthalpy then becomes equal to
internal energy. Internal energy corresponds to the energies including translational kinetic
energy, vibrational and rotational kinetic energy and potential energy arising from
intermolecular forces at microscopic level377.The motion of lipids is affected by temperature
which results in change in the internal energy and thus impacting the enthalpy.
The change in enthalpy observed in Table 6-2 occurs due to lateral separation of lipids induced
by the presence of DSPE-PEG lipids394,443 in the DC8, 9 PC bilayer. Lateral separation is
brought by the heterogeneity of lipids present in the bilayer. Besides, the presence of three
different head groups- zwitterionic PC and PE and PEG chain; the intermolecular acyl tails in
the different lipids as well as the presence of dienes in the tail chain increases the heterogeneity
of the LNP carriers444,445. These groups result in lateral phase separation which is indicated by
the broadening of the transition peaks.
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Furthermore, the main phase transition temperature of DC8, 9 PC bilayer membranes was shifted
to a lower temperature by the addition of DSPE-PEG. The shift became significant as the mole
fraction of DSPE-PEG increased. This may be attributed to several reasons. The presence of
intercalated PEG is their amorphous state in the LNP’s maybe disrupting the hydrogen bonding
between the adjacent PC head groups thereby destroying the structural arrangement of the head
groups. Since the transition temperature is affected by the head group species, the meting point
is decreased as the concentration of DSPE-PEG increases300,446. The presence of salt in the
HBS buffer might have induced an osmotic stress resulting in decrease in size of the LNP’s.
To maintain the shape of the bilayer, some lipid molecules adopt a Pβ’ ripple phase from the
crystalline Lβ phase. This presence of rippled tails results in lowering of phase transition
temperature447,448.
Since the 10mol % DSPE-PEG2000 exhibited greater stability for a period of 4 weeks, we
tested the stability of LNP’s formulation of 10 mol % DSPE-PEG1000 when added to the
DC8,9PC lipids (1K (10)) (Fig 2a). Over the four-week period, there is no change in the Tm (Tm
for this formulation = 42.5 ˚C) and enthalpy increases by 45% (Table 6-2). The increase in
enthalpy in the case of smaller lipid chain (DSPE-PEG1000) might be because of the van der
Waals forces governing the intercalation of PEG chains weakens over time resulting in an
undisrupted bilayer136.
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6.3.4 Effect of higher molecular weight DSPE-PEG (5000) on Phase Transitions of
DC 8,9 PC/PEG- DSPE LNPs without HPPH:

Figure 6-3: The DSC thermograms of binary mixtures of DC8, 9PC/DSPE-PEG 5000 LNP’s
varying in PEG concentrations

Effect of presence of high molecular weight PEG associated with DSPE lipid in mixed
liposomes with DC8,9PC lipids were studied at varying ratios of PEG5000 after weeks 1 and 4.
Fig 6-3 represents the DSC thermographs of DC8, 9PC/DSPE-PEG5000 at 1, 10 and 20 mol%
ratios of PEG5000. This study focused on primarily 1 and 10 mol % ratios, since concentrations
higher concentrations > 20 mol% resulted in the disappearance of the melting peak due to
lateral phase separation161.
In the presence of 1 mol% of DSPE-PEG5000 lipids, the Tm was found to be 42.06 ˚C at the
end of week 1, which increased to 44.11 °C demonstrating a 23% decrease in enthalpy due to
the narrowed peak. Compared to DSPE-PEG2000, where the 1 mol % formulations showed a
31.5% decrease in enthalpy.
With formulation 5K (10), Tm remains the same as 5K (1) at the end of week 1. At the end of
week 4, there is a slight shift in Tm to 42.92 ˚C, with a reduction in peak height and enthalpy
by 79%. At 20 mol% of DSPE-PEG5000, a very broad peak at 43.17˚C with an enthalpy of
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0.49 J/g˚C and ∆T1/2 = 4.8 ˚C, at the end of week 1 was observed. Subsequently, at week 4,
there was a shift of Tm to 42.79 ˚C, with an increase in 28% enthalpy. The reduction in enthalpy
in the DSPE-PEG5000 formulations is congruent with formulations containing 10 and 20
mol% DSPE-PEG2000. The increase in transition temperature and decrease in enthalpy at the
end of four weeks in samples containing DSPE-PEG5000 is caused by the increased length of
PEG chain on the lipid head group as tabulated in Table 6-2. The longer PEG chains in the
DSPE-PEG5000 has an increased mobility resulting in more inter and intra molecular
interactions, thus adding to the internal energy of the system. This increased chain length
results in additional van der Waals forces the between the PEG moieties in the lipid head group,
leading to higher transition temperatures69,449. However, the presence of Pβ’ ripple phase
reduces the enthalpy involved in transition447,448.
Thermal analysis studies, LNP sizes and their PDIs, indicated that the formulations containing
10 and 20 mol% PEG 2000 and 10 mol% of DSPE-PEG 1000 and DSPE-PEG 5000 remain
stable over a period of four weeks. Additionally, the size distribution of these LNP formulations
remain monodisperse. Based on the stability data, HPPH encapsulated LNPs were synthesized
comprising of 10 mol% DSPE-PEG (1000, 2000 &5000) lipids & 20 mol% DSPE-PEG2000.
6.3.5 Effect of incorporation of HPPH on the DC 8, 9 PC/DSPE-PEG LNPs:
The HPPH encapsulated LNPs were monodisperse in nature with a PDI ≤ 0.2 like the
unencapsulated LNPs of the same formulation. However, the presence of HPPH systemized
the bilayer packing and there was a 5-15% reduction in size depending on the mol % and
molecular weight of the DSPE-PEG used in the bilayer. Further, the effects of presence of
HPPH on the DSPE-PEG molecular weight and mol%, can be inferred from the results of the
thermal analysis shown in Fig 6-4.
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Figure 6-4: 90:10 DC8,9PC/DSPE-PEG formulation in the absence of HPPH (a,b); DC 8, 9
PC/DSPE-PEG formulation in the presence of HPPH (c, d)

Fig. 6-4 a, b represents the stability of formulations containing 10 mol% of DSPE-PEG LNP’s
of varying PEG chain length (i.e. 1000,2000,5000). When compared to unencapsulated LNPs
2K (10), during week 1, on incorporating HPPH (Fig 6-4c), there is no significant change in
the enthalpy of transition and the Tm is shifted to a slightly lower temperature (Tm = 42.06 ˚C).
In the week 4, 2K (10)/HPPH, had further shifter to a lower Tm of 41.67 ˚C with an enthalpy of
transition of 2.05 J/g˚C, which was 40% decrease in enthalpy as compared to the plain sample
in Fig 6-4b.
Similar trends of lower Tm & enthalpy have been observed in formulations with HPPH has been
observed with 1K (10), 2K (20) and 5K (10) as tabulated in Table 6-3. However, all the
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formulations with HPPH have their enthalpies lesser than the plain samples at the end of week
four except with 5K (10). This is because HPPH being hydrophobic gets accumulated in the
tail region of the bilayer. HPPH has donor hydrogen electrons in the porphyrin ring which
interact with the acceptor oxygen electrons in the glycerol moieties and form hydrogen
bonds436,437. The presence of HPPH in the hydrophobic alkyl tails also results in van der Waals
forces and results in increased tightness of packing and the membrane curvature. The formation
of these bonds results in lesser mobility of the lipid molecules and thereby reducing the internal
energy of the HPPH loaded liposomes. This is indicated by the decrease of enthalpy in
congruence with the size data 450,451.
Table 6-3: Change in transition temperature and enthalpy of transition on addition of HPPH

Formulation
Name

Week 1

Week 4

Transition
temperature ˚C
(Tm)

Enthalpy of
transition
(J/g ˚C)

Transition
temperature ˚C
(Tm)

Enthalpy of
transition
(J/g ˚C)

1K (10)
1K (10)/HPPH
2K (10)
2K (10)/HPPH
2K (20)
2K (10)/HPPH
5K (10)

42.42
42.32
42.87
42.06
42.04
41.06
42.02

0.81
6.79
8.66
8.08
2.5
0.38
6.08

42.66
42.97
43.04
41.67
41.17
41.37
44.11

1.18
0.468
3.4
2.05
0.74
0.21
1.69

5K (10)/HPPH

42.45

0.89

42.92

1.24

In samples 1K (10)/HPPH and 2K (10)/HPPH &2K (20)/HPPH, the enthalpy reduces from
week 1 to week 4. With 1K (10)/HPPH, 2K (10)/HPPH and 2K(20)/HPPH, the enthalpy
reduction at the end of week 4 is very significant because van der Waals force between the
shorter PEG chains are disrupted by the presence of HPPH in the hydrophobic zone. However,
in 5K (10)/HPPH, there is a significant increase in enthalpy at the end of week 4. This is
assumed due to the strong van der Waals force arising from the intercalation of longer DSPE5000 PEG chains, which counteracts the presence of HPPH. This results in an increased
curvature of the LNP rendering them unsuitable for drug delivery applications.
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Figure 6-5: Schematic representation of a) Mushroom regime b) Brush Regime, due to shorter
chain length; loss of curvature c) packing forces between HPPH and the constituent lipids in LNPs

Thus, we can infer from the size and DSC results that, out of four of the formulations that
encapsulated HPPH, 2K (10)/HPPH is the optimum formulation because size of the carrier
(104 nm) is well within the standard size range of the nano-carriers (70-200nm) used in drug
delivery.
The reduction of enthalpy in the presence of HPPH, which corresponds to phase separation of
formulation, at the end of week 4 is not significant compared to 2K (10)/Week 4. This is
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presumed due to the optimum van der Waals force that counteracts the presence of HPPH in
the hydrophobic zone and is responsible for the stability of the formulation as shown in Fig 65.

6.4 Conclusions
In this work, we have investigated the effect of various chain lengths and molar ratios of DSPEPEG lipids when included with DC8,9PC lipids. The size, dispersity and DSC study reveal that:
1. Inclusion of DSPE-PEG at lower molar ratios (1-20 mol%) induce uniform dispersity
to DC8,9PC vesicles. However, at higher molar concentrations, heterogeneity of lipid
molecules causes lateral phase separation.
2. DSC studies confirm that formulations with 10 and 20 mol % of DSPE-PEG 2000 and
10 mol% of DSPE-PEG 1000 & 5000 form stable LNPs with uniform dispersity.
3. Hydrophobic HPPH forms hydrogen bonds and van der Waals forces with the lipid
moieties resulting in organized packing of the bilayer.
4. The four week DSC stability study also confirm that DSPE-PEG of chain length 2000
has optimum van der Waals force and offers a four-week stability when a hydrophobic
drug is encapsulated as compared to short chain DSPE-PEG1000 and long chain
DSPE-PEG5000.

115

7 Conclusions and Future Recommendations
7.1 Summary:
In this dissertation, amino methyl coumarin was conjugated with hydrophobic alkyl tail chains
to increase the amphiphilicity of the molecule. The interactions studies revealed that binding
to the lipid bilayer was through charge difference. The mechanism of the bilayer destabilization
was alkyl chain length and concentration dependent. Besides, FDA approved photosensitizers
(PS) were encapsulated in PEGylated liposomes. The addition of PEGylated lipids to the
liposomal formulation increased the steric stability and reduced aggregation. The above goals
were achieved by utilizing the versatility of liposomes to function as model cell membrane and
as carriers for drug delivery. This fundamental work is aimed at understanding and improving
the chemical structure and pharmacological properties of photosensitizers, to achieve
therapeutic success in Photo Dynamic Therapy (PDT) for cancer applications.
To realize the goal of understanding the interaction mechanisms of photosensitizers using
biophysical techniques, riboflavin was used as a baseline. The initial studies involved studying
the interactions of zwitterionic DPPC and DPPC/Cholesterol liposomes with riboflavin, a wellknown photosensitizer. One- and two-dimensional NMR was used to understand the
interactions with the phospholipid membrane. However, NMR was insensitive to the liposome
concentrations under study and labor-intensive nature of NMR resulted in an inconclusive
study. The results of the NMR are elucidated in the appendix section. Subsequently, the
interactions between riboflavin with DPPC and DPPC/Cholesterol liposomes was investigated
using Dynamic Light Scattering (DLS) and differential scanning calorimetry (DSC). The
results of this study are elaborated in chapter 4 of this dissertation. DLS studies concluded that
riboflavin bound to the DPPC liposomes predominantly through electrostatic interactions. The
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riboflavin molecules inserted itself in the outer leaflet of the lipid bilayer causing minimal
perturbation of the lipid bilayer. Further insertion was not possible due to the hydrophilic nature
of riboflavin, resulting in its lower bioavailability and efficacy. Encapsulation of riboflavin in
liposomal formulations of DPPC and cholesterol increased the bioavailability. However,
cholesterol caused aggregation of liposomes thus lowering stability and the loading capacity as
well. Thus, we investigated ways to maintain the stability of formulations which is detailed in
our work in Chapter 5 of this dissertation. Aggregation of liposomes is prevented by inducing
steric stabilizations in formulations; this is done by adding PEGylated lipids to the liposomes.
Riboflavin was encapsulated in a formulation containing 90 mol% photo-polymerizable lipid
DC8,9PC and 10 ml% DSPE-PEG 2000. It was found that this formulation had a shelf-life of
four weeks without aggregating and the photo-polymerizable lipid DC8,9PC reduced the
leakage, thus eliminating the need for cholesterol. This solved the bioavailability issue
associated with riboflavin.
However, the efficacy of PDT relies on the penetration power of the PS molecule. Hydrophilic
molecules such as riboflavin, fail to penetrate deeper into the tissues. It has been demonstrated
that amphiphilic fluorophore probes (linked with hydrophobic tails171–173) have better cellular
uptake. Probes with longer hydrophobic tails showed better uptake, due to their ability to
penetrate deeper into the cell membrane due to electrostatic,174,175 hydrophobic,42,176,177 and
hydrogen bonding interactions178,179. However, amphiphilic riboflavin probes have already
been researched upon as components for liposomal formulation for drug delivery
applications452. Another well-known fluorophore is 7-amino-methy coumarin. 7-amino-4methylcoumarin (AMC) is of importance because of the presence of electron donating amino
group in the 7th position, 253,258 which can donate electrons and acts as fluorescence enhancers
for probing applications with longer wavelengths and improved intensity.259,260 We designed
a novel class of amphiphilic amino-coumarin fluorophores Cn, by attaching linear alkyl tail
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chains to amino-coumarin molecules, where n = 5 to 12. These fluorophores were synthesized
by one-step synthesis and demonstrated a higher cellular uptake in cancerous cells. The
mechanism of uptake and cellular destabilization were investigated using liposomes as
described in Chapter 3 of this dissertation.
The model cancerous cell membrane (DPPC/DPPS) was prepared by thin film hydration
technique. The coumarin fluorophores were added to the preformed liposomes and the binding
and interactions were studied using dynamic light scattering (DLS), differential scanning
calorimetry (DSC), fluorescence spectroscopy, isothermal titration calorimetry (ITC) and
molecular dynamics (MD) simulations. Our studies indicated that the amphiphilic coumarin
molecules were first attracted to the bilayer through electrostatic interactions. The penetration
to the bilayer was controlled by the concentration of the molecules and the alkyl chain length
Cn. It is important to note that at smaller concentrations of amphiphilic coumarin, the membrane
remained stable, and the membrane thinning was a consequence of flip-flop of coumarin
molecules in the inner and outer leaflets. The nature of binding and uptake of these molecules
was quantified by ITC studies. It was concluded that enthalpy is the major driving force in the
uptake of coumarin fluorophores. Besides, our preliminary cell studies reveal that these
fluorophores can be used as potential photosensitizers (PS) in Photodynamic Therapy (PDT).
Our work thus clarifies that the efficacy issue surrounding hydrophilic PS molecules can be
overcome by inducing amphiphilicity.
Chapter 6 of this work investigates encapsulation of hydrophobic photosensitizers. HPPH (also
known as Photochlor) well-known hydrophobic photosensitizer, which has demonstrated faster
skin clearance and deeper tumor penetration at lower dosage rates as opposed to various other
FDA approved photosensitizers415–417. To further enhance the penetration power and selectivity
of HPPH, encapsulation with photopolymerizable DC8,9PC and DSPE-PEG. In this work, the
effect of molecular weight of PEG chains and composition on the encapsulation of HPPH was
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studied extensively using DSC and DLS. Dynamic light scattering and differential scanning
calorimetry was used to optimize the composition of lipids and PEG chain length (DSPE-PEG
1000, DSPE-PEG 2000 and DSPE-PEG 5000) and understand the effect of each of the
components on stability. It was concluded that the optimum PEG chain length of 2000 and 10
mol% of PEGylated lipid has optimum van der Waals force and offers a four-week stability
when HPPH is encapsulated as compared to short chain DSPE-PEG1000 and long chain DSPEPEG5000.

7.2 Key Contributions:
The key contributions of this work are as follows
i.

Hydrophilic Photosensitizers such as riboflavin and coumarin interdigitate with the
lipid headgroup and do not penetrate further into the hydrophobic zone. Their efficacy
can be enhanced in two ways a) by conjugating hydrophobic alkyl chains thereby
inducing amphiphilicity b) by encapsulating them in liposomal formulations

ii.

Liposomal formulations containing zwitterionic lipids and cholesterol aggregate
quickly due to the absence of steric stability. Steric stability is induced by coating
liposomes with PEGylated lipids. The addition of PEGylated lipids eliminates the need
for cholesterol in formulations. The molecular weight and composition of PEGylated
lipids determine the stability of the formulations. Short chain PEG lipids (DSPE-PEG
1000) have low intermolecular force of attraction resulting in lesser steric stabilization
Very long chain PEG lipids (DSPE-PEG5000) have very high intermolecular forces of
attraction, resulting in entanglement of polymeric chains. Intermediate chains (DSPEPEG2000) have optimum van der Waals force that helps in sustaining hydrophobic
HPPH and hydrophilic riboflavin photosensitizers in liposomal formulations.

iii.

The conjugation of alkyl chains to hydrophilic coumarin resulted in deeper penetration
into the lipid bilayer. Short chain C5 had more hydrophilic properties and did not reach
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the lipid tails at lower concentrations. At higher concentrations, C5 demonstrated
ejection-reinsertion mechanism at the surface resulting in membrane thinning. Longer
chain C12 is more hydrophobic and penetrates to the lipid bilayer zone. At higher
concentrations, flip-flopping of C12 between inner and outer leaflets results in
membrane destabilization. Enthalpy is the major driving force behind the binding and
insertion process.
iv.

Mechanistic examination of these interactions is established by a combination of
calorimetric and dynamic light scattering techniques in this dissertation. DSC
elaborated on the thermodynamic parameters involved in the interaction and stability
studies, while DLS and ITC provided congruent information on nature and kinetics of
binding. These combinations of these techniques eliminated the need for heavy
spectroscopic and electron microscopic measurements in this dissertation.

v.

The findings from the work are summarized in 7 journal articles and disseminated in
10 conference proceedings (refer section 8.3).
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7.3 Future Recommendations:
This work focused on enhancing PDT by developing amphiphilic photosensitizers and
designing liposomal formulations for PS delivery. However, in some cases, PDT-induced
oxygen can trigger newer angiogenesis activators comprising the efficacy of the
treatment453,454. Small interfering RNA (siRNA) is specific to these angiogenesis activators and
is found to overcome these drawbacks of PDT453–455. Some relevant suggestions to future work
are discussed here:
7.3.1

Amphiphilic Coumarin- siRNAs Complexes:

Small RNA (ribonucleic acids) moieties with two nucleotide 3’-overhangs. Amphiphilic
coumarin investigated in this work can be complexed to siRNA by electrostatically conjugating
positively charged amino groups to the and negatively charged phosphate moieties of siRNA.
The obtained complex is further added to preformed DPPC/DPPS liposomes. The subsequent
binding and insertion of the complex in the bilayer can studied using DSC, ITC, Circular
dichroism and DLS techniques and the mechanism of interaction can be deduced. This can be
challenging because of the presence of RNA subunits. This will aid in understanding the
synergistic effect of siRNA and photosensitizer on the site of the tumor.
7.3.2 Formation and Characterization of Lipoplex for co-delivery of HPPH:
The aim of this work is to enable the delivery of HPPH and siRNA to the site of the tumor,
thereby damaging the cancer cells using HPPH and preventing the recurrence by siRNA. In
this proposed work, PEG-oxime ether complexes are synthesized initially. Further, this
complex is conjugated to lipids. The conjugation of PEG to oxime and PEG-oxime ether to
lipids is outlined in previous literature456,457. Liposomes comprising of PEGylated-Oxime ether

121

lipids and helper lipid DOPE (1,2-Dioleoyl phosphatidylethanolamine) can be formed by thin
layer hydration technique.

Figure 7-1: Structure of a) Oxime Ether lipids b) Helper Lipid DOPE

Further, lipoplexes can prepared by introducing the preformed PEGylated-Oxime ether/DOPE
liposome to DS RNA by incubation and serum washing. The obtained liposomes are then
subjected to dynamic light scattering (DLS) studies, fluorescence anisotropy and ITC to
confirm the attachment of nucleic acids, binding affinities, and morphological characterization.
Further, cell viability assay on cancerous cells using flow cytometer and uptake studies using
fluorescent microscopy is performed to understand the toxicity of these lipoplexes. Further,
these lipoplexes can be encapsulated with HPPH. The drug loading efficiency of HPPH can be
calculated using UV-Vis spectroscopy and Thermogravimetric Analysis.
7.3.3 Stealth Liposomes with conjugated coumarin for co-delivery of siRNA in PDT:
The amphiphilic coumarin examined in this work can be conjugated to the PEG-Oxime-ether
lipids. The conjugation procedure and synthesis routes can be found in prior literature202,456–
458

. The obtained PEG-coumarin-oxime ether lipids is self-assembled with helper DOPE lipids.

The resulting liposomes are characterized for size, charge, morphology, and stability using
DLS, Cryo-TEM and DSC. In-vitro cytotoxicity on cancer cells is assessed using MTT assay,
prior to the MTT-assay the cell culture is treated with light of a particular wavelength to
understand the preliminary photoactivity of these self-assemblies. These proposed liposomes
will not only increase the efficacy of PDT by reducing the drawback but also prevent early
macrophage clearance due to stealth nature.

122

8 Appendix
In this section, all the supporting information pertaining to Chapter 3 - The interaction of
amphiphilic coumarin with DPPC/DPPS lipid bilayer are available. The description of each of
the figure is mentioned throughout chapter 3. 1H NMR and 13C NMR analyses of C9, 1H
NMR, 13C NMR, FTIR and HRMS analyses of C12, flip-flop profiles of C5 and C12 amphiphiles
in the lipid bilayer, and the coarse-grained force field parameters for C5 and C12 amphiphiles.

8.1 Supporting information for interaction studies of Amphiphilic Coumarin

Figure 8-1: 13C-NMR spectra of C9 amphiphile
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Figure 8-2: 1H-NMR spectra of C9 amphiphile
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Figure 8-3: 13C-NMR spectra of C12 amphiphile
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Figure 8-4: 1H-NMR spectra of C12 amphiphile
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Figure 8-5: HR-MS spectra of C12 amphiphile
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Figure 8-6: Fluorescence spectroscopy of amphiphilic fluorometric probes at 37oC & 43oC
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Figure 8-7: Flip-flop modes for 20 randomly selected molecules (each in a unique color) in system
(a) C5-42, (b) C5-166, (c) C5-166, and (d) C5-209. Trajectory of the coumarin ring for each molecule
is shown in a unique color.
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Figure 8-8: Comparison of flip-flop (%) for C5 (blue) and C12 (red) molecules over a range of
concentrations. with (a) ≥1 flip-flop (b) ≥2 flip-flops

Figure 8-9: DSC Thermogram of a) pure DPPC/DPPS(85/15mol%) b) effect of DMSO on
DPPC/DPPS (85/15 mol%)
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Figure 8-10: ITC thermogram of C9 interaction (Type-A Titration-0.5 mM) with DPPC/DPPS
liposomes of concentration a) 2.5 mM b) 5 mM

Figure 8-11: Flip-flop modes for 20 randomly selected molecules (each in a unique color) in system
(a) C12-42 and (b) C12-166. Trajectory of the coumarin ring for each molecule is shown in a unique
color.
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Table 8-1: Equilibrium bond length (req), angle (θeq), and respective force constant for C5 model.
Bond

req(nm)

kbond (kJ mol−1 nm−2)

1-2
1-3
2-4
3-4
3-5
4-5

0.295
0.288
0.303
0.206
0.330
0.393

Constrained
Constrained
Constrained
Constrained
5000
5000

Angle

θeq(deg)

kangle (kJ mol−1)

1-2-4
87
50
2-1-3
75
50
1-3-4
112
50
1-3-5
155
50
2-4-3
86
50
2-4-5
142
50
3-5-6
92
50
5-6
0.347
5000
4-5-6
108
50
Table 8-2: Equilibrium bond length (req), angle (θeq), and respective force constant for C12
model.
Bond
1-2
1-3
2-4
3-4
3-5
4-5
5-6
6-7
7-8

req(nm)
0.295
0.288
0.303
0.206
0.348
0.341
0.339
0.398
0.413

kbond (kJ mol−1 nm−2)
Constrained
Constrained
20000
Constrained
5000
5000
5000
5000
5000
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Angle
1-2-4
2-1-3
1-3-4
1-3-5
2-4-3
2-4-5
3-5-6
4-5-6
5-6-7
6-7-8

θeq(deg)
87
75
112
171
86
158
122
144
120
143

kangle (kJ mol−1)
50
50
50
50
50
50
50
50
50
50

Figure 8-12: Fluorescence Microscopy Images of uptake of coumarin fluorophores in cancerous
cells and specificity of coumarin fluorophores to cancerous cells

Figure 8-13: Apoptotic Studies with C9

133

8.2 NMR studies- Interaction of Riboflavin

8.2.1

1H-NMR

Studies:

In this section, all data pertaining to the NMR analysis (1&2-dimensional NMR) of interaction
of Riboflavin with DPPC & DPPC/Cholesterol are presented as a part of the studies undertaken
in Chapter 4. Additionally, circular dichroism data pertaining to the interactions are also
presented.
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Figure 8-14: 1H NMR spectrum of riboflavin 5’ monophosphate

Figure 8-14 shows the 1H NMR spectrum of riboflavin 5’ monophosphate. The methine
hydrogens that are on the ring structure are correspond to the signals labeled 7 and 8. The
methyl hydrogens of the CH3 groups attached to the ring correspond to the signals that are
labeled 9 and 10. Finally signal 11 corresponds to the methylene and methine hydrogens of the
branch.
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Figure 8-15: 1H NMR spectrum of cholesterol

Figure 8-15 shows the 1H NMR of cholesterol. Signals 12 through 16 correspond to the methyl
and methylene hydrogens that make up the branch attached to the pentane ring and the two
methyl hydrogen groups connected to the cyclic rings. Signal 17 corresponds to the methine
hydrogen of the alcohol carbon. Signal 18 corresponds to the methylene hydrogen of the cyclic
ring with the alcohol. Finally signal 19 corresponds to the methine hydrogen of the double bond
carbon in the second 6 membered ring.
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Figure 8-16: Overlay 1HNMR spectrum of DPPC, DPPC with 0.25 mg/mL riboflavin, and
DPPC with 5 mg/mL riboflavin at 43° C

Figure 8-16 shows the 1H NMR data of the DPPC liposomes by itself, with 0.25 mg/mL
riboflavin ‘monophosphate and with 5 mg/mL riboflavin 5’ monophosphate at 43° C. The
signals 9 and 10 correspond to the methyl hydrogens of the CH3 groups attached to the ring.
Signal 3 corresponds to the methylene protons on the non-polar tail just before the glycerol
moiety. Signal 6 corresponds to the methyl hydrogens on the nitrogen group of the polar head
group. Signal 5 corresponds to the methylene hydrogens on the polar head group. Signal 11
corresponds to the methylene and methine hydrogens of the branch and signals 7 and 8
correspond to the hydrogens of the aromatic ring.
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Comparing the three spectra, the signal given by the methylene protons right before the glycerol
moiety is lost with the addition of riboflavin 5’ monophosphate. Even at the lower
concentration of riboflavin the signal is diminished completely. Also, there is a change in
intensity, and slight chemical shift change in the signal given by the methylene protons on the
polar head group. The signals given by the aromatic protons of riboflavin also become shifted
at the higher concentration of riboflavin when compared to the lower concentration.
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Figure 8-17:Overlay of 1H NMR spectra of DPPC-Chol, DPPC-Chol with 0.25 mg/mL riboflavin,
and DPPC-Chol with 5 mg/mL riboflavin at 43° C

Figure 8-17 shows the 1H NMR data of the DPPC-Chol liposomes by itself, with 0.25 mg/mL
riboflavin ‘monophosphate and with 5 m/mL riboflavin 5’ monophosphate at 43° C. The
signals 1 and 2 correspond to the methyl and methylene protons that make up the non-polar
tail. The signals 9 and 10 correspond to the methyl hydrogens of the CH3 groups attached to
the ring. Signal 3 corresponds to the methylene protons on the non-polar tail just before the
glycerol moiety. Signal 6 corresponds to the methyl hydrogens on the nitrogen group of the
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polar head group. Signal 5 corresponds to the methylene hydrogens on the polar head group.
Signal 11 corresponds to the methylene and methine hydrogens of the branch and signals 7 and
8 correspond to the hydrogens of the aromatic ring.
Comparing the three spectra, the signal given by the methylene protons right before the glycerol
moiety is lost with the addition of riboflavin 5’ monophosphate. Even at the lower
concentration of riboflavin the signal is diminished completely. Also, there is a change in
intensity, and a slight chemical shift change in the signal given by the methylene protons on
the polar head group. The signals given by the aromatic protons of riboflavin also become
shifted at the higher concentration of riboflavin when compared to the lower concentration and
get slightly shifted away from each other.
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Figure 8-18:Overlay of 1H NMR spectra of DPPC, DPPC with 0.25 mg/mL riboflavin, and DPPC
with 5 mg/mL riboflavin at 25° C
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In all cases, the DPPC and DPPC-Chol liposomes completely lost the signal of the methylene
protons that are right before the glycerol moiety and all spectra also saw a shifting of the signal
of the methylene protons in the head group with the addition of riboflavin. The hydrogen peaks
on the aromatic rings of riboflavin 5’ monophosphate shift away from each other at the higher
concentrations of riboflavin. It is hypothesized that this may be caused by the insertion of
riboflavin into the lipid bilayer. The shift of the aromatic protons at the higher concentration
could indicate that the interaction is concentration dependent.
Figure 8-18 shows the 1H NMR data of the DPPC liposomes by itself, with 0.25 mg/mL
riboflavin ‘monophosphate, and with 5 m/mL riboflavin 5’ monophosphate at 25° C. The
signals 1 and 2 correspond to the methyl and methylene protons that make up the non-polar
tail. The signals 9 and 10 correspond to the methyl hydrogens of the CH3 groups attached to
the ring. Signal 3 corresponds to the methylene protons on the non-polar tail just before the
glycerol moiety. Signal 6 corresponds to the methyl hydrogens on the nitrogen group of the
polar head group. Signal 5 corresponds to the methylene hydrogens on the polar head group.
Signal 11 corresponds to the methylene and methine hydrogens of the branch and signals 7 and
8 correspond to the hydrogens of the aromatic ring.
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Figure 8-19:Overlay of 1H NMR spectra of DPPC-Chol, DPPC-Chol with 0.25 mg/mL riboflavin,
and 5 mg/mL riboflavin at 25° C

Comparing the three spectra, the signal given by the methylene protons right before the glycerol
moiety is lost with the addition of riboflavin 5’ monophosphate. Even at the lower
concentration of riboflavin the signal is diminished completely. Also, the signal given by the
methylene protons on the polar head group is almost completely diminished at the highest
concentration of riboflavin. The signal given by the methyl protons on the non-polar head group
is greatly diminished at the higher concentration of riboflavin. The signals given by the
aromatic protons of riboflavin also become shifted at the higher concentration of riboflavin
when compared to the lower concentration and get slightly shifted away from each other. Also,
when looking at the signals given by the aromatic protons in riboflavin, four peaks are seen at
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the higher concentration while only one is seen at the lower concentration. Figure 8-19 shows
the 1H NMR data of the DPPC-Chol liposomes by itself, with 0.25 mg/mL riboflavin
‘monophosphate and with 5 m/mL riboflavin 5’ monophosphate at 25° C. The signals 1 and 2
correspond to the methyl and methylene protons that make up the non-polar tail. The signals 9
and 10 correspond to the methyl hydrogens of the CH3 groups attached to the ring. Signal 6
corresponds to the methyl hydrogens on the nitrogen group of the polar head group. Signal 5
corresponds to the methylene hydrogens on the polar head group. Signal 11 corresponds to the
methylene and methine hydrogens of the branch and signals 7 and 8 correspond to the
hydrogens of the aromatic ring.
Comparing the three spectra, the signal given by the methylene protons on the polar head group
is shifted when comparing the higher concentration of riboflavin to the lower concentration.
The signal given by the methyl protons on the non-polar head group is greatly diminished at
the higher concentration of riboflavin. The signals given by the aromatic protons of riboflavin
also become shifted at the higher concentration of riboflavin when compared to the lower
concentration and get slightly shifted away from each other. Also, when looking at the signals
given by the aromatic protons in riboflavin, four peaks are seen at the higher concentration
while only one is seen at the lower concentration.
In all cases, both 25° C and 43° C the DPPC and DPPC-Chol liposomes saw a shifting of the
signal of the methylene protons in the head group with the addition of riboflavin. In the case
of the DPPC liposomes, the loss of signal from the methylene hydrogens that were connected
to the glycerol moiety and the non-polar tail is shown. The signals given by the aromatic
protons of riboflavin also become shifted at the higher concentration of riboflavin when
compared to the lower concentration. It is hypothesized that riboflavin is becoming inserted
into the lipid bilayer, which causes a slight conformational change in the head group as well as
a restriction of mobility in the non-polar tail. The shift of the aromatic protons at the higher
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concentration could indicate that the interaction is concentration dependent. When comparing
the data at the two different temperatures, it is shown that in the 25° C spectra that the peaks
of the non-polar tails, are less defined and much sharper. This is a result of the liposome being
in the gel phase, which means that the tails are much more rigid resulting in a loss of signal.
For this reason, it was decided that 43° C would be the temperature to run the 31P NMR and
DOSY experiments at.
8.2.2

31P-NMR

Studies:

Figure 8-20:31P NMR of extruded vs non-extruded liposomes

Figure 8-20 shows four different attempts at running 31P NMR on liposomes samples. Figure
A shows no signal, which is due to the sample aggregating outside the coil window. This meant
that the instrument saw no sample, so no signal was obtained. This led to the extrusion of the
samples, so that the chances of aggregation were limited. Figures b, c, and d in D-7 show an
increase in peak height as the length of the run increased. To get the desired spectrum, a 48hour run is necessary.
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Figure 8-21:31P NMR spectra of riboflavin, DPPC-Chol, and DPPC-Chol with 5 mg/mL riboflavin

Figure D-21 shows the

31

P NMR spectra of plain riboflavin as well as the DPPC liposomes

both with and without 5 mg/mL riboflavin. Comparing the DPPC with and without riboflavin,
the liposome peak shifts up-field slightly, and two of the peaks from riboflavin appear in the
spectrum. When comparing the DPPC 5 mg/mL riboflavin spectrum to the spectrum of plain
riboflavin, the liposome peak overlaps the peak of isomer that gave rise to signal 4. The
riboflavin 5’ monophosphate peak and the isomer peak labeled 1 are shifted down field slightly
which causes the signal of the isomer that gave rise to peak 3 to also be overlapped and hidden.
When comparing the riboflavin 5’ monophosphate peak and the peak of the isomer next to it
in the liposome spectrum to those in the plain riboflavin spectrum, it can be seen that the peaks

143

in the liposome spectrum have better resolution. These changes are hypothesized to be caused
by an electrostatic surface between the liposomes and riboflavin.
8.2.3

DOSY-NMR Studies:

Figure 8-22:DOSY spectrum of riboflavin 5’ monophosphate

Figure 8-23: DOSY spectra of DPPC and DPPC-Chol liposomes
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Figure D-22 shows the repeat DOSY data for riboflavin 5’ monophosphate. The spectrum
shows that riboflavin has a diffusion coefficient of -9.32 log (m2/s).
Figure 8-23 shows the repeat DOSY data for the DPPC and DPPC-Chol liposomes. The
spectrum shows that both sets of liposomes have a diffusion coefficient of -9.02 log (m2/s) and
-8.88

log

(m2/s).

Figure 8-24: DOSY spectra of DPPC and DPPC-Chol liposomes with 0.25 mg/mL riboflavin

Figure 8-24 shows the DOSY data for both DPPC and DPPC-Chol liposomes with the addition
of 0.25 mg/mL riboflavin 5’ monophosphate. In both spectra, the values of the diffusion
coefficients remained the same, -9.20 log (m2/s) for riboflavin and -8.96 log (m2/s) for both
liposomes. This means that no interaction between riboflavin 5’ monophosphate and the
liposomes was seen during the experiment.
For both the DPPC and DPPC-Chol liposomes at the two different concentrations, the diffusion
coefficients for riboflavin and DPPC remain the same, which means that no interaction between
riboflavin 5’ monophosphate and the liposomes was seen during the experiment. This,
however, does not necessarily mean that there was no interaction between the riboflavin and
liposomes. The DOSY experiment was set up so that the diffusion delay was 200 milliseconds.
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If the interaction between riboflavin and the liposomes was not permanent, and lasted less than
200 milliseconds, it would be undetectable.

8.2.4

Circular Dichroism Studies:

Figure 8-25: Circular dichroism data of riboflavin, DPPC, and DPPC with 5 mg/mL riboflavin
at 43° C

Figure 8-26: Circular dichroism data for riboflavin, DPPC-Chol, and DPPC-Chol with 5
mg/mL riboflavin at 43° C
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Figures 8-26 and 8-27 show the Circular dichroism data for riboflavin, the liposomes, either
DPPC or DPPC-Chol, and the liposomes with 5 mg/mL riboflavin. The data shows that the
addition of cholesterol does not affect the electrostatic interaction and supports the conclusion
from the zeta potential data that there is an electrostatic interaction between the riboflavin and
liposomes.
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